

# **EXHIBIT A**

UNITED STATES DISTRICT COURT  
FOR THE NORTHERN DISTRICT OF ILLINOIS

**CITY OF ROCKFORD and  
ACUMENT GLOBAL  
TECHNOLOGIES, INC.**  
*on behalf of themselves and  
all others similarly situated,*

Plaintiffs,

v.

**MALLINCKRODT ARD, INC.,  
formally known as QUESTCOR  
PHARMACEUTICALS, INC.;  
MALLINCKRODT PLC; EXPRESS SCRIPTS  
HOLDING COMPANY; EXPRESS SCRIPTS,  
INC.; CURASCRIP, INC., *doing business as*  
CURASCRIP, SD; ACCREDO HEALTH  
GROUP, INC., *and* UNITED BIOSOURCE  
CORPORATION**

Defendants.

Civil Action No.: 3:17-cv-50107

**SECOND AMENDED CLASS  
ACTION COMPLAINT**

**JURY TRIAL DEMANDED**

## TABLE OF CONTENTS

	<u>Page</u>
NATURE OF THE CASE .....	1
JURISDICTION AND VENUE .....	3
PLAINTIFFS .....	5
DEFENDANTS .....	6
FACTUAL BACKGROUND .....	9
RELEVANT MARKETS AND MONOPOLY POWER, .....	29
CLASS ACTION ALLEGATIONS .....	40
COUNT I CITY OF ROCKFORD v. EXPRESS SCRIPTS UNJUST ENRICHMENT .....	44
COUNT II CITY OF ROCKFORD v. MALLINCKRODT UNJUST ENRICHMENT .....	45
COUNT III ACUMENT v. MALLINCKRODT UNJUST ENRICHMENT .....	47
COUNT IV PLAINTIFFS v. ALL DEFENDANTS FRAUD .....	49
COUNT V PLAINTIFFS v. ALL DEFENDANTS CONSPIRACY TO DEFRAUD/CONCERTED ACTION .....	50
COUNT VI PLAINTIFFS v. ALL DEFENDANTS MAINTENANCE OF MONOPOLIZATION OF THE ACTH MARKET (15 U.S.C. § 2).....	52
COUNT VII PLAINTIFFS v. ALL DEFENDANTS ANTI-COMPETITIVE AGREEMENTS IN UNREASONABLE RESTRAINT OF TRADE (15 U.S.C. § 1).....	56

COUNT VIII	
PLAINTIFFS v. ALL DEFENDANTS	
STATE ANTITRUST LAW CLAIMS.....	59
COUNT IX	
PLAINTIFFS v. ALL DEFENDANTS	
Violation of 18 U.S.C. § 1962(c).....	78
COUNT X	
PLAINTIFFS v. ALL DEFENDANTS	
Violation of 18 U.S.C. § 1962(a).....	85
COUNT XI	
PLAINTIFFS v. ALL DEFENDANTS	
Violation of 18 U.S.C. § 1962(d)) .....	86
COUNT XII	
CITY OF ROCKFORD V. EXPRESS SCRIPTS	
BREACH OF CONTRACT	
BREACH OF THE ESI PBM AGREEMENT .....	88
COUNT XIII	
CITY OF ROCKFORD V. EXPRESS SCRIPTS	
PROMISSORY ESTOPPEL.....	89
COUNT XIV	
CITY OF ROCKFORD V. EXPRESS SCRIPTS	
DECLARATORY JUDGMENT THE ESI PBM AGREEMENT .....	90
COUNT XV	
CITY OF ROCKFORD V. EXPRESS SCRIPTS	
BREACH OF THE IMPLIED COVENANT OF	
GOOD FAITH AND FAIR DEALING.....	91
PRAYER FOR RELIEF .....	92
JURY DEMAND .....	93

## **SECOND AMENDED CLASS ACTION COMPLAINT**

The City of Rockford (“the City” or “Rockford”) and Acument Global Technologies, Inc. (“Acument”) (collectively the “Plaintiffs”) on behalf of themselves and the Class described below, allege as follows:

### **NATURE OF THE CASE**

1. Plaintiffs bring this action on their own behalf and on behalf of all other government payors and private payors similarly situated, excepting those expressly excluded from the Class, to challenge an unjust, unfair, and anti-competitive scheme by Defendants, Mallinckrodt ARD Inc., formally known as Questcor Pharmaceuticals, Inc. (“Questcor”) and its parent company, Mallinckrodt plc (collectively “Mallinckrodt”) as well as Mallinckrodt’s exclusive agent for the delivery of its products, Express Scripts Holding Company and Express Scripts, Inc., including their three (3) wholly-owned subsidiaries, CuraScript, Inc., doing business as CuraScript, SD., Accredo Health Group, Inc., and United BioSource Corporation (collectively referred to as “Express Scripts”). The scheme alleged herein sought to maintain and enhance Mallinckrodt’s monopoly power in the U.S. market for adrenocorticotrophic hormone (ACTH) drugs in violation of the antitrust laws.

2. Mallinckrodt manufactures, markets, distributes and sells H.P. Acthar, NDC No. 63004871001 (“Acthar”). Acthar is the only therapeutic ACTH product sold in the United States. Mallinckrodt is the sole provider in the U.S. of approved ACTH drugs. Thus, Mallinckrodt is a monopolist.

3. Mallinckrodt acquired its Acthar monopoly in 2001 when Questcor purchased Acthar from Aventis for \$100,000. By 2014, when Mallinckrodt purchased Questcor, the value of that Acthar monopoly was \$5.9 billion—the price paid for the single-product company.

4. This case does not seek to challenge the lawfulness of Mallinckrodt's monopoly. It seeks to challenge the lawfulness of Mallinckrodt's exercise of its monopoly power by taking actions to maintain and enhance that monopoly power in violation of the antitrust laws.

5. The issue is not whether Mallinckrodt possessed monopoly power for Acthar. It is whether its actions in contracting with the agent of its leading customers, Express Scripts, and in acquiring the only competitive product in the marketplace, Synacthen, constitute unlawful efforts to retain, maintain and enhance Mallinckrodt's monopoly power over Acthar in the ACTH market.

6. Acthar is a "specialty pharmaceutical". It is not sold in retail pharmacies, nor is it distributed through wholesalers to retail pharmacies, as with many prescription drugs. Instead, it is distributed only through "specialty pharmacy distributors".

7. One of the largest specialty pharmacy distributors in America is ESI's CuraScript, which ESI has owned since 2004. In 2007, Mallinckrodt decided to embark on a "new strategy" and it changed its distribution of Acthar. Rather than continue to distribute Acthar to the existing distribution network available for specialty drugs, Mallinckrodt decided to limit Acthar distribution exclusively through ESI's CuraScript. In effect, Mallinckrodt contracted with the agent of its leading customers in order to create an exclusive arrangement whereby both companies would share the financial rewards of the Acthar monopoly.

8. Immediately after signing the exclusive agreement, Mallinckrodt and Express Scripts agreed to raise the price of Acthar from \$1,980 to over \$27,927.80 per vial. As a result, Mallinckrodt was able to charge inflated prices for Acthar to Express Scripts' clients, including the Plaintiffs.

9. In 2015, Rockford spent \$489,057.84 for just nine administrations of Acthar given

to two infant patients at a gross cost per vial of \$54,339.76. When Mallinckrodt acquired the Acthar monopoly from Aventis, the cost of an individual vial was just \$40.00. Just prior to Mallinckrodt's exclusive agreement with Express Scripts, the cost of an individual Acthar vial was \$1,980. That means the total cost to Rockford would have been less than \$15,000, rather than nearly \$490,000, in the absence of the exclusive agreement. As a result, Rockford and other members of the Class paid more for Acthar than they otherwise would have paid in the absence of Mallinckrodt's unlawful actions with Express Scripts to maintain and enhance its monopoly power, and to conspire and agree with Express Scripts to defraud Rockford and the Class of Acthar purchasers.

10. In a 13-month period between December 2015 and December 2016, Acument spent \$894,617.75 for just 13 administrations of Acthar given to the spouse of one of Acument's employees.

11. For this reason, Plaintiffs bring this case on behalf of themselves and a Class of all similarly-situated purchasers of Acthar, to obtain declaratory and injunctive relief, and to recover money damages. Rockford sues all Defendants for unjust enrichment, fraud, conspiracy to defraud, federal antitrust and RICO violations, and violations of Illinois and other states' laws. Rockford also sues Express Scripts for breach of contract, promissory estoppel, declaratory judgment, and breach of the duty of good faith and fair dealing implied by law. Acument sues all Defendants for unjust enrichment, fraud, conspiracy to defraud, federal antitrust and RICO violations, and violations of Tennessee and other states' laws.

### **JURISDICTION AND VENUE**

12. Plaintiffs bring this action pursuant to sections 4 and 16 of the Clayton Act, 15 U.S.C. §§ 15(a) and 26, to recover treble damages, costs of suit, and reasonable attorneys' fees

for the Defendants' violations of sections 1 and 2 of the Sherman Act, 15 U.S.C. §§ 1 and 2. This Court has subject matter jurisdiction pursuant to 28 U.S.C. §§ 1331 and 1337(a).

13. This Court also has subject matter jurisdiction over this action pursuant to the Class Action Fairness Act of 2005, 28 U.S.C. § 1332(d), because the Plaintiffs and members of the Class are diverse from the Defendants and over two-thirds of the Class is situated outside of Illinois. Due to the exorbitant prices charged by Defendants for Acthar to the Class, the aggregate amount in controversy far exceeds \$5,000,000.

14. Further, the Court has supplemental jurisdiction over the Plaintiffs' state common law and statutory claims pursuant to 28 U.S.C. § 1367 because these claims arise from the same occurrence or transaction and are related to the Plaintiffs' federal antitrust and RICO claims as to form part of the same controversy.

15. This Court has personal jurisdiction over the parties because the Defendants conduct substantial business in this State, have had systematic and continuous contacts with this State, and have agents and representatives that can be found in this State.

16. The Court has jurisdiction over the Defendants because they have had sufficient minimum contacts with and/or have purposefully availed themselves of the laws and markets of the State of Illinois through, among other things, their conspiratorial communications between themselves and with others (including telephonic and electronic communications) and their distribution, marketing and sales of Acthar to the residents of Illinois.

17. Furthermore, by the Express Scripts, Inc. Pharmacy Benefit Management Agreement (hereinafter the "ESI PBM Agreement") at issue here, Express Scripts and Rockford agreed that the ESI PBM Agreement "will be construed and governed in all respects according to the laws in the State of Illinois, without regard to the rules of conflict of laws thereof".



18. Venue is proper in this District pursuant to section 12 of the Clayton Act, 15 U.S.C. § 22, because the Plaintiffs are situated in this District, and the Defendants transact business in this District. Venue is also proper because a substantial part of the events giving rise to the Plaintiffs' claims occurred in this District. Defendants engaged in substantial conduct relevant to the claims of the Plaintiffs and the Class, and caused harm to members of the Class in this District. Venue is also proper pursuant to 28 U.S.C. §1391.

19. Acthar is sold in interstate commerce and the unlawful activities alleged in this Second Amended Class Action Complaint have occurred in, and have had a substantial effect upon, interstate commerce.

## **THE PARTIES**

### **PLAINTIFFS**

20. The City of Rockford, Illinois, (the "City" or "Rockford"), employs over a thousand individuals in the service of its citizens. Two such employees have children who had a serious medical condition, for which Acthar was indicated as a treatment option. These employees received Acthar directly from Mallinckrodt's authorized agent, Express Scripts. The City, which pays the health care benefits of its employees, including specialty pharmacy drugs, then paid for these administrations of Acthar. The sum total of these 9 prescriptions (14 administrations) was \$489,057.84. The City paid \$488,787.84 directly to Express Scripts, as agent for Mallinckrodt. These monies were then directly transferred by Express Scripts to Mallinckrodt, after Express Scripts deducted its agreed-upon share of the revenues.

21. Acument Global Technologies, Inc. ("Acument") employs individuals in 12 locations in the United States and Mexico, including in Belvedere, Illinois and Spencer, Tennessee. The spouse of one of Acument's employees suffers from a condition for which

Acthar was indicated as a treatment option. Between December 17, 2015 and December 6, 2016, Acument paid a minimum of 80% of its employees' health care benefits, including specialty pharmacy drugs. Acument paid for the administrations of Acthar to its employee's spouse. The sum total of these administrations/prescriptions was \$894,617.75 or \$68,816.75 per prescription, for which Acument paid the largest share. The employee's co-pay was \$2,600.00 in total.

### **DEFENDANTS**

22. Questcor Pharmaceuticals, Inc. ("Questcor") was acquired by Mallinckrodt on August 14, 2014 for \$5.9 billion, after paying only \$100,000 for Questcor's lone product 13 years earlier. Following the acquisition, Questcor became a wholly-owned subsidiary of Mallinckrodt and its name was changed to Mallinckrodt ARD Inc. Mallinckrodt ARD is a biopharmaceutical company incorporated in California, with offices located at 675 McDonnell Blvd., Hazelwood, Missouri 63042. Mallinckrodt ARD now has locations in Hampton, New Jersey and Bedminster, New Jersey. For clarity, where necessary, the entity that existed prior to the Mallinckrodt acquisition is herein referred to as "Questcor".

23. At the time of the Mallinckrodt acquisition, Questcor's only product sold in the United States was Acthar. As of the date of this Second Amended Class Action Complaint, Mallinckrodt continues to manufacture, distribute and sell Acthar directly to patients, exclusively through Express Scripts, by a program known as the "Acthar Support and Access Program" ("ASAP") described below.

24. Defendant, Mallinckrodt plc ("Mallinckrodt plc"), is an Irish public limited company, with its corporate headquarters in Staines-upon-Thames, United Kingdom. Its principal executive offices are located at 3 Lotus Park, the Causeway, Staines-upon-Thames, Surrey, TW18 3 AG.

25. Mallinckrodt plc, Mallinckrodt ARD and Questcor are collectively referred to as “Mallinckrodt”.

26. Defendants Express Scripts, Inc. and Express Scripts Holding Company are Delaware Corporations with their principle executive offices located at 1 Express Way, Saint Louis, Missouri 63121. Collectively, Express Scripts, Inc. and Express Scripts Holding Company are referred to as “ESI”.

27. Defendant CuraScript, Inc., *d/b/a* CuraScript, SD, *f/k/a* CuraScript Pharmacy, Inc., (“CuraScript”) is a wholly-owned subsidiary of ESI. CuraScript was acquired by ESI in January 2004, and its operation was expanded when ESI acquired Priority Healthcare Corporation (“Priority”) in October 2005. The combined Priority and CuraScript became one of the nation’s largest specialty pharmacy and distribution companies with more than \$3 billion in annual revenue.

28. CuraScript’s corporate headquarters are located at 255 Technology Park, Lake Mary, Florida 32746. This is the same address patients are required to mail any revocation of the broad authorization granted by patients to Mallinckrodt and ESI via the Acthar Start Form (attached to the Complaint, Amended Complaint and this, Second Amended Class Action Complaint as Exhibit “A”). CuraScript is Mallinckrodt's exclusive specialty pharmacy distributor for Acthar.

29. Defendant Accredo Health Group, Inc. (“Accredo”) is a wholly-owned subsidiary of ESI. Accredo became a wholly-owned subsidiary of Medco Health Solutions, Inc. (“Medco”) on August 18, 2005, months before ESI acquired Priority, and then became part of ESI when ESI acquired Medco in 2012.

30. Accredo is a Delaware corporation with its corporate headquarters at 1640

Century Center Parkway, Memphis, Tennessee 38134. Accredo also has operations in Warrendale, Pennsylvania, Corona, California, Greensboro, North Carolina, Orlando, Florida, Indianapolis, Indiana, and Nashville, Tennessee.

31. Defendant United BioSource Corporation (“UBC”) is a Delaware corporation with its corporate headquarters at 920 Harvest Drive, Blue Bell, Pennsylvania 19422. When Rockford filed its initial Class Action Complaint on April 6, 2017, as well as when it filed its subsequent First Amended Class Action Complaint on October 9, 2017, UBC was a wholly-owned subsidiary of ESI. UBC was acquired by ESI in 2012 as part of the Medco merger.

32. On November 27, 2017, ESI announced that it sold UBC to Avista Capital Partners, a private equity firm. As of the date of this filing, Plaintiffs do not know if the sale has been completed.

33. UBC is described as Mallinckrodt’s “agent” on the ASAP form (Exhibit “A” hereto) which Mallinckrodt employs exclusively to operate the ASAP program and to manage ESI’s exclusive distribution, sales and reimbursement of Acthar by its 3 operating arms, CuraScript, Accredo and ESI.

34. As stated in Paragraph 1, ESI, CuraScript, Accredo and UBC are collectively referred to herein as “Express Scripts”.

35. Mallinckrodt and Express Scripts are collectively referred to herein as “Defendants”, as appropriate.

36. The Defendants’ acts alleged in this Second Amended Class Action Complaint to have been done by each of the Defendants were authorized, ordered, done and/or ratified by their respective officers, directors, agents, employees or representatives while engaged in the management, direction, control or transaction of their respective business affairs.

### **FACTUAL BACKGROUND**

37. “I have a Cadillac in my refrigerator.” That is how one Acthar patient named Sharon Keller described an unused 5-ml vial of the medication sitting in her kitchen refrigerator.

38. The tale of how a 65 year-old brand medication could rise in price from \$40 per vial in 2001, to \$40,840.80 per vial by 2015, raising that value of the brand from \$100,000 to \$5.9 billion, is a story of perhaps the most egregious fraud and monopolistic conduct in U.S. history by a prescription drug company.

39. The issue in this case is how Mallinckrodt achieved such a startling outcome.

#### **History of Acthar Development, Distribution and Pricing** **Acthar Development**

40. Acthar was approved by the Food and Drug Administration (“FDA”) in 1952 for over fifty conditions, ranging from alcoholism, poison ivy, and radiation sickness to nephrotic syndrome. Over time, with additional evidence-based requirements for prescription drugs, the list was winnowed to the fewer, present-day nineteen indications.

41. Acthar is adrenocorticotrophic hormone (“ACTH”), which causes the body to produce cortisone and other steroid hormones. Two Mayo Clinic researchers, Drs. Philip Hench and Edward Kendall, developed the treatment, which won them the Nobel Prize for medicine at the time it was developed. Acthar was developed by Armour Pharmaceutical Company. As described by the Seventh Circuit in *Armour & Co. v. Wilson & Co.*, 274 F.2d 143, 145-46 (7th Cir. 1960):

In a human being, . . . (ACTH) appears in the anterior lobe of the pituitary gland located at the base of the brain. When the human body is under stress or attacked by certain diseases, control centers in the brain excite the pituitary, and the pituitary secretes ACTH. In the blood stream the ACTH thus secreted is carried to the adrenal glands situated in the human body above the kidneys. As the ACTH hits the outer wall of the adrenal glands, it stimulates

the adrenals to produce a set of chemical substances such as steroids, including the hormones, cortisone and hydrocortisone.

The cortisone hormones then act in the tissues of the body to suppress inflammations and allergic reactions. ACTH thus is used to relieve such conditions as rheumatoid arthritis and allergies. ACTH does not, itself, directly attack disease. However, it stimulates the adrenals which produce more than twenty-eight steroids, and these hormones attack the diseased tissues. When the human body itself does not supply sufficient ACTH, pharmaceutical ACTH can fill the gap.

42. By the 1960s, injectable ACTH medications faced a variety of competing products. *See id.* at 145 (“Both Armour and Wilson manufacture and sell gelatin-ACTH preparations . . . . Gelatin-ACTH now constitutes more than 80% [o]f all forms of ACTH products sold by Armour and Wilson. Other companies . . . produce similar products”).

43. For the majority of the drug’s lifespan, however, generic corticosteroids, such as prednisone, effectively treated the majority of the indications for which Acthar was approved. That factor tended to limit the market for Acthar to treating infantile spasms (“IS”) which was originally an “off-label” indication. Consequently, because of the limited, off-label market for Acthar, by 2001, the drug was priced at \$40 per vial and accounted for less than a million dollars of revenue for Aventis Pharmaceuticals, Inc. (“Aventis”), the then-owner.

44. In 2001, Questcor acquired Acthar from Aventis for only \$100,000, but in 2014 Mallinckrodt acquired Questcor for \$5.9 billion.

45. Acthar’s value was limited because it was the “gold standard” for treating only one condition, infantile spasms (“IS”). IS is a serious condition in infants, but one with an annual patient population of less than 2,000 children per year. However, Acthar was not originally approved by the FDA to treat IS, further limiting its value. A few years later, the IS indication was approved by the FDA, and orphan drug status was granted.

**Acthar Distribution: Mallinckrodt Adopts a "New Strategy" to Restrict Acthar Distribution to Maintain and Enhance its Monopoly Power over Acthar**

46. Acthar is a specialty pharmaceutical distributed directly to patients, like the beneficiaries of the Plaintiffs and the Class in this case.

47. For decades, Acthar was distributed to any doctor, hospital, wholesaler or specialty pharmacy who requested the drug to treat seriously ill patients. After Questcor acquired the rights to Acthar, it initially maintained that broad distribution network.

48. However, on July 2, 2007, Mallinckrodt restricted its distribution from three wholesalers, termed Wholesalers “A”, “B”, and “C” in its 2007 10-K, to just Express Scripts, the agent of its largest customers. Mallinckrodt’s announcement stated, **“[e]ffective August 1, 2001, Acthar...will be available exclusively through Specialty Pharmacy Distribution.** Acthar Gel will no longer be available from traditional pharmaceutical wholesalers or retail pharmacies.” See July 2, 2017, “Urgent Product Alert H.P. Acthar Gel” (attached to the Amended Complaint and this, Second Amended Complaint at Exhibit “B”). All distribution would now be done exclusively through CuraScript. “[A]ll new Acthar Gel prescriptions should be submitted to the Acthar Support & Access Program.” *Id.* All aspects of Acthar distribution were handled by Express Scripts.

49. The goal of this “new strategy” was to lock patients into receiving Acthar through one distribution channel controlled by Mallinckrodt and Express Scripts, and to ensure prescription distribution and payment through one source, Express Scripts. Mallinckrodt has maintained this exclusive arrangement with Express Scripts since 2007 up through the present. Throughout this time, title, dominion and risk for Acthar remained with Mallinckrodt.

50. Mallinckrodt manages its exclusive arrangement with Express Scripts through a program known as the “Acthar Support & Access Program” or “ASAP.” This program is

structured so that Mallinckrodt ships Acthar directly to patients and receives payment directly from the associated third party payors.

51. Once the patient (or their physician) contacts Mallinckrodt for a prescription of Acthar, they are directed to UBC. Otherwise, patients and/or their providers contact UBC directly, as directed by the Acthar Start Form at Exhibit “A” hereto. UBC then serves as the “HUB” for Mallinckrodt and Express Scripts. It confirms the patient’s insurance coverage or other source of payment, and then arranges for Acthar to be delivered directly to the patient by CuraScript.

52. The process, which is laid out in a form provided by Mallinckrodt, the “Acthar Start Form”, requires patient, physician and payor authorization before Mallinckrodt agrees to ship Acthar to patients via ESI/CuraScript. *See* Exhibit “A” hereto. Thus, Express Scripts is not at risk. The Acthar Start Form consists of 3 sections: (1) a section requiring signature by the “HCP” (or health care professional); (2) a patient authorization requiring signature by the “patient or legal representative”; and (3) information form concerning Acthar indications and usage. The required signature of the patient authorizes “Mallinckrodt and its agents” to do a number of things in relation to the prescription and distribution of Acthar. It further authorizes Mallinckrodt and its agents, “including Mallinckrodt reimbursement support personnel and United BioSource Corporation (“UBC”) or any other operator of the Acthar Support Access Program on behalf of Mallinckrodt (collectively, ‘Designated Parties’)” to provide Acthar and receive payment, among other things.

53. Specifically, the patient authorizes Mallinckrodt, UBC, “or any other operator” of ASAP on behalf of Mallinckrodt, “collectively (‘Designated Parties’), to provide certain services to [the patient], including reimbursement and coverage support, patient assistance and access



programs, medication shipment tracking, and home injecting training.” In other words, the patient directly authorizes Mallinckrodt and its agents to ship Acthar to them directly via CuraScript, and authorizes payment by both the patient and any third party payor prior to obtaining the medication. So, the patient authorizes ESI to bill the payor for Acthar.

54. Similarly, the physician must “authorize[ ] United BioSource Corporation (“UBC”), the current operator of the Acthar Support and Access Program (“Program”), and other designated operators of the program, to perform a preliminary assessment of benefit verification for this patient...”. The physician also “agree(s) that the designated specialty pharmacy receive this prescription via a designated third party, the Program and that no additional confirmation of receipt of prescription is required by the designated specialty pharmacy.”

55. The interaction of all 4 elements of Express Scripts’ functions on behalf of Mallinckrodt are described below.

56. Express Scripts is the largest buyers’ agent for pharmaceuticals in the United States. Express Scripts has substantial buying power as a result of its representation of the largest number of buyers in the pharmaceutical marketplace.

57. Express Scripts styles itself as a “pharmacy benefit manager” or “PBM”, but it does more than simply process claims for prescriptions filled at retail pharmacies. In addition to “retail pharmacy claims processing, formulary management, utilization management and home delivery pharmacy services”, Express Scripts offers “specialty services that deliver . . . high-cost injectable, infused, oral or inhaled drugs,” and “compliance programs, . . . drug therapy management programs, [ ] data analysis, and [ ] distribution services.”<sup>1</sup> Acting “either directly or through its subsidiaries”, Express Scripts acts as a direct pipeline from a pharmaceutical

---

<sup>1</sup> Express Scripts Holding Company Annual Report on Form 10-K for the Fiscal Year Ending December 31, 2012.

manufacturer to the patient, facilitating the direct distribution of a prescription drugs from the factory to the patient's home.

58. Express Scripts is able to act as a manufacturer's direct distributor of specialty drugs to patients because it provides what it calls "integrated specialty services." (emphasis in original).<sup>2</sup> As one Express Scripts' executive put it "we're family." These integrated services include a PBM (ESI), a specialty pharmacy distributor (CuraScript), and a specialty pharmacy provider (Accredo).

59. Express Scripts coordinates all of these functions through its so-called pharmaceutical support services unit, UBC. UBC acts as a "'hub,' that serves as a centralized point of contact for [] patients [] and prescribers"<sup>3</sup> by "[w]orking hand-in-hand with Express Scripts' specialty pharmacy and specialty distribution organizations, Accredo and CuraScript [],"<sup>4</sup> to coordinate delivery of and reimbursement for specialty pharmaceuticals.

60. In total, UBC operates "an integrated service model that involves UBC . . . manag[ing] multiple system applications that support one product. [UBC's] services include the UBC coordinating center, nurse coordination . . . product fulfillment through Accredo and wholesale fulfillment through CuraScript[]. When a patient is prescribed [a specialty] medication, the doctor sends a referral to the Reimbursement Hub. [UBC's] team serves as the liaison among doctors, patients, and insurance companies as [UBC] . . . navigate[s] the coverage process. [UBC] . . . ensure[s] a smooth transition from enrollment through shipment of the medication."

61. Part of the reimbursement hub process is coordination with ESI's CuraScript,

---

<sup>2</sup> <https://curascriptsd.com/corporate-overview>

<sup>3</sup> <http://www.ubc.com/services/loyalty/reimbursement-patient-assistance>

<sup>4</sup> <http://www.ubc.com/about/about-ubc>

which acts as an “integrated delivery network” connecting patients to manufacturers through “end-to-end distribution services.”<sup>5</sup> Simply put, CuraScript is similar to a FedEx, DHL, or UPS for specialty prescription drugs. CuraScript advertises that it is “recognized by the manufacturing community as [] a reliable partner in the management of brands” through CuraScript’s “integrated specialty services,” which deliver medications to patients “alongside sister organizations Accredo and UBC.”<sup>6</sup>

62. To facilitate these end-to-end distribution services, UBC coordinates CuraScript’s activities with Accredo, which provides so-called specialty pharmacy services. By acting as the hub, UBC ensures that a patient whose pharmacy benefits are managed by ESI can get a specialty medication delivered to him or her by coordinating direct shipment through CuraScript and Accredo and direct payment through ESI. “As one UBC executive has explained “if UBC is the Hub and Accredo is the [specialty pharmacy] . . . we can send the patient’s prescription over to Accredo, and they will not have to duplicate any of our efforts, which another pharmacy would be compelled to do because of risk. Accredo trusts us.”

63. Accredo provides specialty pharmacy and related services for patients with certain complex and chronic health conditions. Accredo’s staff is comprised of a team of specialty-trained pharmacists, nurses, patient care advocates, social workers and insurance coordinators whom, among other things, “handle everything about” a patients’ medications and/or specialty therapy.

64. Along with UBC, Accredo provides: (a) support to orphan and ultra orphan patient populations; (b) HUB employees to navigate insurance requirements, like prior authorizations, for patients and prescribers; (c) clinicians who are available 24/7 to address

---

<sup>5</sup> <https://curascriptsd.com/Rare-Disease-Specialty-Distribution-Program>

<sup>6</sup> <https://curascriptsd.com/supplier-relations>

patient concerns and provide guidance on mitigating adverse events; (d) reimbursement HUB specialists to steer patients to funding solutions, and (e) an integrated solution allowing patients to start therapy twice as fast.

65. The Rockford patients at issue dealt with Accredo for her fulfillment of Acthar. Accredo publicly represents that by using Accredo's specialty pharmacy services, plan sponsors, like Rockford, can save money by managing their specialty spend through Accredo. Accredo further promises patients the most effective and affordable medications while ensuring appropriate utilization, manage unit costs, drive out waste and reduce related medical expenses.


66. The Acument patient at issue dealt with CVS Caremark for their fulfillment of Acthar. It is believed, and therefore averred, that UBC coordinated the shipment of Acthar directly to the spouse of Acument's employee via the same integrated "hub" network with the lone exception being that Acument's payment was made to its PBM, CVS Caremark, before being routed to Mallinckrodt.

67. In simple terms, through UBC's coordination with Accredo, CuraScript, and ESI, Express Scripts delivers a prescription drug directly from the manufacturer to the patient, removing all impediments to delivery and payment, whether medical, logistical or financial.

68. With respect to Acthar, Mallinckrodt has a contract with UBC to coordinate the delivery of Acthar through what it has called the ASAP Program. Beginning with its July 2, 2007 announcement, Mallinckrodt directed physicians to prescribe Acthar through the ASAP program. *See* Exhibit "B". In this announcement, Mallinckrodt directed physicians that "all new Acthar [] prescriptions should be submitted to the [ASAP program]." Prescriptions are submitted to the ASAP program through the "Acthar Start Form." *See* Exhibit "A". This form authorizes UBC to coordinate reimbursement with ESI and direct the prescription to a

“designated specialty pharmacy.” This designated specialty pharmacy is Accredo. Accredo dealt with the Acument patients in 2015. Part of UBC’s activities involve coordinating the shipment of Acthar from CuraScript through Accredo to the patient. Indeed, in order to revoke UBC’s authorization to perform these services, the patient must mail a letter to CuraScript’s address in Florida. It is believed and therefore averred that Acument’s patient provided a similar authorization to UBC for shipment from CuraScript.

69. The Acthar distribution arrangement between Express Scripts and Mallinckrodt is illustrated in the following two figures. In Figure 1, the distribution arrangement is described in aggregate.




**Figure 1**

70. Figure 2, below, illustrates how Acthar is prescribed, authorized, distributed and paid for through Express Scripts. Payment flows are represented by green arrows traveling from payor and patient to Mallinckrodt, while product flows are represented by black chevrons flowing from Mallinckrodt to the patient. Although these payments pass through Express

Scripts, payment flows and products flows are ultimately aligned between Mallinckrodt and UBC, Express Scripts' reimbursement hub, through a contract with Mallinckrodt to operate the ASAP program, which ostensibly operates to confirm the medical necessity of the prescription (by Accredo), to arrange payment (to ESI or CVS Caremark) for shipment (from CuraScript) of Acthar to patients. CuraScript has a contract with Mallinckrodt to ship Acthar. Through these contractual arrangements, Acthar travels from Mallinckrodt directly to the patient, and payments are channeled back to Mallinckrodt.

71. The patient, on the other hand, has prescription insurance coverage through his or her health plan. In this case, Rockford had the health plan that covered its two employees. The health plan has a contract with ESI, which requires ESI to collect payments for the price of Acthar. Acument similarly had a contract with CVS Caremark which covered its employees and his spouse. CVS Caremark is required to collect payments for the price of Acthar.

72. By these arrangements, Acthar product flows directly from Mallinckrodt through Express Scripts to the patient, while the money flows directly from the patient and payor through Express Scripts back to Mallinckrodt.



**Figure 2**

73. Wielding both the largest collection of patients in the United States and a direct shipment channel for specialty drugs, Express Scripts is in a unique position to negotiate the most competitive, discount prices for specialty drugs in the United States. This bargaining power has allowed Express Scripts to push back against attempts by pharmaceutical drug manufacturers to charge inflated prices for drugs above the actual market value of the drugs.

74. Mallinckrodt leveraged and enhanced its monopoly power by limiting the distribution of its sole specialty drug to just one specialty pharmacy distributor, CuraScript, and employing as its agents, ESI's Accredo and UBC, along with CuraScript, to coordinate all aspects of the distribution and sales of Acthar: from prescription by the physician, to direct home delivery to the patient, to direct reimbursement by the payor. This allowed Mallinckrodt to raise its prices tenfold initially, and nearly double in the ensuing years.

75. Mallinckrodt Executive Vice-President, Steve Cartt, admitted “[w]e did some market research,’ . . . [t]alking to physicians and others about pricing ‘gave us some comfort that

the [new] strategy would work, and physicians would continue to use the drug, and payers would pay’ . . . . ‘The reality was better than we expected.’ ” See Milt Freudenheim, *Benefit Managers Profit by Specialty Drug Rights*, New York Times, C1, April 19, 2008 (titled The Middleman’s Markup in New York Print Ed.).

**Rockford’s PBM Contract with Express Scripts**

76. In 2015, Rockford contracted with Express Scripts to provide pharmacy benefit services, among other things. ESI’s Vice President of its Commercial Division, David Brodsky, executed the agreement with Rockford on behalf of Express Scripts (hereinafter, the “ESI PBM Agreement”). The term of the ESI PBM Agreement was for three years, from the commencement date of January 1, 2015 and remains in force.

77. Under the ESI PBM agreement, ESI agreed to provide Rockford the following services:

- a. pharmacy network contracting;
- b. pharmacy claims processing;
- c. mail and specialty drug pharmacy;
- d. cost containment;**
- e. clinical programs;
- f. safety programs;
- g. adherence programs, and
- h. formulary and rebate administration.

These services were defined as “PBM Services” in the agreement (emphasis added).

78. ESI bargained with Rockford to serve as Rockford’s exclusive specialty pharmacy provider and distributor. Thus, under the contract, ESI became Rockford’s exclusive provider of



the above-stated PBM Services, including the supply of specialty drugs.

79. One of the specialty medications Rockford contracted for ESI to supply exclusively was Mallinckrodt's Acthar Gel injection. Acthar was listed as a "specialty drug" in the agreement, and was identified for use to treat "CNS disorders". Infantile spasms is a type of CNS disorder.

80. Rockford agreed to pay ESI certain reimbursement rates for specialty pharmacy drugs as established by ESI for each such drug. The reimbursement rates for each drug varied from a discount of 0% to 54.25%. For Acthar, Mallinckrodt charged Rockford at a discounted rate of 13.5% off the "average wholesale price", as set forth in the ESI PBM Agreement. Mallinckrodt set the average wholesale prices of Acthar used by Express Scripts for reimbursement.

81. In 2015, Mallinckrodt had Acthar shipped directly to the children of two Rockford employees (hereinafter identified as "Employee 1" and "Employee 2"). ESI then charged Rockford for the Acthar, pursuant to the terms of the ESI PBM Agreement. Rockford paid ESI such charges.

82. Despite its express obligation to provide "cost containment" as one of the contracted PBM Services, on April 1, 2015, ESI caused Acthar to be delivered to one of Rockford's employees and Rockford was charged \$100,457.64 for the 30-day supply of Acthar.

83. While "cost containment" is not a defined term in the ESI PBM Agreement, the plain meaning of the words denotes the act, process or means of keeping something within limits, and preventing the expansion of something. Here, the "something" which ESI contracted to "contain" was the "cost" of specialty pharmacy drugs, like Acthar. However, ESI charged Rockford \$488,787.84 for the sale of nine Acthar prescriptions to Rockford employees. These

charges by ESI were in breach of the obligation under the ESI PBM Agreement to provide cost containment.

84. Because Express Scripts had entered into an exclusive arrangement with the manufacturer of Acthar for direct distribution of Acthar to patients, ESI had no incentive to fulfill its contractual obligation to obtain a lower cost for Acthar than Mallinckrodt wished to charge. In other instances, including with other specialty pharmaceuticals covered by the ESI PBM Agreement, Express Scripts used its bargaining power to extract lower prices from the manufacturers. One such example, described below, involved Turing's Daraprim.

#### **ESI and Daraprim**

85. Turing Pharmaceuticals, LLC ("Turing") acquired the rights to Daraprim, and proceeded to increase the price 5000% from \$13.50 to \$750.00 per pill. One year's course of treatment rose from \$6,500 to \$361,000.

86. Strikingly, ESI employed its market power to counter Turing's action. It worked to create an alternative that was much less expensive than Daraprim.

87. On December 1, 2015, ESI announced that it would "partner with Imprimis Pharmaceuticals to drive access to a low-cost alternative to Daraprim." ESI, ESI Champions \$1 per Pill Access to an Alternative for Daraprim, Dec. 1 2015, <http://lab.express-scripts.com/lab/insights/drug-options/express-scripts-champions-1-per-pill-access-to-an-alternative-for-daraprim>. In partnership with ESI, "Imprimis [] offer[ed] a compounded oral formulation of pyrimethamine and leucovorin (a form of folic acid) for as low as \$1 per capsule for people whose pharmacy benefit is managed by ESI." *Id.* When it is in ESI's interest, it acts to "improve access and affordability." *Id.*

88. ESI's Chief Medical Officer, Dr. Steve Miller, stated that ESI had found a way to

deliver “a safe, high-quality and extremely cost-effective way to provide access to a Daraprim alternative.” However, because of its agreement with Mallinckrodt, ESI has not served as an effective agent for pharmaceutical buyers to seek to lower the cost of Acthar, or the availability of reasonably priced alternatives.

### **Acthar Pricing**

89. Mallinckrodt acquired the rights to Acthar from Aventis in 2001. At acquisition, the end payor price of a vial of Acthar was approximately \$40.00. After acquisition, Mallinckrodt raised the per vial, end payor price of Acthar to approximately \$748.00. From 2001 until Mallinckrodt executed its new strategy in 2007, the end payor price of Acthar grew to \$1,980.00.

90. When Mallinckrodt implemented its new strategy on August 27, 2007, the end payor price of Acthar rose to a staggering \$27,922.80 – a 1,310% increase in the span of a month, and a 69,707% increase from the time Mallinckrodt acquired the drug.

91. Until Mallinckrodt obtained FDA approval for the IS indication, the price of Acthar remained stable. However, in 2011, Mallinckrodt increased the price of Acthar 5% on January 3, 2011, another 5% on June 1, 2011, and executed a third price increase on December 27, 2011. In 2012, Acthar’s end payor price was \$34,150.00.

92. Near in time to Mallinckrodt plc’s \$5.9 billion acquisition of Questcor, in 2014, the price of Acthar rose to \$40,840.80. Under Mallinckrodt plc’s stewardship, the end payor price of Acthar rose in 2016 to \$42,942.60, and to \$43,658.40 in 2017.

93. Since the acquisition of Acthar in 2001, the end payor price of Acthar has grown 109,046% reflecting the precipitous rise in the value of the Acthar assets from \$100,000 in 2001 to \$5.9 billion in 2014 – a 5,899,900% increase in value. The dramatic increase in value of the

Acthar assets, coupled with the durable and repeated ability to raise the price of Acthar, underscore the monopoly power wielded by Mallinckrodt in the ACTH market. Mallinckrodt's tactics described in this Complaint, however, reflect Mallinckrodt's willingness to undertake actions to maintain and grow its monopoly in the ACTH market, in violation of the antitrust laws.

**The Views of Express Scripts' Chief Medical Officer,  
Dr. Steve Miller, on Express Scripts' Market Power**

94. Beginning in 2007, Express Scripts became the exclusive agent of Mallinckrodt for the distribution of Acthar. *See* Freudenheim, *supra*. When Mallinckrodt chose to increase the price of this 50-plus year old medication, Express Scripts did not push back. Instead, when confronted with the 2007 price increase, ESI's Chief Medical Officer Steve Miller stated that "[t]he increase was a manufacturing decision. I can't comment on it." *Id.*

95. The circumstances demonstrate why Dr. Miller chose to stay silent in the face of Express Scripts' decision to join Mallinckrodt in overcharging payors for Acthar.

96. By the time the Plaintiffs' beneficiaries were prescribed Acthar in 2015, Express Scripts was handling each and every aspect of Acthar distribution through the above-described functions. CuraScript was the exclusive specialty pharmaceutical distributor, Accredo was the specialty pharmacy provider, and UBC coordinated both the product and money flows through the ASAP Program. As Mallinckrodt's exclusive agent, Express Scripts had no interest in lowering the price for Acthar because it was making money off all aspects of its exclusive arrangement with the manufacturer. In other words, by helping Mallinckrodt maintain and enhance its monopoly power in the ACTH market, Express Scripts along with Mallinckrodt realized greater profits at the expense of payors, like Plaintiffs.

97. In the spring of 2017, ESI's Senior Vice President, Supply Chain and Specialty

Pharma, Everett Neville, stated “I don’t think [Acthar is] a very great [drug] – it’s a pretty poor drug with a very limited need and certainly [Express Scripts Chief Medical Officer, Dr.] Steve[Miller] could comment.” He went on to say “I think [Dr. Miller] and I both would agree, and **I think everybody in our company would agree, that [Acthar] is vastly overpriced for the value.**” (emphasis added). Mr. Neville went on to state that he “personally told [Mallinckrodt’s] management team that their drug is hugely overpriced and that he “know[s] [Dr. Miller] has as well.”

98. In the same public setting, Dr. Miller stated, “[i]f you look at the data, the indications for the drug are . . . in the compendium, it’s listed under a lot of indications, its real use should be very, very limited. It’s an old drug. There’s better products in the marketplace and so we’re going to continue to be very vigilant in our utilization management.”

99. Despite this express acknowledgment by Express Scripts’ Chief Medical Officer, in the weeks and months following Mallinckrodt’s settlement with the FTC, Express Scripts has not acted or made any efforts to contain costs or provide a reasonable alternative for Acthar.

100. Dr. Miller, Express Scripts Chief Medical Officer, has articulated the power of Express Scripts in the prescription drug marketplace to extract lower prices for its customers, using its tremendous buying power and influence. He has made all of the following public comments:

“When I joined the company, we represented 12 million members. We’re at 85 million today. That gives us extraordinary sway in the marketplace. If you think about any other aspect of health care, no one else has that many lives that they can represent.”<sup>7</sup>

---

<sup>7</sup> *Managed Care Magazine Online*, “A Conversation with Steve Miller, MD: Come in and Talk With Us, Pharma,” by Peter Wehrwein, April 2015, <https://www.managedcaremag.com/archives/2015/4/conversation-steve-miller-md-come-and-talk-us-pharma>

“We have tremendous scale, which allows us to get the best deals for our plan sponsors from both the pharmaceutical manufacturers and also the pharmacies. If any pharmacy chain ever becomes too large, we’re able to move our patients and ... get the lowest cost.”<sup>8</sup>

“I think that because of the continued escalation of cost, you need a PBM now more than ever. And what a best-in-class PBM like Express Scripts does really ensure is great health outcomes and more affordable costs.”<sup>9</sup>

“Pharma has shown that they feel very emboldened with their pricing power. We’re using our clout in the marketplace to really tamp these down for our clients.”<sup>10</sup>

“There are pharma companies that recognize this is in their best interest,” he says. “They, like us, want to get to a sustainable marketplace. They know if they’re overcharging for drugs that have very little efficacy, that puts them in a competitive disadvantage.”<sup>11</sup>

“Discussions to control costs have never been more important, as recent estimates put global drug spend at \$1.5 trillion by 2021, according to data from Quintiles IMS Holding. Yet sometimes, in the drug pricing debate, blame is placed on one part of the drug distribution system when, in fact, all of us – pharmaceutical companies, pharmacy benefit managers (PBMs), policymakers and payers – have a role to play in achieving better affordability and accessibility for medicine. As the largest PBM, our job is to make sure our patients, and our clients who provide them a pharmacy benefit, are getting medicines at the lowest net cost while working with

---

<sup>8</sup> *Business Insurance*, “Q&A: Dr. Steve Miller, Express Scripts Holding Co.,” by Shelby Livingston, May 22, 2016, <http://www.businessinsurance.com/article/00010101/STORY/305229991/Q&A-Dr-Steve-Miller,-Express-Scripts-Holding-Co>

<sup>9</sup> *Managed Care Magazine Online*, “A Conversation with Steve Miller, MD: Come in and Talk With Us, Pharma,” by Peter Wehrwein, April 2015, <https://www.managedcaremag.com/archives/2015/4/conversation-steve-miller-md-come-and-talk-us-pharma>

<sup>10</sup> *Nightly Business Report*, “Express Scripts Looks to Limit Drug Price Increases,” by Meg Tirrell, October 2, 2015, <http://nbr.com/2015/10/07/express-scripts-looks-to-limit-drug-price-increases/>

<sup>11</sup> *Medical Marketing and Media*, “Express Scripts’ Steve Miller Takes on Drug Industry in Pricing Battle,” by Jaimy Lee, February 1, 2015, <http://www.mmm-online.com/payersmanaged-markets/express-scripts-steve-miller-takes-on-drug-industry-in-pricing-battle/article/460559/>

our industry partners to make that possible.”<sup>12</sup>

“...[I]t is incumbent upon the pharmacy benefits managers to more forcefully illustrate the critical role we play in making medicine more affordable and accessible. For example, we partnered with a drug maker who was willing to lower the price of its hepatitis C drug. In doing so, we were able to provide 50,000 patients affordable access to this medication.”<sup>13</sup>

“The biggest problem is not new expensive drugs but repricing old ones, and not just ones being purchased by Martin Shkreli or Valeant. ‘You have no new research. You have no innovation. You have nothing but increased drug prices.’”<sup>14</sup>

“We are constantly trying to be vigilant and chase the bad actors out of the marketplace.”<sup>15</sup>

101. Through such statements, Express Scripts acknowledged its strong influence on pharmaceutical markets. The striking feature of the current circumstance is that Express Scripts has not asserted its influence to effectuate lower prices for Acthar.

102. While acknowledging the “value” of the medication does not warrant its high prices, Express Scripts has facilitated, rather than forestalled, Mallinckrodt’s desire for ever growing profits by “repricing” an “old drug”.

---

<sup>12</sup> *Real Clear Health*, “Is Drug Pricing at an Inflection Point?” by Dr. Steve Miller, April 14, 2017, [http://www.realclearhealth.com/articles/2017/04/14/is\\_drug\\_pricing\\_at\\_an\\_inflection\\_point\\_110550.html](http://www.realclearhealth.com/articles/2017/04/14/is_drug_pricing_at_an_inflection_point_110550.html)

<sup>13</sup> *Real Clear Health*, “Is Drug Pricing at an Inflection Point?” by Dr. Steve Miller, April 14, 2017, [http://www.realclearhealth.com/articles/2017/04/14/is\\_drug\\_pricing\\_at\\_an\\_inflection\\_point\\_110550.html](http://www.realclearhealth.com/articles/2017/04/14/is_drug_pricing_at_an_inflection_point_110550.html)

<sup>14</sup> *Forbes, Pharma & Healthcare*, “Solving Pharma’s Shkreli Problem,” by Matthew Herper, January 20, 2016, <https://www.forbes.com/sites/matthewherper/2016/01/20/solving-pharmas-shkreli-problem/#6dcce78c6be3>

<sup>15</sup> The New York Times, “Specialty Pharmacies Say Benefit Managers Are Squeezing Them Out,” by Katie Thomas, January 9, 2017, <https://www.nytimes.com/2017/01/09/business/specialty-pharmacies-say-benefit-managers-are-squeezing-them-out.html>

103. With Acthar, “[y]ou have nothing but increased drug prices,” due in large part to Express Scripts’ decision to withhold its market power to effectuate cost containment through lower prices.

#### **THE MALLINCKRODT SYNACTHEN ACQUISITION**

104. Since 2007, Acthar has represented 98% or more of Mallinckrodt’s revenue. Acthar was so important to Questcor that its then-CEO, Don Bailey told investors it “is basically a single product company.”

105. Through its exorbitant price increases, Mallinckrodt was able to grow its revenue from Acthar sales from less than \$1 million in 2001 to \$798.9 million in 2013. Much of this increase occurred between 2011 and 2013 when Mallinckrodt’s revenues increased \$218.2 million to \$798.9 million.

106. However, by 2013, Mallinckrodt had identified a competitive threat. Novartis AG (“Novartis”) had developed Synacthen Depot (cosyntropin depot) (“Synacthen”), a synthetically derived ACTH medication, which, like Acthar, could be injected intra-muscularly. While it was used outside the United States, it was not yet approved by the FDA for use in the United States. Recognizing that the entry of Synacthen in the U.S. market for ACTH drugs would threaten its exercise of its monopoly power, Mallinckrodt first attempted to buy the rights to Synacthen in 2009. It failed.

107. As of 2013, Novartis agreed to sell Synacthen to Retrophin, Inc., which at the time was helmed by Mr. Shkreli. Mr. Shkreli founded Turing (the maker of Daraprim) after he departed Retrophin.

108. When faced with a competitive threat to its monopoly, Mallinckrodt disrupted the bidding process for Synacthen by intervening at the last minute to pay multiple times what had



been offered by three competitors, including Retrophin. Retrophin had agreed to buy Synacthen for \$16 million. Upon learning of this imminent threat, Mallinckrodt acted to protect and enhance its monopoly power by licensing Synacthen for a minimum of \$135 million from Novartis. It licensed the U.S. exclusive rights to Synacthen from Novartis, not to bring this viable synthetic alternative to Acthar to market, but to eliminate the nascent competitive threat posed by an independently owned Synacthen.

109. These actions allowed Mallinckrodt to maintain and enhance its monopoly power in the ACTH market. The Synacthen acquisition had the purpose and effect of suppressing competition and allowing Mallinckrodt to continue to raise prices for Acthar, which it did.

110. From 2013 through 2017, Mallinckrodt raised the price of Acthar from \$36,144 to \$43,658.

**RELEVANT MARKETS AND MONOPOLY POWER,  
AND THE FTC COMPLAINT AGAINST MALLINCKRODT**

111. The supracompetitive and exorbitant prices that Mallinckrodt charges for Acthar, and its limitations on distribution through the entry into an exclusive distribution arrangement with Express Scripts in 2007, are direct evidence of Mallinckrodt's monopoly power and actions to maintain and enhance such monopoly power, in violation of the antitrust laws. That Acthar holds a dominant share of the relevant market for ACTH drugs in the United States shows Mallinckrodt's monopoly power by indirect evidence.

112. The relevant product market is the sale of ACTH drugs, dominated by just one product, Acthar. The geographic market is the United States. In this market, Mallinckrodt is the single seller, and the third party payors are the leading buyers.

113. That market is and has been characterized by significant barriers to entry.

114. There are no medical or reasonably available substitutes for Acthar. The only

potential substitute was Synacthen, which Mallinckrodt purchased the rights to from Novartis in 2013, only to shelve the product rather than seek to bring it to market in the United States.

115. On January 18, 2017, the Federal Trade Commission (“FTC”) sued Mallinckrodt, alleging that Mallinckrodt exercised, and continues to exercise, monopoly power in the United States in the sale of Acthar. *See generally*, Complaint for Injunctive Relief and Other Equitable Relief (“FTC Complaint”) at Exhibit “B” to the original Complaint (Dkt. No. 1-2, filed 04/06/17).

116. The FTC alleged that such purchases “extinguished a nascent competitive threat to [Mallinckrodt’s] monopoly.” FTC Complaint, ¶ 1.


117. At all relevant times material to this case, Mallinckrodt possessed monopoly power—the ability to profitably raise price significantly above competitive levels without losing significant sales—in the relevant product market. None of the vast price increases taken by Mallinckrodt between 2007 and the present have caused a significant loss of sales. To the contrary, Mallinckrodt’s sales have increased during that time.

118. Mallinckrodt has repeatedly and profitably raised Acthar’s price from the time it acquired the product for \$100,000 in 2001 from Aventis to the present. Mallinckrodt has been able to raise prices unchecked, as set forth above, and achieve corresponding revenue growth to more than \$1 billion.

119. Mallinckrodt has encountered no competitive constraints on its ability to repeatedly increase Acthar’s price and, by extension, its revenue and profit margins. Mallinckrodt does not set the price of Acthar in reference to the price of any of the other drugs that are prescribed to treat the same indications that Acthar treats. Acthar is priced significantly higher than non-ACTH drugs used to treat the same indications, except for IS.

120. Indeed, one Mallinckrodt executive commented that the price for Acthar “was chosen by looking at the prices of other specialty drugs and estimating how much insurers and employers would be willing to bear.” Mallinckrodt took “some comfort that the strategy would work, and physicians would continue to use the drug, and payers would continue to pay.” In fact, according to Mallinckrodt, “reality was better than expected.”

121. In its Annual Report on Form 10-K for the Fiscal Year ended December 31, 2007,



	Cumulative Total Return*					
	12/02	12/03	12/04	12/05	12/06	12/07
QUESTCOR PHARMACEUTICALS, INC.	100.00	75.51	54.08	106.13	151.02	588.78
AMEX COMPOSITE INDEX	100.00	143.18	175.20	215.26	257.04	299.37
NASDAQ PHARMACEUTICAL INDEX	100.00	144.89	160.46	160.65	163.42	154.46

\* \$100 invested on 12/31/02 in stock or index-including reinvestment of dividends. Fiscal year ended December 31.

This stock performance graph shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Questcor illustrated the effect of its monopolization strategy on its “5 Year Cumulative Total Return”, illustrating a 290% return between 2006 and 2007 as follows:

122. FDA approval is required to market pharmaceuticals to U.S. consumers. As a result, drugs sold outside of the United States are not viable competitive alternatives for U.S. consumers, even in the event of a significant price increase for ACTH drugs available in the

United States.

123. Acthar has a 100% share of the market for ACTH drugs in the United States. No other ACTH drug is FDA-approved for therapeutic use.

124. The United States ACTH market is characterized by high barriers to entry. Developing a long-acting, depot-injection formulation of a drug product containing ACTH (natural or synthetic) that is stable, safe, and effective would require significant time, cost, and effort, with no guarantee of success. The requirements for entry include sourcing the active pharmaceutical ingredient, formulating a sustained-release depot-injection formulation, scaling production to clinical scale, and successfully conducting clinical trials necessary for FDA approval. Mallinckrodt's former CEO Don Bailey assured investors that Acthar "has significant durability in the marketplace" because "it will be very difficult for this product to be replicated in any way [by] a generic."

125. Former CEO Don Bailey also claimed that one of the barriers to entry is the Acthar drug formulation. While Acthar is a biologic extraction of porcine pituitaries, Bailey claimed, "[i]t's an undisclosed composition, so that's a trade secret." He also claimed "[t]he manufacturing process is also a trade secret. It's complex, it's unique, and we own all elements of the manufacturing process. ...The composition of Acthar that comes out of the manufacturing process is tied to the process, so if you don't know the process you can't figure out what's actually in Acthar."

126. If what the former CEO was saying was that Questcor enjoyed a natural monopoly, that does not necessarily imply the absence of market constraints. These constraints can come from a new competitive product or from a dominant buyer on the other side of the market. Both of these factors are relevant here.

**Mallinckrodt Engaged in Anticompetitive Conduct By Acquiring the Only  
Competitor Drug, Synacthen**

127. Synacthen posed a threat to Mallinckrodt's ACTH drug monopoly, so Questcor intervened at the time when other firms were attempting to acquire the U.S. rights to Synacthen from Novartis. Questcor submitted a bid that included substantially more guaranteed money than the other bidders had offered, effectively ending the bidding process. By acquiring Synacthen, Questcor eliminated the possibility that another firm would develop it and compete against Acthar.

128. Synacthen constituted a nascent competitive threat to Questcor's ACTH drug monopoly, notwithstanding the uncertainty that Synacthen, a preclinical drug, would be approved by the FDA.

129. For years, Questcor viewed Synacthen as a significant potential competitive threat to its monopoly.

130. When Questcor first decided to pursue an "orphan drug" (*i.e.*, high) pricing model for Acthar, it recognized the potential threat Synacthen posed to Acthar's revenue growth.

131. Nevertheless, in 2007, it adopted and pursued the above-described "new strategy", consolidating Acthar distribution to just one distributor and streamlining its control over sales and distribution through the implementation of ASAP. These functions were consolidated in one significant company, Express Scripts.

132. In 2009, Questcor approached Novartis about acquiring Synacthen. At that time, Questcor continued to view Synacthen as a possible future competitor, especially given the increasing prices Questcor was commanding for Acthar. Unsuccessful in that initial attempt, Questcor continued to monitor the competitive threat from Synacthen.

133. Then in 2012, Questcor again concluded that Synacthen posed a more immediate

threat to Acthar if Synacthen was approved for sale in the United States.

134. By 2013, Questcor feared that if another company were to acquire Synacthen and obtain FDA approval, it could undermine its business model.

135. On information and belief, as long as Questcor believed no other firm was seeking to bring Synacthen to the United States, Questcor did not make further attempts to acquire it. Indeed, just months before Questcor began pursuing the acquisition of Synacthen, top Questcor officials questioned whether Synacthen would provide any affirmative value to Questcor.

**Other Bidders Planned to Use Synacthen to Challenge Acthar's Monopoly**

136. Unbeknownst to Questcor at the time, Novartis decided in late 2011 to divest exclusive rights to seek FDA approval for Synacthen and commercialize it in the United States, along with the marketing rights for Synacthen in over thirty-five other countries where the drug was already approved and sold. Dozens of companies contacted Novartis and expressed interest in acquiring Synacthen. Three firms proceeded through several rounds of negotiations with Novartis, submitted formal offers, and drafted near-final agreements.

137. It is alleged that each of the three firms planned to develop Synacthen for IS and to use Synacthen to compete directly with Acthar. With this indication, each firm expected to capture a significant share of the U.S. ACTH market from Questcor by pricing Synacthen below Acthar's prices. Having the requisite pharmaceutical expertise and financing, the three firms independently conducted due diligence, crafted business plans and regulatory approval strategies, and took other affirmative steps in furtherance of developing Synacthen for the U.S. ACTH market.

### **The Value of the Synacthen Assets**

138. The Synacthen assets and related rights provide a proven formulation for a long-acting, depot-injection drug containing synthetic ACTH. The drug product manufactured using the Synacthen formulation has been safely and effectively used to treat patients suffering from IS and other conditions worldwide for decades. The Synacthen assets would therefore facilitate commercializing a synthetic ACTH therapy in the United States.

139. The asset package being sold by Novartis included valuable trade secrets, including technical documentation detailing both the precise formulation for the Synacthen drug product and the manufacturing process.

140. In possession of the Synacthen assets, a buyer would not need to create a synthetic ACTH drug formulation *de novo*, nor would it need to develop from scratch the manufacturing and testing protocols necessary for production of the drug product.

### **Questcor Disrupted the Synacthen Bidding Process**

141. It is alleged that, on October of 2012, Questcor learned that at least one unidentified firm was attempting to acquire Synacthen from Novartis to develop it to compete with Questcor for the U.S. ACTH market. Questcor immediately reached out to Novartis, signed a confidentiality agreement with Novartis, and submitted a confidential offer for the purchase of Synacthen.

142. Novartis negotiated with the three alternative bidders in parallel with Questcor. By the spring of 2013, all three of the alternative bidders had submitted offers for Synacthen, with plans to develop and launch Synacthen in the United States in direct competition with Acthar. At the point where those negotiations left off, each company exchanged deal terms with Novartis and submitted formal offers. The offers by the three alternative bidders were

comparable in value and structured similarly, and included an upfront payment, milestone payments upon FDA approval, and significant royalties on U.S. sales of Synacthen.

143. Unlike the three alternative bidders, Questcor had only incomplete plans for Synacthen and conducted limited due diligence when it submitted its initial offer to Novartis. Retrophin ultimately prevailed in the bidding war with a bid of \$16 million.

144. However, on June 11, 2013, the day Retrophin was to sign its agreement with Novartis, Questcor and Novartis entered into a Licensing Agreement, Asset Purchase Agreement, and Supply Agreement (collectively, “the Agreements”). By the Agreements, Questcor gained the exclusive rights to develop, market, and sell Synacthen in the United States and over thirty-five other countries. Under the Agreements, Questcor is obligated to pay a minimum of \$135 million, and likely will pay \$300 million to Novartis for Synacthen.

145. In other words, Questcor swept in at the eleventh hour to overpay—at least 8 times more than the market had determined—for the only immediate competitive threat to its monopoly for Acthar. Despite paying this amount, they did not seek FDA approval to bring the product to market.

#### **The Lawsuit Between Retrophin and Questcor for Questcor's Antitrust Violations**

146. In January 2014, Retrophin sued Questcor for antitrust violations in the United States Federal District Court for the Central District of California. *See* Retrophin, Inc., v. Questcor Pharmaceuticals, Inc., CV-14-00026-JLS (C.D.Cal) (“Retrophin Complaint”) (attached to the Complaint and this, Second Amended Complaint at Exhibit “C”). (To the extent relevant to Plaintiff’s Complaint, the averments of antitrust conduct interposed by Retrophin are incorporated by reference herein).



147. In the Retrophin Complaint, Retrophin claimed,

"[i]n June of 2013, plaintiff Retrophin was poised to challenge Questcor's monopoly. It had negotiated an agreement to purchase from Novartis AG ("Novartis"), the rights to sell in the US a product called Synacthen. ...

Retrophin planned to obtain FDA approval to sell Synacthen in the US and compete head to head against Questcor by dramatically undercutting Questcor's price for Acthar. It had negotiated and was ready to sign an agreement to purchase the US rights to Synacthen from Novartis. The signing was scheduled for June 11, 2013. The signing of the agreement was so imminent that a press release had been prepared to announce the deal.

On June 11, 2013, the day Retrophin was to sign its agreement with Novartis, Questcor swept in and acquired the rights to Synacthen. In doing so, it preserved and entrenched its ACTH monopoly in US and eliminated the competitive threat posed by Retrophin's acquisition of Synacthen. There was no procompetitive aspect of Questcor's acquisition of Synacthen.

Retrophin Complaint, ¶¶ 4-6, at Exhibit "C" to the original Complaint (Dkt. No. 1-3, filed 04/07/17).

148. The FTC apparently agreed with Retrophin's assessment.

149. Nevertheless, the government, in its 2017 FTC complaint, mirrored Retrophin's 2014 allegations that Questcor engaged in anticompetitive conduct in violation of the antitrust laws.

150. Mallinckrodt chose to settle the Retrophin lawsuit for \$15.5 million, slightly less than the \$16 million Retrophin bid to purchase Synacthen from Novartis.

**Mallinckrodt's Acquisition of Synacthen Harmed Competition**

151. Mallinckrodt's strategy to protect its monopoly power in the market for ACTH drugs was successful. But for Mallinckrodt's acquisition of Synacthen, one of the three alternative bidders, including Retrophin, would have acquired Synacthen and pursued its plan to

develop Synacthen for IS to compete directly with Acthar at a lower price. With the acquisition of Synacthen, Mallinckrodt was able to thwart an imminent threat to its Acthar monopoly and thereby harmed competition.

152. Mallinckrodt claimed that it acquired Synacthen to develop it for new, non-Acthar indications, but given the similarities between the two drugs, any therapeutic indication that Mallinckrodt was to pursue for Synacthen could easily have been pursued for Acthar.

153. Fourteen months after acquiring Synacthen, Mallinckrodt acquired Questcor for \$5.9 billion. The vast majority of Questcor's value was attributable to Acthar and Synacthen.

154. However, despite its claims, Mallinckrodt has not brought Synacthen to market for any indication. Instead, it keeps Synacthen off the market to protect its monopoly power and high prices for Acthar.

#### **Mallinckrodt settles with the FTC**

155. On January 18, 2017, the FTC announced that Questcor and its parent Mallinckrodt agreed to pay \$100 million to settle FTC charges that Questcor and Mallinckrodt violated antitrust laws when Questcor acquired the rights to Synacthen from Novartis in 2013.

156. According to FTC Chairwoman Edith Ramirez, "Questcor took advantage of its monopoly to repeatedly raise the prices of Acthar, from \$40 in 2001 (when it acquired the rights to sell Acthar for \$100,000) to more than \$34,000 per vial today – an 85,000 percent increase."

157. The brunt of these monopoly prices was borne by self-funded payors, like Plaintiffs, located throughout the country, whose employees and beneficiaries whom were at the mercy of Mallinckrodt and treated with Acthar.

158. From the time it sought FDA approval for the treatment of IS, Mallinckrodt has raised the price of Acthar to over \$43,000.

159. Questcor claimed that these exorbitant price increases were in response to demand. But its former Chief Executive Officer, Don Bailey, acknowledged in 2009 that “we only have about 800 patients a year. It’s a very, very small – tiny – market.” Consequently, the limited use of the product did not justify an over 58,000% price increase from acquisition until 2009.

160. Since the Acthar market for the treatment of IS was so limited, Questcor sought to expand its use. By 2012, Acthar was prescribed for Medicare recipients 3,387 times. To Medicare alone, this represented a cost of \$141,500,000 in 2012.

161. Quantified another way, Dr. William Shaffer, a neurologist in Greeley, Colorado who was the highest prescriber of Acthar in 2012, wrote only 78 prescriptions for the drug, but the prescribed Acthar cost Medicare \$4,000,000.

162. Acthar represented 98% or more of Questcor’s sales and revenue from sales since 2007. Its manipulation of the market has resulted in a 266% increase in revenue year-over-year from 2011 to 2013. Total net sales for Questcor in 2011 were \$218.2 million, \$509.3 million in 2012, and \$798.9 million in 2013. In each of those years, Acthar represented at least 95% of Questcor’s net sales – over \$1.45 billion in revenue.

163. In the words of former CEO Don Bailey “Questcor is basically a single-product company.” But, by flexing its monopoly power, Questcor has been able to raise Acthar prices and increase revenue from Acthar in a “tiny market” from less than \$1 million for fiscal 2001 to \$799 million for fiscal 2013 - a nearly 80,000% increase. It did so in conjunction with Express Scripts.

164. Mallinckrodt's decision to exclusively contract with the agent for its largest customer to provide limited distribution for Acthar removed ESI’s competitive pressure in the

marketplace to cause Acthar prices to be lower. Instead, by entering into an exclusive arrangement with Express Scripts, Mallinckrodt was able to enhance its monopoly power and to raise its Acthar prices above competitive prices throughout the relevant time period from 2007 through the present.

### **CLASS ACTION ALLEGATIONS**

165. Plaintiffs bring this action pursuant to Rules 23(a), (b)(2) and (b)(3) of the Federal Rules of Civil Procedure, on behalf of itself and other similarly-situated persons and entities, and their beneficiaries, in Illinois and throughout the country. The proposed Class includes:

All third party payors and their beneficiaries in the United States and its Territories that paid for Acthar from August 2007 through the present.

Excluded from the above Class are: (a) Defendants and any entity in which Defendants have a controlling interest, and their legal representatives, offices, directors, assignees and successors, (b) any co-conspirators with Defendants, (c) any Medicare Advantage Organization (“MAU”), their representatives, assignors, assignees or related entities, and (d) the States of Alaska, Maryland, New York, Texas and Washington.

#### **Numerosity**

166. The proposed Class consists of potentially hundreds of public and private payors in the proposed Class located throughout Illinois and the United States, based on the fact that Mallinckrodt has sold thousands of vials of Acthar in each quarter over the last few years alone. Thus, the Class is so numerous that joinder of all of its members is impractical.

167. Despite the size of the Class, its members are easily identifiable, as each patient was required by Defendants since 2007 to fill out an Acthar Start Form (Exhibit “A” hereto) which forms were returned to, and have been maintained by, Express Scripts and/or UBC. As a

result, the records needed to identify the members of the Class are in the hands of the Defendants.

Typicality

168. Plaintiffs' claims are typical of the claims of the Class, in that the representative Plaintiffs are entities whom, like other Class Members, paid for Acthar at the inflated prices due to the unlawful conduct of the Defendants. Plaintiffs, like all similarly-situated Class members, are damaged and sustained or continue to sustain economic injuries in the form of overcharges by the misconduct of the Defendants, because it paid higher prices than it would have paid absent Defendants' improper actions.

Adequacy of Representation

169. Plaintiffs can and will fairly and adequately represent and protect the interests of the Class. Plaintiffs have no interest that conflicts with or is antagonistic to the interests of the Class.

170. Plaintiffs are represented by counsel who are experienced and competent in the prosecution of complex actions, including antitrust, RICO and consumer fraud class actions.

Commonality

171. The factual and legal bases for the Defendants' misconduct are common to Class members and represent a common thread of antitrust racketeering and consumer fraud resulting in injury to Plaintiffs and the Class. Common questions of law and fact in this case include, but are not limited to, the following:

- a. whether the Defendants artificially inflated the prices of Acthar;
- b. whether Plaintiffs and the Class have been overcharged and thus damaged by paying artificially inflated prices for Acthar as a result of the unlawful conduct of Defendants;

- c. whether the Defendants have been unjustly enriched by their unlawful conduct;
- d. whether the Defendants defrauded Plaintiffs and the Class;
- e. whether the Defendants engaged in a conspiracy and/or concerted conduct in deceiving and defrauding Plaintiffs and the Class about Acthar and Acthar pricing, and concealing the truth about their unlawful conduct in colluding to artificially inflate the prices of Acthar;
- f. whether Defendants had a monopoly in the market for ACTH drugs;
- g. whether Mallinckrodt exercised monopoly power with respect to Acthar;
- h. whether Defendants took actions to maintain and enhance Mallinckrodt's monopoly power in the ACTH market;
- i. whether Defendants unlawfully impaired or impeded competition in the market for ACTH drugs;
- j. whether Defendants engaged in anticompetitive conduct in order to disadvantage Mallinckrodt's competitors and maintain Mallinckrodt's monopoly power in the market for ACTH drugs;
- k. the effects of Mallinckrodt's anticompetitive conduct on Acthar prices;
- l. whether Mallinckrodt formed the ASAP enterprise with Express Scripts for the purpose of carrying out the scheme to overcharge patients and payors for Acthar;
- m. whether Defendants used the U.S. mails and interstate wire facilities to carry out an unfair ASAP scheme;
- n. whether the Defendants are liable to Plaintiffs and the Class for statutory damages for conduct actionable under the Illinois Consumer Fraud and Deceptive Practices Act, and the antitrust and consumer protection laws of other states;
- o. whether Plaintiffs and members of the Class are entitled to declaratory and injunctive relief as to Defendants' conduct;
- p. whether Plaintiffs and members of the Class are entitled to compensatory damages, and, if so, the nature of such damages;
- q. whether Plaintiffs and members of the Class are entitled to statutory damages, including treble damages;

- r. the proper measure of damages; and
- s. whether Plaintiffs and members of the Class are entitled to an award of punitive damages, reasonable attorneys' fees, prejudgment interest, post-judgment interest, costs of suit, and other appropriate relief under the circumstances of this case.

Predominance

172. These questions of law and fact common to the members of the Class predominate over questions, if any, that may affect only individual members because Defendants have acted and refused to act on grounds generally applicable to the entire Class. Such generally applicable conduct is inherent in Defendants' anticompetitive conduct in monopolizing and attempting to monopolize the ACTH drug market, and other conduct as more fully alleged herein.

Superiority

173. A class action is superior to any other available method for the fair and efficient adjudication of this controversy in that, among other things, such treatment will permit a large number of similarly situated persons and entities to prosecute their common claims in a single forum simultaneously, efficiently, and without the unnecessary duplication of effort and expense that numerous individual actions would engender.

174. The prosecution of separate actions by individual members of the Plaintiffs Class would create a risk of inconsistent or varying adjudications with respect to individual members of the Class. These adjudications would establish incompatible standards of conduct for the Defendants which would, as a practical matter, be disparities of the claims of the other members not parties to the adjudications or substantially impair or impede their ability to protect their interests.

175. The Defendants have acted or refused to act on grounds generally applicable to all members of the Class, thereby making appropriate final injunctive relief or corresponding declaratory relief with respect to the Class as a whole.

176. Accordingly, class certification is appropriate under Rule 23(b)(1)(A), 23(b)(1)(B), 23(b)(2) and 23(b)(3).

**COUNT I**  
**CITY OF ROCKFORD v. EXPRESS SCRIPTS**  
**UNJUST ENRICHMENT**

177. Rockford hereby incorporates by reference the averments of the foregoing paragraphs as if fully set forth herein and further alleges as follows.

178. This Count alleges unjust enrichment against Express Scripts.

179. Rockford agreed to retain Express Script's services exclusively and in good faith and in reasonable reliance on Express Script's conduct and representations described herein.

180. Among other things, Rockford at all times had a reasonable expectation that Express Scripts' conduct would result in affordable services, including "cost containment" for specialty drugs like Acthar.

181. Rockford and its beneficiaries made direct payments to Express Scripts which were valuable to Express Scripts, and Express Scripts was unjustly enriched by such direct payments, in that, the reimbursement rates charged by Express Scripts at extremely high prices with inequitable discounts were valuable and beneficial to Express Scripts.

182. By engaging in the conduct described in this Second Amended Class Action Complaint, Express Scripts has knowingly obtained benefits from Rockford and the Class, namely grossly inflated revenue from its direct involvement in coordinating all aspects of Rockford's receipt of and payments for Acthar, under circumstances such that it would be



inequitable and unjust for Express Scripts to retain such benefits.

183. By engaging in the unlawful conduct described herein, Express Scripts has been knowingly enriched by the amount charged for Acthar over and above what it could have charged in a competitive market, wherein Express Scripts would use its market power to extract lower prices from Mallinckrodt, in fulfillment of its obligation to contain costs, what it could have charged if it had engaged in appropriate cost containment measures.

184. By assisting Mallinckrodt in maintaining and enhancing its monopoly, and its exercise of monopoly power through increasing prices over a decade, and engaging in other unlawful acts and practices, Express Scripts was able to extract exorbitant revenue from Rockford and the Class beyond what it could have received in the absence of such unlawful conduct. This conduct violated the federal and state antitrust laws, federal RICO and state consumer fraud and antitrust laws, as well as the common law of Illinois and other states and, as such, interfered with the legally protected interests of Rockford and the Class.

185. Rockford and each member of the Class are therefore entitled to an award of compensatory damages in an amount to be determined at trial, or the imposition of a constructive trust upon the monies derived by the Defendants by means of the above-described actions.

**WHEREFORE**, Rockford demands that judgment be entered in its favor, and in favor of the Class, and against Express Scripts, in an amount to be determined at trial, including but not limited to costs, attorneys' fees, and such other relief deemed just and appropriate by this Court.

**COUNT II**  
**CITY OF ROCKFORD v. MALLINCKRODT**  
**UNJUST ENRICHMENT**

186. Rockford hereby incorporates by reference the averments of the foregoing paragraphs as if fully set forth herein and further alleges as follows.

187. This Count alleges unjust enrichment against Mallinckrodt.

188. Rockford's covered beneficiaries received direct shipments of Acthar from Mallinckrodt via its exclusive distribution mechanism established with Express Scripts. In exchange for such Acthar, Rockford made direct payments to Express Scripts for the benefit of Mallinckrodt. Indeed, such payments were transferred by Express Scripts to Mallinckrodt pursuant to an understanding between the two that the total amount would be forwarded to Mallinckrodt, less a certain amount previously agreed to by Mallinckrodt and Express Scripts. The amount charged by Mallinckrodt for the Acthar was the amount paid by Rockford, pursuant to its agreement with Express Scripts.

189. The amounts paid by Rockford were valuable to Mallinckrodt and Mallinckrodt was unjustly enriched by such direct payments, in that, the reimbursement rates charged by Mallinckrodt at extremely high prices were valuable and beneficial to Mallinckrodt.

190. By engaging in the conduct described in this Second Amended Class Action Complaint, Mallinckrodt has knowingly obtained benefits from Plaintiffs and the Class, namely grossly inflated revenue from its direct involvement in coordinating all aspects of Rockford's receipt of and payments for Acthar, under circumstances such that it would be inequitable and unjust for Mallinckrodt to retain such benefits.

191. By engaging in the unlawful conduct described herein, Mallinckrodt has been knowingly enriched by the amount charged for Acthar over and above what it could have charged in a competitive market and what it could have charged if it had engaged in appropriate cost containment measures.

192. By maintaining and enhancing its monopoly, and its exercise of monopoly power through increasing prices over a decade, and engaging in other unlawful acts and practices,

Mallinckrodt was able to extract exorbitant revenue from Rockford and the Class beyond what it could have received in the absence of such unlawful conduct. This conduct violated the federal and state antitrust laws, federal RICO and state consumer fraud and antitrust laws, as well as the common law of Illinois and other states and, as such, interfered with the legally protected interests of Rockford and the Class.

193. Rockford and each member of the Class are therefore entitled to an award of compensatory damages in an amount to be determined at trial, or the imposition of a constructive trust upon the monies derived by the Defendants by means of the above-described actions.

**WHEREFORE**, Rockford demands that judgment be entered in its favor, and in favor of the Class, and against Mallinckrodt, in an amount to be determined at trial, including but not limited to costs, attorneys' fees, and such other relief deemed just and appropriate by this Court.

**COUNT III**  
**ACUMENT v. MALLINCKRODT**  
**UNJUST ENRICHMENT**

194. Plaintiffs hereby incorporate by reference the averments of the foregoing paragraphs as if fully set forth herein and further alleges as follows.

195. This Count alleges unjust enrichment against Mallinckrodt.

196. Acument's covered beneficiary received direct shipments of Acthar from Mallinckrodt via CVS Caremark. In exchange for Acthar, Acument made direct payments to CVS Caremark for the benefit of Mallinckrodt. Indeed, such payments were transferred by CVS Caremark to Mallinckrodt pursuant to a likely understanding between the two that the total amount would be forwarded to Mallinckrodt, less a certain amount previously agreed to by Mallinckrodt and CVS Caremark. The amount charged by Mallinckrodt for the Acthar was the amount paid by Acument, less any applicable co-pays by the beneficiary.

197. The amounts paid by Acument were valuable to Mallinckrodt and Mallinckrodt was unjustly enriched by such payments, in that, the prices charged by Mallinckrodt at extremely high prices were valuable and beneficial to Mallinckrodt.

198. By engaging in the conduct described in this Second Amended Class Action Complaint, Mallinckrodt has knowingly obtained benefits from Plaintiffs and the Class, namely grossly inflated revenue from its coordination all aspects of Acument's receipt of and payments for Acthar, under circumstances such that it would be inequitable and unjust for Mallinckrodt to retain such benefits.

199. By engaging in the unlawful conduct described herein, Mallinckrodt has been knowingly enriched by the amount charged for Acthar over and above what it could have charged in a competitive market.

200. Mallinckrodt was able to extract exorbitant revenue from Acument and the Class beyond what it could have received in the absence of such unlawful conduct. This conduct violated the federal and state antitrust laws, federal RICO and state consumer fraud and antitrust laws, as well as the common law of Tennessee and other states and, as such, interfered with the legally protected interests of Acument and the Class.

201. Acument and each member of the Class are therefore entitled to an award of compensatory damages in an amount to be determined at trial, or the imposition of a constructive trust upon the monies derived by the Defendants by means of the above-described actions.

**WHEREFORE**, Acument demands that judgment be entered in its favor, and in favor of the Class, and against Mallinckrodt, in an amount to be determined at trial, including but not limited to costs, attorneys' fees, and such other relief deemed just and appropriate by this Court.

**COUNT IV**  
**PLAINTIFFS v. ALL DEFENDANTS**  
**FRAUD**

202. Plaintiffs hereby incorporate by reference the averments of the foregoing paragraphs as if fully set forth herein and further allege as follows.

203. Defendants' acts violate the common law against negligent misrepresentation and fraud.

204. In setting the prices for Acthar, which prices Plaintiffs paid, the Defendants made material misrepresentations that those prices represented a calculation of real and fact-based prices for their drugs, and that they represented the actual value of the product in the marketplace.

205. These representations were material to the transactions at hand in that Plaintiffs and the Class used and relied upon these prices as the amount to pay and/or reimburse for Acthar.

206. As set forth more fully above, these prices were artificial prices, unrelated to any actual, reasonable price in the marketplace, or actual value of Acthar, but created and manipulated by the Defendants for the purpose of generating exorbitant revenue, thus constituting false representations which the Defendants knew or, in the absence of recklessness, should have known to be false.

207. The Defendants made these false representations about the prices of Acthar with the intent of misleading Plaintiffs and the Class into relying on the prices as real and fact-based prices, rather than artificially inflated prices.

208. Plaintiffs and the Class justifiably relied upon these false misrepresentations in purchasing and/or reimbursing Acthar at the amount charged by Express Scripts and CVS

Caremark based on the price set by Mallinckrodt.

209. Rockford's and the Class' contracts with Express Scripts all provide for "cost containment" and all provide for discounted prices for specialty drugs at varying rates, intended to reflect the efforts of Express Scripts to provide cost containment. The prices for Acthar set forth in such contracts were prices set by Mallinckrodt and set forth by Express Scripts in its contracts. Acument's and the Class' contracts with CVS Caremark also provide for cost containment, and the prices for Acthar in such contracts were the prices set by Mallinckrodt. As such, all Defendants communicated these false prices directly to Plaintiffs and the Class for the Acthar sold.

210. As a direct and proximate result of the false representations of the Defendants, as set forth above, Plaintiffs and the Class were harmed in that they were unaware of the artificial, inflated prices of Acthar, would not have paid and/or reimbursed the artificially inflated prices for Acthar had they known of the false representations and, in fact, overpaid for the Acthar because of the false representations.

**WHEREFORE**, Plaintiffs demand that judgment be entered in their favor, and in favor of the Class, and against Defendants, in an amount to be determined at trial, including but not limited to costs, attorneys' fees, and such other relief deemed just and appropriate by this Court.

**COUNT V**  
**PLAINTIFFS v. ALL DEFENDANTS**  
**CONSPIRACY TO DEFRAUD/CONCERTED ACTION**

211. Plaintiffs hereby incorporate by reference the averments of the foregoing paragraphs as if fully set forth herein and further allege as follows.

212. As set forth more fully above, beginning at least as early as 2007, the exact date being unknown to Plaintiffs, and continuing thereafter until the present, Defendants and other

unnamed co-conspirators, between and among themselves and others, entered into an agreement and/or otherwise engaged in a continuing conspiracy to defraud and deceive Plaintiffs and the Class by causing them to pay more for Acthar than they otherwise would have paid in the absence of the Defendants' conspiracy and concerted action.

213. Pursuant to the unfair and deceptive scheme to distribute, market and sell Acthar to derive substantial profits, and the conspiracy alleged herein, and in furtherance thereof, Defendants and their co-conspirators engaged in a wide range of activities, the purpose and effect of which was to deceive Plaintiffs and the Class, and acted or took substantial steps in furtherance of the conspiracy. Those acts include the following:

- a. discussing and agreeing among themselves and with their co-conspirators that they would directly control the price at which Plaintiffs and the Class paid for Acthar;
- b. discussing and agreeing among themselves and with their co-conspirators that they would increase the price at which Plaintiffs and the Class paid for Acthar;
- c. discussing and agreeing among themselves and with their co-conspirators that they would directly control the ASAP program materials and website which enrolled patients into an exclusive distribution network for the administration of Acthar, allowing Defendants to conduct their unfair pricing scheme for Acthar;
- d. discussing and agreeing among themselves and with their co-conspirators that they would directly control the exclusive distribution network for Acthar through the ASAP Program;
- e. discussing and agreeing among themselves and with their co-conspirators that they would rely on employees to promote the ASAP Program through the marketing alleged herein, and through use of the mail and the wires;
- f. discussing and agreeing among themselves and with their co-conspirators that they would participate in the affairs of the ASAP program by using a fraudulent scheme to market and sell Acthar at inflated prices; and
- g. discussing and agreeing among themselves and with their co-conspirators that they would conceal and suppress the truth about the Acthar inflated prices, the

monies earned from payors, like Plaintiffs and the Class, and their exclusive arrangement to maintain and enhance Mallinckrodt's monopoly power as alleged herein.

214. In addition to the specific facts set forth above, it is alleged the Defendants and their co-conspirators engaged in conspiratorial meetings, among the purposes of which meetings were to discuss the importance of controlling the direct distribution, marketing, sale and administration of Acthar to Plaintiffs and the Class, and deriving substantial profits from these activities.

215. The Defendants performed the conspiratorial acts set forth herein intending to injure payors of Acthar, like Plaintiffs and the Class, by causing them to pay inflated prices so that the Defendants could derive substantial profits.

216. The Defendants performed the acts alleged herein in furtherance of the common plan or design for the conspiracy with intent and/or with knowledge of the injury and damage it would cause to the Plaintiffs and the Class, and with knowledge and intent to cause such injuries and/or with reckless disregard for the consequences.

217. As a direct and proximate result of the Defendants' conspiracy as alleged herein, Plaintiffs and the Class have been injured and damaged, and the Defendants are jointly and severally liable for such injuries and damages.

**WHEREFORE**, Plaintiffs demand that judgment be entered in their favor, and in favor of the Class, and against Defendants, in an amount to be determined at trial, including but not limited to costs, attorneys' fees, and such other relief deemed just and appropriate by this Court.

**COUNT VI**  
**PLAINTIFFS v. ALL DEFENDANTS**  
**MAINTENANCE OF MONOPOLIZATION OF**  
**THE ACTH MARKET (15 U.S.C. § 2)**

218. Plaintiffs hereby incorporate by reference the averments of the foregoing



paragraphs as if fully set forth herein and further allege as follows.

219. Mallinckrodt has, and at all relevant times, had, monopoly power in the market for the sale of ACTH drugs in the United States. While the genesis of this monopoly power may be natural, since 2007 Mallinckrodt has acted and conspired with Express Scripts to maintain and enhance its monopoly power in the ACTH market.

220. As described above, Acthar's value was limited because it was the "gold standard" for treating only one condition, infantile spasms ("IS"). IS is a serious condition in infants, but one with an annual patient population of less than 2,000 patients per year. However, by 2015, Mallinckrodt was able to grow sales of Acthar to approximately \$1.1 billion.

221. In 2007, Mallinckrodt announced a "New Strategy" in order to maintain and enhance its monopoly. This new strategy could not have succeeded without the involvement of Express Scripts as Mallinckrodt's exclusive agent.

#### **Anticompetitive Act 1: Restricted Distribution**

222. On July 2, 2007, Mallinckrodt decided to restrict distribution from three wholesalers, termed Wholesalers "A", "B", and "C" in its 2007 10-K, to Express Scripts. The goal of this strategy was to lock patients into receiving Acthar through one channel and prevent a competitive product from entering the market.

223. When Mallinckrodt began its new strategy on July 16, 2007, it established the ASAP Program. *See* Exhibit "B". July 2, 2007 Urgent Product Alert H.P. Acthar Gel. The ASAP Program allowed Mallinckrodt to limit its direct distribution of the drug to the patient to just one avenue, through Express Scripts. Mallinckrodt entered an exclusive arrangement with Express Scripts to provide Acthar directly to patients, and to receive payments for Acthar directly from patients. *See* Freudenheim, *supra*.

224. Express Scripts was Mallinckrodt's exclusive agent to operate the ASAP Program. Through ASAP, UBC facilitated all aspects of Acthar's distribution and payment as Mallinckrodt's exclusive agent. UBC's utilized Express Script's pharmacy arrangement services (Accredo), specialty drug distribution (CuraScript) and direct billing and payment (ESI) functions to allow Mallinckrodt to maintain and enhance its monopoly power in the ACTH market.

225. Mallinckrodt has willfully maintained its monopoly power in the ACTH drug market through its exclusive arrangement with Express Scripts from 2007 through 2017. Having Express Scripts as its exclusive agent, Mallinckrodt was able to raise its prices tenfold initially, and nearly double in the ensuing years.

### **Anticompetitive Act 2: The Synacthen Acquisition**

226. By 2013, Mallinckrodt had identified a competitive threat to its monopoly power, despite its exclusive arrangements with Express Scripts. When Novartis decided to sell Synacthen Depot to a competitor, Mallinckrodt acted to protect its monopoly. Recognizing that the entry of Synacthen to the ACTH market would threaten its monopoly power, Mallinckrodt first attempted to buy the rights to Synacthen in 2009, it was unable to do so.

227. When Novartis agreed to sell Synacthen to Retrophin in 2013, Mallinckrodt disrupted the bidding process for Synacthen by intervening at the last minute to pay multiple times what had been offered by Retrophin. Retrophin had agreed to buy Synacthen for \$16 million, Mallinckrodt paid \$135 million. It licensed the U.S. rights to Synacthen from Novartis, but did not bring this viable synthetic alternative to market. Instead, it acted only to eliminate the nascent competitive threat to its monopoly posed by an independently owned Synacthen.

228. This conduct contributed to Mallinckrodt's maintenance of monopoly power.

Both anticompetitive acts – the exclusive arrangement with Express Scripts and the Synacthen acquisition had the purpose and effect of suppressing rather than promoting competition in the ACTH market. Mallinckrodt was able to raise prices at will.

229. Mallinckrodt used its enhanced monopoly power to inflate the prices of Acthar as set forth herein. Today the prices stand at over \$43,000.

230. The challenged conduct caused Plaintiffs and the Class to pay artificially inflated prices for Acthar in the ACTH drug market.

231. There is no procompetitive justification for the conduct of Mallinckrodt and Express Scripts. Rather these two companies combined to lock Acthar into a restricted distribution model, overseen by the ASAP program, to ensure enhanced monopoly profits for both of them. The Synacthen acquisition only prevented competition, and preserved the enhanced monopoly power Mallinckrodt enjoyed due to Express Scripts' collusion.

**Plaintiffs are Direct Purchasers of Acthar Harmed by Defendants' Anti-Competitive Conduct**

232. The Plaintiffs have been directly injured in their businesses and property by reason of Mallinckrodt's unlawful monopolization in concert with Express Scripts. Plaintiffs' injuries consist of paying higher prices to purchase Acthar than they would have paid absent the conduct of Mallinckrodt and its exclusive agents, Express Scripts. Plaintiffs' injuries are the type of harm the antitrust laws were designed to prevent and flow from which makes Mallinckrodt's and Express Scripts' conduct unlawful.

233. The product ships from Mallinckrodt's agent directly to the patient. Payments flow directly from Rockford to Express Scripts, for the benefit of Mallinckrodt, from Acument to CVS Caremark, for the benefit of Mallinckrodt. Express Scripts only deducts its agreed-upon share of Rockford's payments before forwarding them to Mallinckrodt. CVS Caremark does the

same.

234. Plaintiffs are also direct purchasers because of the conspiracy between Express Scripts and Mallinckrodt, as Rockford and Acument are direct purchasers from co-conspirators.

235. As described herein Defendants' acts and practices constitute monopoly maintenance in violation of Section 2 of the Sherman Act, 15 U.S.C. § 2.

**WHEREFORE**, Plaintiffs demand that judgment be entered in their favor, and in favor of the Class, and against Defendants, in an amount to be determined at trial, including but not limited to costs, attorneys' fees, and such other relief deemed just and appropriate by this Court.

**COUNT VII**  
**PLAINTIFFS v. ALL DEFENDANTS**  
**ANTI-COMPETITIVE AGREEMENTS IN UNREASONABLE**  
**RESTRAINT OF TRADE (15 U.S.C. § 1)**

236. Plaintiffs hereby incorporate by reference the averments of the foregoing paragraphs as if fully set forth herein and further allege as follows.

237. As set forth above, Mallinckrodt has entered into exclusive agreements with the agent for its largest customers, Express Scripts. These agreements preserved and extended Mallinckrodt's monopoly power, and allowed both Mallinckrodt and Express Scripts to raise the prices for Acthar to Express Scripts' clients, including Rockford.

**The Role of Express Scripts in the Specialty Drug Market**

238. The maintenance of Mallinckrodt's monopoly over the ACTH market would not be possible without its agreement in restraint of trade with Express Scripts.

239. Express Scripts is the largest buying agent of pharmaceuticals in the country. It has substantial buying power as a result of its position as the largest representative of pharmaceutical purchasers.

240. ESI has developed a consolidated network of specialty pharmaceutical

management, distribution and reimbursement that creates a direct pipeline between the manufacturer and the patient. Express Scripts operates a specialty pharmaceutical distributor, a specialty pharmacy, and a reimbursement HUB, all of which operate in service of the specialty drug manufacturer concomitantly with ESI's service as a pharmacy benefit manager for health plans and patients.

241. Because ESI represents more than 80% of pharmaceutical buyers in the United States, it has the unique position to push back against high pharmaceutical prices, especially specialty drugs like Acthar. Express Scripts has demonstrated its ability to wield its market power to effectuate lower costs for high priced specialty drugs.

242. The example of Turing's Daraprim is stark in that Express Scripts has produced a comparable drug for \$1. Instead of the \$750.00 per pill charged by Turing, Express Scripts charges its clients \$1. Instead of one year's course of treatment costing \$361,000, it costs less than \$100.

**Express Scripts' Agreement with Mallinckrodt to Fix Prices for Acthar**

243. In 2007, when Express Scripts entered its exclusive arrangement with Mallinckrodt's predecessor Questor, it did not push back against Questcor's decision to raise prices. Instead, when confronted with the price increase, Dr. Miller asserted that "[t]he increase was a manufacturing decision. I can't comment on it." *Id.*

244. There was no legitimate business justification on the part of Express Scripts to agree to charge the inflated end payor prices set by Questcor to its clients, but it so agreed.

245. By 2015, Express Scripts contracted with Rockford to be its exclusive agent for specialty drugs, including Acthar. But, Express Scripts accepted the inflated end payor prices set by Mallinckrodt, and included them in the ESI PBM Agreement with Rockford.

246. It is believed and therefore averred that when Acument contracted with CVS Caremark for the provision of specialty drugs, like Acthar, to its employee beneficiaries, CVS Caremark simply charged the same prices based on the prices set by Mallinckrodt in agreement with Express Scripts, as the product continued to flow directly from Express Scripts to the patients of other PBMs, like CVS Caremark. As a result, the Mallinckrodt-ESI agreement to fix prices preserved and enhanced Mallinckrodt's monopoly power and injured payors like Acument being charged the same artificially inflated prices for Acthar.

247. As a result, Express Scripts conspired and agreed with Mallinckrodt to fix and charge artificially inflated prices for Acthar to Express Scripts clients, like Rockford.

248. At all relevant times, Mallinckrodt's exclusive agreements with Express Scripts assisted Mallinckrodt in: (a) effectively excluding less expensive, potentially superior competitive products from the ACTH drug market; (b) maintaining Mallinckrodt's dominant market share and monopoly power in the ACTH drug market; (c) maintaining prices at artificially high levels for Acthar; and (d) otherwise reaping the benefits of its Mallinckrodt's enhanced monopoly power.

249. There is no procompetitive justification for the conduct of either Mallinckrodt or Express Scripts.

250. Plaintiffs have been injured in their businesses and property by reason of the alleged collusion and conspiracy between Mallinckrodt and Express Scripts, its exclusive agent, which had the purpose and effect of raising and stabilizing inflated prices for Acthar. Express Scripts facilitated, enabled, assisted, and furthered Mallinckrodt's substantial foreclosure and exclusion of competition and monopolization of the ACTH drug market.

251. Plaintiffs' injuries consist of paying higher prices to purchase Acthar than they

would have paid absent the unlawful conduct of Mallinckrodt and Express Scripts. Plaintiffs' injuries are the type the antitrust laws were designed to prevent and flow from that which makes Defendants' conduct unlawful.

252. Defendants' acts and practices constitute anti-competitive agreements in unreasonable restraint of trade in violation of Section 1 of the Sherman Act, 15 U.S.C. §1.

**WHEREFORE**, Plaintiffs demand that judgment be entered in its favor, and their favor of the Class, and against Defendants, in an amount to be determined at trial, including but not limited to costs, attorneys' fees, and such other relief deemed just and appropriate by this Court.

**COUNT VIII**  
**PLAINTIFFS v. ALL DEFENDANTS**  
**STATE ANTITRUST LAW CLAIMS**

253. Plaintiffs hereby incorporate by reference the averments of the foregoing paragraphs as if fully set forth herein and further allege as follows.

254. In the event the Court finds the Acthar purchases of either Plaintiff were indirect as to Mallinckrodt, they remain direct as to Express Scripts, and Plaintiffs' aforesaid federal antitrust claims may be maintained against Express Scripts. In such event, alternatively, Plaintiffs and the Class seek relief as indirect purchasers as allowed by state and federal law. Under federal antitrust law, as indirect purchasers, Plaintiffs and the Class are allowed to seek an injunction against both Mallinckrodt and Express Scripts for their anticompetitive conduct.

255. Under the statutory and decisional law of the states identified below, Plaintiffs and the Class are also permitted to seek damages as indirect purchasers against Defendants, including but not limited to the laws of Illinois and Tennessee where the patients covered by Plaintiffs reside and were treated.

256. Plaintiffs set forth the following allegations in this state law-related section such

that each and every allegation as to the factual basis for the violation of the law of one state, no matter where it appears, is incorporated by reference as support for the violation of the law of every state identified herein. Plaintiffs also incorporate the preceding factual allegations of antitrust conduct by the Defendants.

257. Illinois: 740 ILCS 10/7(2) authorizes any person, including municipalities, townships, and any other political subdivision to seek an injunction, damages, and reasonable attorneys fees to prevent and ameliorate the anticompetitive conducted described herein.

258. The acts and circumstances described herein demonstrate that Mallinckrodt and Express Scripts acted willfully within the meaning of 740 ILCS 10/7(2), such that Plaintiffs and the class may be awarded treble damages.

259. Rockford is a political subdivision within the meaning of 740 ILCS 10/7(2) and is therefore a person within the ambit of the statute. Acument is a corporation doing business in Illinois, and made payments for Acthar out of Illinois, and is therefore a “person” within the ambit of the Illinois law. Plaintiffs and the Class were injured as a result of Defendants’ conduct in violation of Illinois law, and hereby seek damages.

260. Tennessee: The Tennessee Unfair Trade Practices Act declares unlawful and void “[a]ll arrangements, contracts, agreements, trusts or combinations between persons or corporations designed, or which tend, to advance, reduce, or control the price or the cost to the producer or the consumer of any such product or article.” Tenn. Code Ann. § 47-25-101. Persons injured may recover “the full consideration or sum... for any goods, wares, merchandise, or articles, the sale of which is controlled by such combination or trust.” Tenn. Code Ann. § 47-25-106. *In Sherwood v. Microsoft Corp.*, 2003 WL 21780975, \*29 (Tenn. Ct. App. July 31, 2003), the Tennessee Court of Appeal held that indirect purchasers have standing to bring an action



under the Act to recover damages resulting from price-fixing. *See Freeman Indus. LLC v. Eastman Chem Co.*, 172 S. W.3d 512, 519 (Tenn. 2005).

261. Tennessee municipalities and TPPs, like Acument, have standing to sue within the meaning of Tenn. Code Ann. § 47-25-106. *See Metro. Gov't of Nashville & Davidson Cnty. v. Ashland Oil, Inc.*, 535 F. Supp. 328 (M.D. Tenn. 1982).

262. As described in this Complaint, Mallinckrodt and Express Scripts agreed to maintain the supracompetitive price of Acthar through the ASAP Program, limiting distribution of the drug and stifling the ability of a competitor to enter the ACTH market. Further, to maintain these supracompetitive prices, Mallinckrodt acquired Synacthen. This conduct caused Tennessee municipalities and TPPs, like Acument, to pay prices for Acthar significantly greater than in a competitive market. Therefore, Tennessee municipalities and TPPs are entitled to relief under Tennessee law.

263. Acument and the Class were injured as a result of Defendants' conduct in violation of Tennessee law, and hereby seek damages.

264. Arizona: The Arizona Uniform Antitrust Act, A.R.S. § 44-1401, et seq., makes unlawful any "contract, combination, or conspiracy between two or more persons in restraint of, or to monopolize, trade or commerce" and confers standing to persons and political subdivisions as indirect purchasers to bring an action for damages, injunctive relief, and attorneys fees and costs. A.R.S. §§ 44-1402, 1408.

265. Plaintiffs bring this action on behalf of all third party payors ("TPP"), cities, towns, municipalities, and any other state political subdivision (collectively, "municipality") that has paid for prescriptions of Acthar. The TPP purchasers of Acthar in Arizona have standing as a class to seek relief against Mallinckrodt and Express Scripts for their scheme to fix the price of

Acthar at supracompetitive levels and maintain Mallinckrodt's monopoly power.

266. Plaintiffs and the Class were injured as a result of Defendants' conduct in violation of Arizona law, and hereby seek damages.

267. Arkansas: The Arkansas Deceptive Trade Practices Act forbids "[d]eceptive and unconscionable trade practices." A.C.A. § 4-88-107(a). It makes illegal "any [] unconscionable, false, or deceptive act or practice in business, commerce, or trade." A.C.A. § 4-88-107(a)(10). Courts have recognized a private right of action for indirect purchasers in antitrust actions. The improper use of economic leverage qualifies as one such unconscionable business practice.

268. Plaintiffs and the Class were injured as a result of Defendants' conduct in violation of Arkansas law, and hereby seek damages.

269. California: California's antitrust law, the Cartwright Act, prohibits combinations between two or more persons to "[a]gree in any manner to keep the price of [a product] . . . at a fixed or graduated figure," or to "[e]stablish or settle the price of any [product] . . . , so as directly or indirectly to preclude a free and unrestricted competition among themselves, or any purchasers or consumers in the sale or transportation of [the product]." Cal. Bus. & Prof. Code § 16720(e)(2)-(3). Price-fixing is considered a business practice that, due to its pernicious effect on competition and lack of any redeeming virtue is conclusively presumed to be unreasonable and, therefore, illegal without elaborate inquiry as to the precise harm it has caused or the business excuse for its use.

270. California TPPs and municipalities are persons within the meaning of Section 16750 and 16702.

271. As alleged in greater detail herein, California TPPs and municipalities suffered economic injury due to Mallinckrodt's and Express Scripts' maintenance of monopoly prices.

272. The facts alleged herein establish that California TPPs and municipalities were injured in their property by paying exorbitant prices above what would be paid in a freely competitive market.

273. Mallinckrodt and Express Scripts created restrictions on trade and commerce through the creation of the exclusive arrangement for Acthar.

274. Mallinckrodt and Express Scripts agreed to raise the prices of Acthar.

275. Plaintiffs and the Class were injured as a result of Defendants' conduct in violation of California law, and hereby seek damages.

276. Florida: The Florida Deceptive and Unfair Trade Practices Act is designed to protect "the consuming public from those who engage in unfair methods of competition, or unconscionable, deceptive, or unfair acts or practices in the conduct of any trade or commerce," and mandates that the act be liberally construed to promote that policy. F.S.A. § 501.202. Florida courts have interpreted this law "as a clear statement of legislative policy to protect consumers through the authorization of [] indirect purchaser actions." *Mack v. Bristol Meyers Squibb*, 673 So. 2d 100, 108 (Fla. 1st D.C.A. 1996).

277. As set forth herein, Florida municipalities and TPPs act as fiduciaries for their employees who receive prescription and health benefits through the TPP or municipality . As such, they are consumers within the meaning of Fla. Stat. § 501.203(7).

278. As consumers, Florida TPPs and municipalities have suffered losses as a result of the anticompetitive conduct of Mallinckrodt and Express Scripts. Therefore, Florida TPPs and municipalities may recover their actual damages and their attorneys' fees and costs.

279. Plaintiffs and the Class were injured as a result of Defendants' conduct in violation of Florida law, and hereby seek damages.

280. Hawaii: Hawaii has declared unlawful “[e]very contract, combination in the form of trust or otherwise, or conspiracy, in restraint of trade or commerce,” including one that seeks to “[f]ix, control, or maintain, the price of any commodity” or engage in activities “with the result of fixing, controlling or maintaining its price.” Haw. Rev. Stat. §§ 480-4(a)-(b).

281. In addition, Hawaii law provides that “indirect purchasers injured by an illegal overcharge shall recover [] compensatory damages, and reasonable attorney’s fees.”

282. Hawaii municipalities and TPPs are persons within the meaning of Haw. Rev. Stat. § 480-1.

283. As articulated herein, Mallinckrodt possessed monopoly power in the ACTH market. Acting in concert with Express Scripts, Mallinckrodt willfully enhanced its monopoly power by limiting the distribution of Acthar and acquiring Synacthen. This conduct allowed Mallinckrodt to set the prices for Acthar far higher than the value of the product thus injuring Hawaii municipalities and TPPs. Express Scripts agreed to charge these inflated prices to its clients. Accordingly, Hawaii municipalities and TPPs are entitled to relief under Hawaii law.

284. Plaintiffs and the Class were injured as a result of Defendants’ conduct in violation of Hawaii law, and hereby seek damages.

285. Iowa: The Iowa Competition Law prohibits the “attempt to establish, maintain, or use a monopoly of trade or commerce in a relevant market for the purpose of excluding competition or of controlling, fixing or maintaining prices.” Iowa Code § 553.5.

286. Iowa Code § 553.12 authorizes any “person who is injured or threatened with injury” to sue to “[p]revent or restrain conduct. . . through injunction,” to “[r]ecover actual damages resulting from” prohibited conduct, the costs of suit, and reasonable attorney fees. Iowa Code § 553.12. When the prohibited conduct is willful, a person may recover twice their

damages. Id.

287. Iowa TPPs and municipalities are persons within the meaning of Iowa Code § 553.3.

288. The facts and circumstances described herein demonstrate that Mallinckrodt and Express Scripts acted willfully in their exclusive arrangement, injuring Iowa TPPs and municipalities through the maintenance and enhancement of monopoly prices for Acthar.

289. Plaintiffs and the Class were injured as a result of Defendants' conduct in violation of Iowa law, and hereby seek damages.

290. Kansas: Kan. Stat. Ann. § 50-101 outlaws any "combination of capital, skill, or acts, by two or more persons" carried out for the purpose of restricting trade or commerce; increasing or reducing the price of goods; or preventing competition. Kan. Stat. Ann. § 50-101. In addition, "all arrangements, contracts, agreements, trusts or combinations between persons, designed or which tend to advance, reduce or control the price or the cost to the producer or to the consumer of any such products or articles" are unlawful under Kansas law. Kan. Stat. Ann. § 50-112. Under Kansas law, any person who has suffered a financial loss, "regardless of whether such injured person dealt directly or indirectly with the defendant" may sue. Kan. Stat. Ann. § 50-163(d)(2).

291. As described herein, Mallinckrodt and Express Scripts entered into exclusive arrangements that raised and maintained monopoly prices for Acthar and restrained competitors from entering the ACTH market, causing Kansas municipalities and TPPs to overpay for Acthar.

292. Plaintiffs and the Class were injured as a result of Defendants' conduct in violation of Kansas law, and hereby seek damages.

293. Massachusetts: Massachusetts' unfair and deceptive trade practices statute

declares as unlawful “[u]nfair methods of competition and unfair or deceptive acts or practices in the conduct of any trade or commerce.” Mass. Gen. Laws, c. 93A, § 2(a). Massachusetts law allows both consumers and participants in trade or commerce to bring claims for actual damages, multiple recovery for willful violations and attorneys’ fees for a prevailing plaintiffs. *See* Mass. Gen. Laws, c. 93A, §§ 9, 11. The Massachusetts Supreme Court “read[s] the language of G.L. c. 93A as a clear statement of legislative policy to” allow indirect purchasers to seek relief for antitrust conduct. *Ciardi v. F. Hoffmann-La Roche, Ltd.*, 436 Mass. 53, 66-67 (2002).

294. Massachusetts TPPs and municipalities qualify as consumers or participants in trade in commerce within the meaning of Mass. Gen. Laws, c. 93A.

295. Within respect to the injuries suffered by Massachusetts TPPs and municipalities only, the majority of the injurious conduct occurred within Massachusetts.

296. As alleged in this Complaint, the facts and circumstances demonstrate that Mallinckrodt and Express Scripts acted willfully within the meaning of Mass. G.L. c. 93A entitling Massachusetts TPPs and municipalities to multiple damages for the maintenance of the Acthar monopoly through their exclusive arrangement and the Synacthen acquisition. Therefore, Massachusetts municipalities and TPPs are entitled to relief under Massachusetts law.

297. Plaintiffs and the Class were injured as a result of Defendants’ conduct in violation of Massachusetts law, and hereby seek damages.

298. Michigan: The Michigan Antitrust Reform Act deems any “contract, combination, or conspiracy between 2 or more persons in restraint of, or to monopolize, trade or commerce in a relevant market [] unlawful.” MCLS § 445.772. In addition, it prohibits the “establishment, maintenance, or use of a monopoly, or any attempt to establish a monopoly, of trade or commerce in a relevant market by any person, for the purpose of excluding or limiting

competition or controlling, fixing, or maintaining prices.” MCLS § 445.773. It allows any political subdivision or person “threatened with injury or injured . . . indirectly” to seek injunctive or equitable relief, damages, interest, costs, and attorneys fees for a violation of the Act.

299. Michigan municipalities and TPPs are units of government or persons within the meaning of MCLS § 445.771.

300. Mallinckrodt and Express Scripts are persons within the meaning of MCLS § 445.771.

301. The facts and circumstances, as articulated in this complaint, demonstrate that Mallinckrodt and Express Scripts agreed to maintain and enhance Mallinckrodt’s monopoly in the ACTH market through their exclusive arrangement and the Synacthen acquisition. This conduct resulted in Michigan municipalities and TPPs paying far more than they would in a competitive market for Acthar. Therefore, Michigan municipalities and TPPs are entitled to relief under the Michigan Antitrust Reform Act.

302. Plaintiffs and the Class were injured as a result of Defendants’ conduct in violation of Michigan law, and hereby seek damages.

303. Minnesota: Under Minnesota law, “[a] contract, combination or conspiracy between two or more persons in unreasonable restraint of trade or commerce is unlawful.” Minn. Stat. § 325D.51. In addition, section 325D.53 prohibits the maintenance or use of monopoly power to affect competition or control, fixe or maintain prices. *See* Minn. Stat. ¶ 325D.52. By law, “any person . . . injured directly or indirectly by a violation of [section 325D.51] shall recover three times the actual damages sustained, together with costs and disbursements, including reasonable attorneys’ fees.” Minn. Stat. § 325D.57. “Minnesota

antitrust law expressly provides damages for indirect purchasers injured by antitrust violations.” *Gordon v. Microsoft Corp.*, 2001 WL 366432, at \*2 (Minn. Dist. Ct. Mar. 30, 2001); *see also*, *Lorix v. Crompton Corp.*, 736 N.W.2d 619 (Minn. 2007).

304. Acthar is a commodity within the meaning of Minn. Stat. § 325D.50.

305. The exclusive arrangement between Mallinckrodt and Express Scripts represents a contract, combination, or conspiracy within the meaning of Minn. Stat. § 325D.50.

306. Minnesota municipalities and TPPs are persons within the meaning of Minn. Stat. § 325D.50 with standing to seek relief from the anticompetitive practices of Mallinckrodt and the ESI Defendants.

307. As described in this Complaint, Mallinckrodt and Express Scripts agreed to maintain the supracompetitive prices of Acthar through the ASAP Program, limiting distribution of the drug and stifling the ability of a competitor to enter the ACTH market. Further, to maintain these supracompetitive prices, Mallinckrodt acquired Synacthen. This conduct caused Minnesota municipalities and TPPs to pay prices for Acthar significantly greater than in a competitive market. Therefore, Minnesota municipalities and TPPs are entitled to relief under Minnesota law.

308. Plaintiffs and the Class were injured as a result of Defendants’ conduct in violation of Minnesota law, and hereby seek damages.

309. Mississippi: Under Mississippi law trusts are unlawful, and this includes any “combination, contract, understanding or agreement” that would be inimical to public welfare and the effect of which would be . . . to restraint trade”, including any “increase . . . [on] the price of a commodity.” Miss. Code. Ann. §§ 75-21-1(a)-(c).

310. Mississippi law allows any party injured by any aforementioned form of trust to



seek their full damages and a civil penalty of \$500.00 per injury, no matter whether they are a direct or indirect purchaser. Miss. Code. Ann. § 75-21-9. As such Mississippi municipalities and TPPs have standing to sue under Mississippi law.

311. As described in this Complaint, Mallinckrodt and Express Scripts agreed to maintain the supracompetitive price of Acthar through the ASAP Program, limiting distribution of the drug and stifling the ability of a competitor to enter the ACTH market. Further, to maintain these supracompetitive prices, Mallinckrodt acquired Synacthen. This conduct caused Mississippi municipalities and TPPs to pay prices for Acthar significantly greater than in a competitive market. Therefore, Mississippi municipalities and TPPs are entitled to relief under Mississippi law.

312. Plaintiffs and the Class were injured as a result of Defendants' conduct in violation of Mississippi law, and hereby seek damages.

313. Nebraska: In Nebraska, the Junkin Act prohibits any "any "contract, combination in the form of trust or otherwise, or conspiracy in restraint of trade of commerce" in Nebraska. R.R.S. Neb. § 59-801. The Nebraska Consumer Protection Act, in relevant part, duplicates the Junkin Act's analogues of the Sherman Act and states that "Unfair methods of competition and unfair or deceptive acts or practices in the conduct of any trade or commerce shall be unlawful . . . Any contract, combination, in the form of trust or otherwise, or conspiracy in restraint of trade or commerce shall be unlawful." R.R.S. Neb. §§ 59-1602-1603. Indirect purchasers injured by price-fixing practices can sue for damages under both statutes, and recover the costs of suit and a reasonable attorney's fee. *See* R.R.S. Neb. § 59-821.

314. Nebraska municipalities are persons within the meaning of Section 59-822 and have such have standing under the Junkin and Consumer Protection Acts.

315. As described in this Complaint, Mallinckrodt and Express Scripts agreed to maintain the supracompetitive price of Acthar through the ASAP Program, limiting distribution of the drug and stifling the ability of a competitor to enter the ACTH market. Further, to maintain these supracompetitive prices, Mallinckrodt acquired Synacthen. This conduct caused Nebraska municipalities and TPPs to pay prices for Acthar significantly greater than in a competitive market. Therefore, Nebraska municipalities and TPPs are entitled to relief under Nebraska law.

316. Plaintiffs and the Class were injured as a result of Defendants' conduct in violation of Nebraska law, and hereby seek damages.

317. Nevada: Nevada has declared several categories of activities that constitute a "contract, combination or conspiracy in restraint of trade, including price fixing, which consists of raising, depressing, fixing, pegging or stabilizing the price of any commodity or service." Nev. Rev. Stat. Ann. § 598A.060. In addition, Nevada provides a right of action and treble damage remedy for "any person injured or damaged directly or indirectly" by an antitrust violation. Nev. Rev. Stat. Ann. § 598A.210.

318. Nevada municipalities and TPPs have standing to seek relief under Nevada law.

319. As described in this Complaint, Mallinckrodt and Express Scripts agreed to maintain the supracompetitive price of Acthar through the ASAP Program, limiting distribution of the drug and stifling the ability of a competitor to enter the ACTH market. Further, to maintain these supracompetitive prices, Mallinckrodt acquired Synacthen. This conduct caused Nevada municipalities and TPPs to pay prices for Acthar significantly greater than in a competitive market. Therefore, Nevada municipalities and TPPs are entitled to relief under Nevada law.

320. Plaintiffs and the Class were injured as a result of Defendants' conduct in violation of Nevada law, and hereby seek damages.

321. New Mexico: The New Mexico Antitrust Act prohibits "[e]very contract, agreement, combination or conspiracy in restraint of trade or commerce, any part of which trade or commerce is within" New Mexico. N.M. Stat. Ann. § 57-1-1. Additionally, the statute expressly provides that indirect purchasers who are "threatened with injury or injured" have standing to assert a claim and "may bring an action for appropriate injunctive relief, up to threefold the damages sustained and costs and reasonable attorneys' fees." N.M. Stat. Ann. § 57-1-3(A).

322. New Mexico municipalities and TPPs have standing to sue under the New Mexico Antitrust Act. *See City of Sunland Park v. Macias*, 75 P.3d 816 (N.M. Ct. App. 2003).

323. As described in this Complaint, Mallinckrodt and Express Scripts agreed to maintain the supracompetitive price of Acthar through the ASAP Program, limiting distribution of the drug and stifling the ability of a competitor to enter the ACTH market. Further, to maintain these supracompetitive prices, Mallinckrodt acquired Synacthen. This conduct caused New Mexico municipalities and TPPs to pay prices for Acthar significantly greater than in a competitive market. Therefore, New Mexico municipalities and TPPs are entitled to relief under New Mexico law.

324. Plaintiffs and the Class were injured as a result of Defendants' conduct in violation of New Mexico law, and hereby seek damages.

325. New York: New York's Donnelly Act declares that every contract, agreement, arrangement or combination" that restrains, may restrain, or has for its purpose the restraint of competition, the free exercise of any commercial activity, or the performance of a service to be

unlawful. N.Y. Gen. Bus. Law § 340(1). Among other provisions, the Donnelly Act specifically extends protection to indirect purchasers. *See* N.Y. Gen. Bus. Law § 340(6). The statute also provides that a successful plaintiff “shall recover threefold the actual damages sustained thereby,” as well as costs and attorneys’ fees. N.Y. Gen. Bus. Law § 340(5).

326. New York municipalities and TPPs have standing to sue under the Donnelly Act because they are persons or political subdivisions within the meaning of N.Y. Gen. Bus. Law §§ 340(5)-(6).

327. As described in this Complaint, Mallinckrodt and Express Scripts agreed to maintain the supracompetitive price of Acthar through the ASAP Program, limiting distribution of the drug and stifling the ability of a competitor to enter the ACTH market. Further, to maintain these supracompetitive prices, Mallinckrodt acquired Synacthen. This conduct caused New York municipalities and TPPs to pay prices for Acthar significantly greater than in a competitive market. Therefore, New York municipalities and TPPs are entitled to relief under New York law.

328. Plaintiffs and the Class were injured as a result of Defendants’ conduct in violation of New York law, and hereby seek damages.

329. North Carolina: North Carolina’s Monopolies, Trusts, and Consumer Protection Act, N.C. Gen. Stat. §§ 75-1, et seq., declares any “conspiracy in restraint of trade or commerce” illegal. N.C. Gen. Stat. § 75-1. To prevail under the Act, Plaintiffs must show: (1) defendants committed an unfair or deceptive act or practice; (2) in or affecting commerce; and (3) that plaintiff was injured thereby. *Stetser v. TAP Pharmaceutical Products, Inc.*, 165 N.C. App. 1 (2004). “A trade practice is ‘unfair’ if it is immoral, unethical, oppressive, unscrupulous, or substantially injurious to consumers”). The Act also provides standing for individual plaintiffs

(§ 75-16), which right was specifically extended to indirect purchasers in *Hyde v. Abbott Labs.*, 123 N.C. App. 572, 584 (1996).

330. North Carolina municipalities and TPPs have standing as indirect purchasers.

331. As described in this Complaint, Mallinckrodt and Express Scripts agreed to maintain the supracompetitive price of Acthar through the ASAP Program, limiting distribution of the drug and stifling the ability of a competitor to enter the ACTH market. Further, to maintain these supracompetitive prices, Mallinckrodt acquired Synacthen. This conduct caused North Carolina municipalities and TPPs to pay prices for Acthar significantly greater than in a competitive market. Therefore, North Carolina municipalities and TPPs are entitled to relief under North Carolina law.

332. Plaintiffs and the Class were injured as a result of Defendants' conduct in violation of North Carolina law, and hereby seek damages.

333. North Dakota: The North Dakota Antitrust Act provides that, "[a] contract, combination, or conspiracy between two or more persons in restraint of, or to monopolize, trade or commerce in a relevant market is unlawful." N.D. Cent. Code § 51-08.1-02. The statute expressly provides a cause of action for indirect purchasers, who may obtain injunctive relief and recover damages. N.D. Cent. Code § 51-08.1-08.

334. North Dakota municipalities and TPPs have standing as indirect purchasers within the meaning of N.D. Cent. Code § 51-08.1-08.

335. As described in this Complaint, Mallinckrodt and Express Scripts agreed to maintain the supracompetitive price of Acthar through the ASAP Program, limiting distribution of the drug and stifling the ability of a competitor to enter the ACTH market. Further, to maintain these supracompetitive prices, Mallinckrodt acquired Synacthen. This conduct caused

North Dakota municipalities and TPPs to pay prices for Acthar significantly greater than in a competitive market. Therefore, North Dakota municipalities and TPPs are entitled to relief under North Dakota law.

336. Plaintiffs and the Class were injured as a result of Defendants' conduct in violation of North Dakota law, and hereby seek damages.

337. Oregon: Oregon's Antitrust Law declares illegal "[e]very contract, combination in the form of trust or otherwise, or conspiracy in restraint of trade or commerce". Or. Rev. Stat. Ann. § 646.725. In addition, Oregon provides a right of action and treble damages for antitrust violation, "regardless of whether the plaintiff dealt directly or indirectly with the adverse party." Or. Rev. Stat. Ann. § 646.780(1)(a). In addition, indirect purchasers may recover "reasonable attorney fees, expert witness fees and investigative costs." Or. Rev. Stat. Ann. § 646.780(3)(a)-(b)(A)

338. Oregon municipalities and TPPs fall within the meaning of political subdivision and person as articulated in Or. Rev. Stat. Ann. § 646.780(1)(a), therefore they have standing to sue regardless if they are indirect purchasers.

339. As described in this Complaint, Mallinckrodt and Express Scripts agreed to maintain the supracompetitive price of Acthar through the ASAP Program, limiting distribution of the drug and stifling the ability of a competitor to enter the ACTH market. Further, to maintain these supracompetitive prices, Mallinckrodt acquired Synacthen. This conduct caused Oregon municipalities and TPPs to pay prices for Acthar significantly greater than in a competitive market. Therefore, Oregon municipalities and TPPs are entitled to relief under Oregon law.

340. Plaintiffs and the Class were injured as a result of Defendants' conduct in

violation of Oregon law, and hereby seek damages.

341. Rhode Island: Rhode Island law declares “[e]very contract, combination, or conspiracy in restraint of, or to monopolize, trade or commerce” unlawful. R.I. Gen. Laws. Ann. § 6-36-4. That a person “has no dealt directly with the defendant” does not “bar or otherwise limit recovery”. R.I. Gen. Laws Ann. § 6-36-12(g). Plaintiffs may obtain an injunction recovery treble damages, costs of suit, and a reasonable attorneys fee under Rhode Island law.

342. Rhode Island municipalities and TPPs may bring suit pursuant to section 6-36-11 because they are public bodies or persons within the meaning of section 6-36.3. *See* R.I. Gen. Laws Ann. §§ 6-36-3, 11(a).

343. As described in this Complaint, Mallinckrodt and Express Scripts agreed to maintain the supracompetitive price of Acthar through the ASAP Program, limiting distribution of the drug and stifling the ability of a competitor to enter the ACTH market. Further, to maintain these supracompetitive prices, Mallinckrodt acquired Synacthen. This conduct caused Rhode Island municipalities and TPPs to pay prices for Acthar significantly greater than in a competitive market. Therefore, Rhode Island municipalities and TPPs are entitled to relief under Rhode Island law.

344. Plaintiffs and the Class were injured as a result of Defendants’ conduct in violation of Rhode Island law, and hereby seek damages.

345. South Dakota: The South Dakota antitrust statute declares unlawful, “[a] contract, combination, or conspiracy between two or more persons in restraint of trade or commerce any part of which is within this state S.D.C.L. § 37-1-3.1. Under the statute, any person injured directly or indirectly by an antitrust violation may sue for injunctive and equitable relief as well as to recover treble damages. S.D.C.L. §§ 37-1-14.3, 37-1-33.

346. South Dakota payors have standing to seek relief within the meaning of S.D.C.L. § 37-1-3.1.

347. As described in this Complaint, Mallinckrodt and Express Scripts agreed to maintain the supracompetitive price of Acthar through the ASAP Program, limiting distribution of the drug and stifling the ability of a competitor to enter the ACTH market. Further, to maintain these supracompetitive prices, Mallinckrodt acquired Synacthen. This conduct caused South Dakota municipalities and TPPs to pay prices for Acthar significantly greater than in a competitive market. Therefore, South Dakota municipalities and TPPs are entitled to relief under South Dakota law.

348. Plaintiffs and the Class were injured as a result of Defendants' conduct in violation of South Dakota law, and hereby seek damages.

349. Utah: Utah law declares illegal "[e]very contract, combination in the form of trust or otherwise, or conspiracy in restraint of trade or commerce". Utah Code Ann. § 76-10-3104. Persons injured by such antitrust conduct may recover three times their damages in addition to an injunction, the costs of suit, and reasonable attorneys' fees. *See* Utah Code Ann. § 76-10-3109(1). Political subdivisions may recover actual damages in addition to in addition to injunctive relief, costs of suit, and reasonable attorney fee. *See* Utah Code Ann. § 76-10-3109(3).

350. Utah municipalities and TPPs are persons or political subdivisions within the meaning of Utah Code Ann. § 76-10-3109(1) and therefore have standing to obtain relief.

351. As described in this Complaint, Mallinckrodt and Express Scripts agreed to maintain the supracompetitive price of Acthar through the ASAP Program, limiting distribution of the drug and stifling the ability of a competitor to enter the ACTH market. Further, to



maintain these supracompetitive prices, Mallinckrodt acquired Synacthen. This conduct caused Utah municipalities and TPPs to pay prices for Acthar significantly greater than in a competitive market. Therefore, Utah municipalities and TPPs are entitled to relief under Utah law.

352. Plaintiffs and the Class were injured as a result of Defendants' conduct in violation of Utah law, and hereby seek damages.

353. Wisconsin: The Wisconsin Antitrust Act provides that "[e]very contract, combination in the form of trust or otherwise, or conspiracy, in restraint of trade or commerce is illegal." Wis. Stat. Ann. § 133.03(1). Any person injured directly or indirectly by an antitrust violation may seek injunctive relief and recover treble damages. Wis. Stat. Ann. §§ 133.16, 133.18(1)(a).

354. Wisconsin municipalities and TPPs are persons within the meaning of Wis. Stat. Ann. § 133.02 and therefore have standing to seek relief.

355. As described in this Complaint, Mallinckrodt and Express Scripts agreed to maintain the supracompetitive price of Acthar through the ASAP Program, limiting distribution of the drug and stifling the ability of a competitor to enter the ACTH market. Further, to maintain these supracompetitive prices, Mallinckrodt acquired Synacthen. This conduct caused Wisconsin municipalities and TPPs to pay prices for Acthar significantly greater than in a competitive market. Therefore, Wisconsin municipalities and TPPs are entitled to relief under Wisconsin law.

356. Plaintiffs and the Class were injured as a result of Defendants' conduct in violation of Wisconsin law, and hereby seek damages.

**WHEREFORE**, Plaintiffs demand that judgment be entered in its favor, and in favor of the Class, and against Defendants, in an amount to be determined at trial, including but not

limited to costs, attorneys' fees, and such other relief deemed just and appropriate by this Court.

**COUNT IX**  
**PLAINTIFFS v. ALL DEFENDANTS**  
**Violation of 18 U.S.C. § 1962(c)**

357. Plaintiffs hereby incorporate by reference the averments of the foregoing paragraphs as if fully set forth herein and further allege as follows:

358. Defendants are each "persons" within the meaning of 18 U.S.C. § 1961(3), who each conducted the affairs of an association in fact enterprise affecting interstate commerce through a pattern of racketeering activity in violation of 18 U.S.C. § 1962(c). Plaintiffs and the members of the Class are also persons.

359. Each Defendant violated 18 U.S.C. § 1962(c) as follows:

- a. Mallinckrodt plc. At all times relevant hereto, Mallinckrodt plc participated in the wrongful conduct of Questcor and Express Scripts as stated herein.
- b. Questcor. At all times relevant hereto, Questcor committed the predicate acts of mail and wire fraud through its own acts and through the ASAP Enterprise as stated herein. Questcor's predicate acts were not limited to the allegations stated herein.
- c. Express Scripts Holding Company. At all times relevant hereto, Express Scripts Holding Company committed the predicate acts of mail and wire fraud through its own acts and through the ASAP Enterprise as stated herein. Express Scripts Holding Company's predicate acts were not limited to the allegations stated herein.
- d. Express Scripts, Inc. At all times relevant hereto, Express Scripts, Inc. committed the predicate acts of mail and wire fraud through its own acts and

through the ASAP Enterprise as stated herein. Express Scripts, Inc.'s predicate acts were not limited to the allegations stated herein.

- e. UBC. At all times relevant hereto, UBC committed the predicate acts of mail and wire fraud through its own acts and through the ASAP Enterprise as stated herein. UBC's predicate acts were not limited to the allegations stated herein.
- f. CuraScript. At all times relevant hereto, CuraScript committed the predicate acts of mail and wire fraud through its own acts and through the ASAP Enterprise as stated herein. CuraScript's predicate acts were not limited to the allegations stated herein.
- g. Accredo. At all times relevant hereto, Accredo committed the predicate acts of mail and wire fraud through its own acts and through the ASAP Enterprise as stated herein. Accredo's predicate acts were not limited to the allegations stated herein.

360. At all relevant times, in violation of 18 U.S.C. § 1962(c), Mallinckrodt plc and Questcor, collectively Mallinckrodt, Express Scripts Holding Company, Express Scripts, Inc., UBC, CuraScript, and Accredo, collectively Express Scripts, and other co-conspirators conducted the affairs of an association-in-fact enterprise within the meaning of 18 U.S.C. § 1961(4) consisting of Mallinckrodt and Express Scripts, including their directors, employees, and agents, which is manifested in the ASAP program (the "ASAP Enterprise").

- a. The ASAP Enterprise was established to streamlined and cover-up the use of mail and wires to commit fraud so all Defendants could unfairly and illegally profit from the monopolistic and anti-competitive sale of Acthar.

- b. These predicated acts of wire fraud and mail fraud occurred over the course of ten (10) years.

361. The ASAP Enterprise was established in 2007 and is an ongoing and continuing business organization consisting of both the Defendants and individuals associated for the common purpose of illegally profiting from the distribution, marketing, selling, purchasing, and administration of Acthar to Plaintiffs and the Class, and deriving substantial profits from these activities.

362. The ASAP Enterprise through each Defendant individually and collectively engages in and affects interstate commerce because it engages in the following activities across state boundaries: the manufacture, distribution, marketing, sale, and/or purchase of Acthar, the transmission of ASAP program literature (including the Acthar Start Form at Exhibit “A” hereto), the operating of the ASAP program website, and the transmission and/or the receipt of invoices and payments related to the prescription and use of Acthar. Through these activities the ASAP Enterprise distributes Acthar to thousands of individual patients, including those receiving prescription drug benefits from the Plaintiffs and the Class.

363. The ASAP Enterprise itself and through each Defendant individually and collectively functioned as a continuing unit as evidenced by the continuing coordination of activities between Mallinckrodt and Express Scripts. There is a common communication network by which Mallinckrodt and Express Scripts shared and continue to share information on a regular basis for all times relevant to this lawsuit, but beginning at least in 2007 and continuing through the present. Typically, this communication occurred by use of the wires and mails, in which Mallinckrodt and Express Scripts all agree to charge inflated prices for Acthar to Plaintiffs and other Class members. These entities functioned as a continuing unit for the purposes of

implementing the fraudulent scheme to inflate the prices of Acthar by and through ASAP. When issues arose during the fraudulent scheme, each agreed to take actions to hide the scheme and to continue its existence.

364. Mallinckrodt and Express Scripts exerted control over the ASAP Enterprise, have associations with the ASAP Enterprise, and have directly or indirectly conducted or participated in the conduct of the affairs of the ASAP Enterprise in the following ways:

- a. Mallinckrodt establishes the prices of Acthar through fraudulent conduct;
- b. Mallinckrodt and Express Scripts directly controlled the prices at which Plaintiffs and the Class reimburse for Acthar;
- c. Mallinckrodt and Express Scripts directly controlled the ASAP Program materials and website which enroll patients in an exclusive distribution network for the administration of Acthar, allowing Mallinckrodt to conduct its unconscionable and unfair pricing of Acthar;
- d. Mallinckrodt and Express Scripts directly controlled the exclusive distribution network for Acthar through the ASAP Enterprise;
- e. Mallinckrodt and Express Scripts relied on their employees to promote the ASAP Program through the marketing alleged herein, through the mail and the wires; and
- f. Mallinckrodt and Express Scripts participated in the affairs of the ASAP Enterprise by using a fraudulent scheme to market and sell Acthar at inflated prices.

365. Mallinckrodt and Express Scripts conducted and participated in the affairs of the ASAP Enterprise through a pattern of racketeering activity that includes acts indictable under 18 U.S.C. § 1341, relating to mail fraud, and 18 U.S.C. § 1345, relating to wire fraud.

366. Mallinckrodt committed mail fraud when they utilized the mail and wires to defraud patients and purchases including Plaintiffs and the Class. Specific examples of the fraud are, included but not limited to:

- a. Express Scripts explicitly advertised to all existing and prospective patients

and payors that the ASAP Program would benefit them providing lower and affordable sales prices;

- b. Mallinckrodt and Express Scripts misled Rockford by fraudulently stating over the internet and through the mail that Rockford and the Class would receive affordable healthcare and contained costs of Acthar;
- c. Despite its explicit promises to the contrary, Express Scripts refused to use its market strength and related bargaining power to convince Mallinckrodt to lower the price of Acthar, because Express Scripts was serving as Mallinckrodt's exclusive agent and conducting the ASAP Enterprise; and *inter alia*,
- d. Processing prescriptions via mail and the wire and receiving payments from Rockford as follows:
  - i. On April 30, 2015, Rockford paid \$100,457.64 for 15 80-Unit (or 29 days of therapy) doses of Acthar;
  - ii. On September 10, 2015, Rockford paid \$70,654.58 for 10 80-Unit (or 12 days of therapy) doses of Acthar;
  - iii. On September 24, 2015, Rockford paid \$35,327.29 for 5 80-Unit (or 16 days of therapy) doses of Acthar;
  - iv. On October 8, 2015, Rockford paid \$35,327.29 for 5 80-Unit (or 20 days of therapy) doses of Acthar;
  - v. On October 22, 2015, Rockford paid \$35,327.29 for 5 80-Unit (or 22 days of therapy) doses of Acthar;
  - vi. On October 29, 2015, Rockford paid \$35,327.29 for 5 80-Unit (or 10 days of therapy) doses of Acthar;
  - vii. On November 12, 2015, Rockford paid \$35,327.29 for 5 80-Unit (or 10 days of therapy) doses of Acthar;
  - viii. On November 19, 2015, Rockford paid \$35,327.29 for 5 80-Unit (or 10 days of therapy) doses of Acthar and
  - ix. On December 3, 2015, Rockford paid \$105,981.88 for 15 80-Unit (or 30 days of therapy) doses of Acthar.
- f. Processing prescriptions via mail and the wire and receiving payments from Acument as follows:

- i. On December 17, 2015, Acument paid \$68,616.75 for 10 80-Unit (or 22 days of therapy) doses of Acthar;
- ii. On January 4, 2016, Acument paid \$68,616.75 for 10 80-Unit (or 22 days of therapy) doses of Acthar;
- iii. On January 21, 2016, Acument paid \$68,616.75 for 10 80-Unit (or 22 days of therapy) doses of Acthar;
- iv. On February 18, 2016, Acument paid \$68,616.75 for 10 80-Unit (or 22 days of therapy) doses of Acthar;
- v. On March 14, 2016, Acument paid \$68,616.75 for 10 80-Unit (or 22 days of therapy) doses of Acthar;
- vi. On April 7, 2016, Acument paid \$68,616.75 for 10 80-Unit (or 22 days of therapy) doses of Acthar;
- vii. On April 26, 2016, Acument paid \$68,616.75 for 5 80-Unit (or 22 days of therapy) doses of Acthar;
- viii. On May 24, 2016, Acument paid \$68,616.75 for 10 80-Unit (or 22 days of therapy) doses of Acthar;
- ix. On June 15, 2016, Acument paid \$68,616.75 for 10 80-Unit (or 22 days of therapy) doses of Acthar;
- x. On July 11, 2016, Acument paid \$68,616.75 for 10 80-Unit (or 22 days of therapy) doses of Acthar;
- xi. On August 9, 2016, Acument paid \$68,616.75 for 10 80-Unit (or 22 days of therapy) doses of Acthar;
- xii. On November 2, 2016, Acument paid \$68,616.75 for 10 80-Unit (or 22 days of therapy) doses of Acthar and
- xiii. On December 6, 2016, Acument paid \$68,616.75 for 10 80-Unit (or 22 days of therapy) doses of Acthar.

367. Defendants' pattern of racketeering activity likely involved hundreds, if not thousands, of separate instances of the use of the United States mail, private shipping services, facsimiles, or interstate wires, including the internet, in furtherance of its fraudulent and unlawful scheme. Each of these fraudulent mailing and interstate wire transmissions separately constitutes

a “racketeering activity” within the meaning of 18 U.S.C. § 1961(1). Collectively, these violations constitute a “pattern of racketeering activity” within the meaning of 18 U.S.C. § 1961(5) in which the Mallinckrodt and Express Scripts intended to defraud Plaintiffs and members of the Class.

368. Each of these payments were made by electronic transfer from Rockford to Express Scripts in St. Louis, Missouri, or from Acument via CVS Caremark to Express Scripts.

369. By conducting the ASAP Enterprise via the fraudulent activities stated herein through the mail and wires, the Defendants both individually and collectively engaged in a repeated, fraudulent, and unlawful course of conduct constituting a pattern of racketeering.

370. Defendants’ pattern of racketeering activity likely involved hundreds, if not thousands, of separate instances of the use of the United States mail, private shipping services, facsimiles, or interstate wires, including the internet, in furtherance of its fraudulent and unlawful scheme. Thousands of ASAP forms, like the one attached hereto as Exhibit “A” were transmitted via facsimile to Express Scripts offices in multiple states. Thousands more phone calls were conducted between physicians and patients with Express Scripts, as directed by the ASAP form (Ex. A). Each of these fraudulent mailing and interstate wire transmissions separately constitutes a “racketeering activity” within the meaning of 18 U.S.C. § 1961(1). Collectively, these violations constitute a “pattern of racketeering activity” within the meaning of 18 U.S.C. § 1961(5) in which the Mallinckrodt and Express Scripts intended to defraud Plaintiffs and members of the Class.

371. Mallinckrodt’s and Express Scripts’ violations and pattern of racketeering activity directly and proximately caused Plaintiffs harm insofar as Rockford paid \$488,787.84 and Acument paid \$894,617.75 in inflated reimbursements and other payments for Acthar.



372. Likewise the Class is harmed by Mallinckrodt's and Express Scripts' violations and pattern of racketeering activity by making similar inflated payments for Acthar.

373. By virtue of these violations of 18 U.S.C. § 1962(c), Mallinckrodt and Express Scripts are jointly and severally liable to Plaintiffs and the Class for three times the damages Plaintiffs and the Class have sustained, plus the costs of this suit, including reasonable attorneys fees.

**WHEREFORE**, Plaintiffs demand that judgment be entered in their favor, and in favor of the Class, and against Mallinckrodt and Express Scripts, in an amount to be determined at trial, including but not limited to costs, attorneys' fees, and such other relief deemed just and appropriate by this Court.

**COUNT X**  
**PLAINTIFFS v. ALL DEFENDANTS**  
**Violation of 18 U.S.C. § 1962(a)**

374. Plaintiffs hereby incorporate by reference the averments of the foregoing paragraphs as if fully set forth herein and further allege as follows.

375. Throughout the Class Period, Defendants have violated the RICO statute by using and investing income that was derived from a pattern of racketeering activity as described herein. This income was used to acquire, establish, and/or operate the ASAP Enterprise in and affecting interstate commerce.

376. The enterprise at issue is an association-in-fact within the meaning of 18 U.S.C. § 1961(4) consisting of Mallinckrodt and Express Scripts, including their directors, employees, and agents, which is manifested in the ASAP program (the "ASAP Enterprise"). The ASAP Enterprise is an ongoing and continuing business organization consisting of both corporations and individuals associated for the common purpose of selling, purchasing, and administering

Acthar to Plaintiffs and their individual participants, and deriving profits from these activities. Defendants engaged in a pattern of racketeering activity described in greater detail herein.

377. Plaintiffs and members of the Class have been directly and proximately injured in their property by the Defendants' use and investment of the racketeering income in the acquisition, establishment, and operation of the ASAP Enterprise. The injury to Plaintiffs and the Class' businesses or property stemming from these violations has been realized by the overpayment for Acthar.

378. The use and investment of racketeering income by Mallinckrodt and Express Scripts directly and proximately injured the Plaintiffs and the Class in a manner than was distinct from the injury caused by the pattern of racketeering activity described herein.

379. By virtue of these violations of 18 U.S.C. § 1962(a), Defendants are jointly and severally liable to Plaintiffs and the Class for three times the damages Plaintiffs and the Class have sustained, plus the costs of this suit, including reasonable attorneys fees.

**WHEREFORE**, Plaintiffs demand that judgment be entered in their favor, and in favor of the Class, and against Express Scripts, in an amount to be determined at trial, including but not limited to costs, attorneys' fees, and such other relief deemed just and appropriate by this Court.

**COUNT XI**  
**PLAINTIFFS v. ALL DEFENDANTS**  
**Violation of 18 U.S.C. § 1962(d)**

380. Plaintiffs hereby incorporate by reference the averments of the foregoing paragraphs as if fully set forth herein and further allege as follows.

381. Mallinckrodt and Express Scripts violated 18 USC § 1962(d) by conspiring to associate with a racketeering enterprise, in violation of 18 U.S.C. § 1962(c). Mallinckrodt

explicitly contracted with Express Scripts to have Express Scripts serve as Mallinckrodt's exclusive agent in the conduct of the ASAP Program and the ASAP Enterprise, and conspired with Express Scripts to inflate the prices and limit distribution of Acthar in violation of § 1962(c).

382. Mallinckrodt and Express Scripts knew and adopted the criminal purpose of the ASAP Enterprise. Mallinckrodt communications reflect an express illegal agreement between Mallinckrodt and Express Scripts to limit the distribution of Acthar in order to charge inflated prices.

383. Additionally, Mallinckrodt's conduct in sending e-mails, faxes and other communications to Express Scripts to direct the exclusive distribution, sale and reimbursement of Acthar through ASAP is consistent with the existence of an agreement to carry out the scheme to inflate prices and maximize profits. Express Scripts, in turn, communicated Mallinckrodt's inflated prices to its clients, including Rockford, in its contract schedules and subsequent invoices for Acthar. These same prices were communicated to the other PBMs, like CVS Caremark, for inclusion in their contracts with payors, like Acument.

384. Mallinckrodt and Express Scripts actively furthered the goals of the ASAP Enterprise to defraud end payors, like the Plaintiffs. Mallinckrodt changed its distribution scheme with Acthar with the intention that the changes would affect the prices of Acthar; it engaged in frequent discussions with all other Defendants about its plan to raise Acthar prices in the marketplace; it made requests that Express Scripts change the Acthar prices charged to its clients in conjunction with its price increases; and it publicly boasted about the effects of the scheme without disclosing its details.

385. Plaintiffs and other members of the Class have been injured in their business or

property because they have paid thousands of dollars in overpayments that they would not have made had Defendants not conspired to engage in racketeering activity.

386. As co-conspirators, Mallinckrodt plc, Questcor, Express Scripts Holding Company, Express Scripts, Inc., UBC, CuraScript, and Accredo are jointly and severally liable for all damage that occurred as a result of both their actions and those of Mallinckrodt plc, Questcor, Express Scripts Holding Company, Express Scripts, Inc., UBC, CuraScript, and Accredo, respectively, in furtherance of the conspiracy to raise prices of Acthar. All Defendants are liable for all damages arising from Mallinckrodt plc's, Questcor's, Express Scripts Holding Company, Express Scripts, Inc., UBC's, CuraScript's, and Accredo's respective conduct in furtherance of the scheme.

387. Under the provisions of Section 1964(c) of RICO, Mallinckrodt plc, Questcor, Express Scripts Holding Company, Express Scripts, Inc., UBC, CuraScript, and Accredo are jointly and severally liable to Plaintiffs for three times the damages that Plaintiffs have sustained, plus the costs of bringing this suit, including reasonable attorneys' fees.

**WHEREFORE**, Plaintiffs demand that judgment be entered in their favor, and in favor of the Class, and against Mallinckrodt and Express Scripts, in an amount to be determined at trial, including but not limited to costs, attorneys' fees, and such other relief deemed just and appropriate by this Court.

**COUNT XII**  
**CITY OF ROCKFORD V. EXPRESS SCRIPTS**  
**BREACH OF CONTRACT**  
**BREACH OF THE ESI PBM AGREEMENT**

388. Rockford hereby incorporates by reference the averments of the foregoing paragraphs as if fully set forth herein and further alleges as follows.

389. This Count alleges breach of the ESI PBM Agreement against Express Scripts.

390. By its representations, manifestations of assent, customs and practices, ESI is bound to and by the terms of the ESI PBM Agreement.

391. By the foregoing conduct, specifically ESI's failure to provide "cost containment" services either through nonfeasance or malfeasance, ESI breached the ESI PBM Agreement, repudiated its obligations under the ESI PBM Agreement, and is in default of the ESI PBM Agreement.

392. Rockford performed and met all of its obligations under the ESI PBM Agreement to date and has a right to and is entitled to all remedies ascribed to it under the ESI PBM Agreement and Illinois law.

393. Rockford has been damaged as a direct and proximate result of ESI's failure to perform under the terms of the ESI PBM Agreement.

**WHEREFORE**, Rockford demands that judgment be entered in its favor, and in favor of the Class, and against Express Scripts, in an amount to be determined at trial, including but not limited to costs, attorneys' fees, and such other relief deemed just and appropriate by this Court.

**COUNT XIII**  
**CITY OF ROCKFORD V. EXPRESS SCRIPTS**  
**PROMISSORY ESTOPPEL**

394. Rockford hereby incorporates by reference the preceding and following paragraphs hereof as if fully set forth herein.

395. This Count alleges promissory estoppel against Express Scripts. It charges that ESI's conduct described above constitutes a promise to perform under the terms of the ESI PBM Agreement; and a promise upon which Rockford relied upon to its detriment.

396. Rockford seeks enforcement of ESI's promise to continue with ESI's obligations under the ESI PBM Agreement.

397. ESI utterly refused and failed to fulfill its representations and promises concerning the terms and obligations under the ESI PBM Agreement, including the promise of cost containment with respect to Acthar.

398. Rockford relied on the conduct described above and in justifiable reliance thereon, and as a direct and proximate result of its reliance thereon, Rockford has been damaged.

399. Injustice can be avoided only by enforcing ESI's representations and promises concerning the expectations that it created regarding ESI's obligations under the ESI PBM Agreement, and awarding Rockford damages based on ESI's failure to fulfill its representations and promises.

**WHEREFORE**, Rockford demands that judgment be entered in its favor and in favor of the Class, and against Express Scripts, in an amount to be determined at trial, including but not limited to costs, attorneys' fees, and such other relief deemed just and appropriate by this Court.

**COUNT XIV**  
**CITY OF ROCKFORD V. EXPRESS SCRIPTS**  
**DECLARATORY JUDGMENT**  
**THE ESI PBM AGREEMENT**

400. Rockford hereby incorporates by reference the preceding and following paragraphs hereof as if fully set forth herein.

401. This Count seeks declaratory judgment under 28 U.S.C. §§2201 and 2202, because an actual, present and substantial controversy exists between Rockford and Express Scripts concerning the ESI PBM Agreement, and Rockford's entitlement to continue to receive the benefit of its bargain with Express Scripts in the ESI PBM Agreement.

402. Rockford is statutorily entitled to declarations of its rights, status or relations.

403. **WHEREFORE**, Rockford demands that judgment be entered in its favor, and in favor of the Class, declaring that:

- a. ESI has repudiated its obligations to perform under the ESI PBM Agreement and is therefore in default of the ESI PBM Agreement; and
- b. ESI is estopped from denying its obligations to comply with the provisions of the ESI PBM Agreement.

**COUNT XV**  
**CITY OF ROCKFORD V. EXPRESS SCRIPTS**  
**BREACH OF THE IMPLIED COVENANT OF**  
**GOOD FAITH AND FAIR DEALING**

404. Rockford hereby incorporates by reference the averments of the foregoing paragraphs as if fully set forth herein and further alleges as follows.

405. The general duty of good faith and fair dealing in the performance of a contract is found in the Restatement (Second) of Contracts, Section 205, which provides that “every contract imposes upon each party a duty of good faith and fair dealing in its performance and its enforcement.”

406. In Illinois and other states, the duty of good faith is defined as honesty in fact in the conduct or transaction concerned.

407. The duty to perform contractual obligations in good faith applies to the ESI PBM Agreement and requires ESI to use its best efforts to fulfill its promise to provide “cost containment” services.

408. By failing to provide “cost containment” services and costing Rockford \$488,787.64 for 9 prescriptions of Acthar over the course of 8 months, ESI breached the covenant of good faith and fair dealing.

409. ESI’s breach of the covenant of good faith and fair dealing was the direct and proximate result of injury and damages to Rockford.

**WHEREFORE,** Rockford demands that judgment be entered in its favor and in favor of the Class, and against Mallinckrodt and Express Scripts, in an amount to be determined at trial,

including but not limited to costs, attorneys' fees, and such other relief deemed just and appropriate by this Court.

**PRAYER FOR RELIEF**

WHEREFORE, Plaintiffs and the Class request the Court to enter the following relief:

- a. Certify this case as a class action pursuant to Rule 23 of the Federal Rules of Civil Procedure, and denominate Plaintiffs as an adequate representative for the Class and their undersigned counsel as counsel for the Class;
- b. Declare unlawful the acts and practices alleged herein, enjoin the Defendants from committing the acts alleged herein, and restore the status quo before the unlawful conduct took place;
- c. Enter judgment against all Defendants for the violations alleged herein;
- d. Award the actual damages incurred by Plaintiffs and the members of the Class as a result of the wrongful acts complained of, along with pre-judgment and post-judgment interest at the maximum rate allowed by law;
- e. Award statutory damages set forth herein under the statutory claims alleged;
- f. Award treble damages or multiple damages by operation of law;
- g. Award punitive damages;
- h. Award Plaintiffs the costs of this action, including reasonable attorneys' fees, and, where applicable, expert fees; and
- i. Award such other and further relief as the Court may deem just and appropriate.



**JURY DEMAND**

Plaintiffs and the Class demand a trial by jury of all issues so triable in this cause.

Respectfully submitted,

By: /s/ Donald E. Haviland, Jr.  
Donald E. Haviland, Jr.  
*haviland@havilandhughes.com*  
William H. Platt, II  
*platt@havilandhughes.com*  
Haviland Hughes  
201 South Maple Avenue  
Suite 110  
Ambler, PA 19002  
Phone: (215) 609-4661  
Fax: (215) 392-4400

Peter J. Flowers, Esquire  
(IL Attorney ID No. 06210847)  
*pjf@meyers-flowers.com*  
Meyers & Flowers, LLC  
3 North Second Street, Suite 300  
St. Charles, IL 60174  
Ph: (630) 232-6333  
Fax: (630) 845-8982

Kerry F. Partridge, Esquire  
City Attorney  
*kerry.partridge@rockfordil.gov*  
425 East State Street  
Rockford, IL 61104-1068  
Ph: (779) 348-7154  
Fax: (815) 967-6949

*Attorneys for Plaintiffs and the Class*

**CERTIFICATE OF SERVICE**

I hereby certify that on December 8, 2017, a true and correct copy of the foregoing Second Amended Class Action Complaint was electronically filed with the Clerk of Court using the CM/ECF system, which will send notification of such filing to all counsel of record.

s/ Donald E. Haviland, Jr.

# EXHIBIT A

1. PATIENT INFORMATION

Patient has been notified of referral ☐ YES ☐ NO

PATIENT FIRST NAME

PATIENT MIDDLE INITIAL

PATIENT LAST NAME

DATE OF BIRTH

GENDER

HOME ADDRESS

CITY

STATE

ZIP

SHIPPING ADDRESS (IF NOT HOME ADDRESS)

CARE OF (IF NOT ADDRESSED TO PATIENT)

CITY

STATE

ZIP

HOME PHONE

MOBILE

OK TO TEXT

BEST TIME TO CALL

PREFERRED LANGUAGE IF NOT ENGLISH

EMAIL ADDRESS

PATIENT REPRESENTATIVE

RELATIONSHIP

TELEPHONE

2. INSURANCE INFORMATION (PLEASE INCLUDE COPIES OF CARDS)

PHARMACY BENEFITS

SUBSCRIBER ID #

GROUP #

TEL #

PRIMARY MEDICAL INSURANCE

POLICY HOLDER

RELATIONSHIP

SUBSCRIBER ID #

GROUP #

TEL #

3. HEALTHCARE PROVIDER (HCP) INFORMATION

HCP FIRST NAME

HCP LAST NAME

HCP MIDDLE INITIAL

NPI #

GROUP NPI # (IF APPLICABLE)

STATE LICENSE #

SPECIALTY: NEPHROLOGY

NEUROLOGY

PULMONOLOGY

RHEUMATOLOGY

OPHTHALMOLOGY

OTHER

IF OTHER PLEASE INDICATE

FACILITY NAME

TELEPHONE

FAX

ADDRESS

CITY

STATE

ZIP

OFFICE CONTACT NAME

CONTACT TELEPHONE

EMAIL ADDRESS

PREFERRED METHOD OF COMMUNICATION

4. PRESCRIPTION: H.P. ACTHAR<sup>®</sup> GEL

NDC# 63004-8710-1 5 mL multidose vial containing 80 USP units per mL

PRIMARY DIAGNOSIS:

ICD-10:

INITIATE PATIENT WITH:

DOSE: 

UNITS

ML

SCHEDULE/FREQUENCY:

QUANTITY OF 5 ML MULTIDOSE VIALS:

REFILLS:

ROUTE OF ADMINISTRATION: 

INTRAMUSCULAR

SUBCUTANEOUS

ADDITIONAL SPECIAL INSTRUCTIONS, OR TAPER DOSE, IF APPLICABLE:

ALLERGIES:

SUPPLIES:

SYRINGE SIZE: 1 mL 3 mL Other size

QUANTITY:

NEEDLE SIZE: 20 g needle, 1 inch 23 g needle, 1 inch 25 g needle, 1 inch 25 g needle, 5/8 inch (other):

QUANTITY:

PATIENT WEIGHT (FOR WEIGHT-BASED DOSING ONLY):

SUPPLY REFILLS:

SHARPS CONTAINER:

OTHER SUPPLIES:

HOME INJECTION TRAINING SERVICES (HITS)

By initialing here (original required) I request that company-funded HITS services be arranged for my patient. I understand that HITS is for one instruction visit only and NOT a home health nursing service. I also understand that all reasonable efforts will be made to schedule the HITS training visit within 24 hours of the patient's receipt of drug shipment.

INITIALS

DATE

5. PRESCRIPTION, CONSENT AND STATEMENT OF MEDICAL NECESSITY: HCP SIGNATURE REQUIRED

I certify that H.P. Acthar<sup>®</sup> Gel is medically necessary for this patient and that I have reviewed this therapy with the patient and will be monitoring the patient's treatment. I verify that the patient and healthcare provider information on this enrollment form is complete and accurate to the best of my knowledge. I understand that I must comply with my practicing state's specific prescription requirements such as, e-prescribing, state specific prescription form, fax language, etc. Non-compliance of state specific requirements could result in outreach to me by the dispensing pharmacy.

I authorize United BioSource Corporation ("UBC"), the current operator of the Acthar Support and Access Program ("Program"), and other designated operators of the Program, to perform a preliminary assessment of benefit verification for this patient and furnish information requested by the patient's insurer that is available on this form. I understand that insurance verification is ultimately the responsibility of the provider and third-party reimbursement is affected by a variety of factors. While UBC tries to provide accurate information, they and Mallinckrodt make no representations or warranties as to the accuracy of the information provided.

I understand that representatives from the Program or UBC may contact me or my patient for additional information relating to this prescription. I acknowledge and agree that the designated specialty pharmacy receive this prescription via a designated third party, the Program and that no additional confirmation of receipt of prescription is required by the designated specialty pharmacy

HCP Prescriber Signature - Please sign ONE LINE below

DISPENSE AS WRITTEN

DATE

SUBSTITUTIONS ALLOWED

DATE

Prescriber signature required to consent and validate prescriptions. Prescriber attests that this is her/his signature. NO STAMPS. By signing, I certify that the above is medically necessary.

1

For Patient: \_\_\_\_\_ DOB: \_\_\_\_\_

**6. DIAGNOSIS AND MEDICAL INFORMATION****Diagnosis****Please select diagnosis and responses to associated questions**☐ **Ankylosing spondylitis**☐ **Dermatomyositis**☐ **Infantile spasms**

Has diagnosis been confirmed by EEG?

☐ YES ☐ NO

Patient's weight: \_\_\_\_\_

Requested drug delivery date: \_\_\_\_\_

☐ **Multiple sclerosis**

Is Acthar to be used to treat an acute exacerbation?

☐ Exacerbation ☐ Other \_\_\_\_\_ Must check one

Onset of acute exacerbation Date: \_\_\_\_\_

☐ **Optic neuritis**☐ **Polymyositis****Proteinuria in nephrotic syndrome**

Please indicate etiology:

☐ Focal segmental glomerular sclerosis (FSGS)☐ IgA nephropathy (IgAN)☐ Lupus nephritis☐ Membranous nephropathy (MN)☐ Other: \_\_\_\_\_☐ **Psoriatic arthritis**☐ **Rheumatoid arthritis**☐ **Sarcoidosis**☐ **Systemic lupus erythematosus**

Is Acthar to be used to treat an acute exacerbation?

☐ YES ☐ NO Must check one**Lupus nephritis?**☐ YES ☐ NO☐ **Uveitis**☐ **Other diagnosis** \_\_\_\_\_**7. HISTORY OF CORTICOSTEROID USE (IF APPLICABLE) PLEASE ADD DETAILS IN SECTION 8 BELOW****Please check all that apply****A corticosteroid was tried with the following response(s):**☐ Corticosteroid use failed, but same response not expected with Acthar☐ Patient hypersensitive or allergic to corticosteroids☐ Patient intolerant to corticosteroids☐ Other: \_\_\_\_\_

OR

**A corticosteroid was not tried due to the following response(s):**☐ Corticosteroid use is contraindicated for this patient☐ Intravenous access is not possible for this patient☐ Patient has known intolerance to corticosteroids☐ Other: \_\_\_\_\_**8. CONCURRENT MEDICATIONS****9. RELEVANT TREATMENT HISTORY (INCLUDING RECENT STEROID HISTORY)**

Therapy Name	Dose	Start Date	Stop Date (if applicable)	Explain Outcome With Detail (ex. type of outcome)

(Attach additional pages as necessary)

**OTHER RELEVANT CLINICAL INFORMATION****HCP SIGNATURE: REQUIRED FOR DOCUMENTATION**

NAME

SIGNATURE

DATE



10. PATIENT AUTHORIZATION(S)

For Patient Review and Completion. If patient is not available, authorization will be obtained from patient by Acthar Support and Access Team upon receipt of referral.

By signing this authorization, I authorize my physician(s), my health insurance company, my pharmacy providers and Mallinckrodt ARD Inc., the distributor of Acthar (“Mallinckrodt”), and its agents, authorized designees and contractors, including Mallinckrodt reimbursement support personnel and United BioSource Corporation (“UBC”) or any other operator of the Acthar Support and Access Program on behalf of Mallinckrodt (collectively, “Designated Parties”), to use and disclose to other Designated Parties health information relating to my medical condition, treatment, and insurance coverage (my “Health Information”) in order for them to (1) provide certain services to me, including reimbursement and coverage support, patient assistance and access programs, medication shipment tracking, and home injection training, (2) provide me with support services and information associated with my Acthar therapy, (3) for internal business purposes, such as for marketing research, internal financial reporting and operational purposes, and (4) to carry out the Designated Parties’ respective legal responsibilities.

Once my Health Information has been disclosed to the Designated Parties, I understand that it may be re-disclosed by them and no longer protected by federal and state privacy laws. However, the Designated Parties agree to protect my Health Information by using and disclosing it only for the purposes detailed in this authorization or as permitted or required by law.

I understand that I may refuse to sign this authorization and that my physician and pharmacy will not condition my treatment on my agreement to sign this authorization form, and my health plan or health insurance company will not condition payment for my treatment, insurance enrollment or eligibility for insurance benefits on my agreement to sign this authorization form. I understand that my pharmacies and other Designated Parties may receive payment in connection with the disclosure of my Health Information as provided in this authorization. I understand that I am entitled to receive a copy of this authorization after I sign it.

I may revoke (withdraw) this authorization at any time by mailing a letter to Acthar Support and Access, 255 Technology Park, Lake Mary, FL 32746. Revoking this authorization will end further disclosure of my Health Information to Designated Parties by my pharmacy, physicians and health insurance company when they receive a copy of the revocation, but it will not apply to information they have already disclosed to the Designated Parties based on this authorization. I also know I may cancel my enrollment in a patient support program at any time in writing by contacting Mallinckrodt via fax at 877-937-2284.

This authorization is in effect for 1 year or until the conclusion of any ongoing coverage support, whichever is longer, once I have signed it unless I cancel it before then.

PATIENT NAME OR LEGAL REPRESENTATIVE	PATIENT SIGNATURE	IF LEGAL REPRESENTATIVE, RELATIONSHIP TO PATIENT	DATE
--------------------------------------	-------------------	--------------------------------------------------	------

I authorize Mallinckrodt and its agents to receive, use, and disclose my health information relating to my medical condition, treatment, insurance coverage, and contact information from me, my healthcare providers, my pharmacies, and my health insurance company in order to (1) contact me about participation in Acthar patient programs, (2) provide me with educational or other informational materials, (3) administer its education and other patient-related programs, (4) conduct surveys that request my feedback, and (5) for Mallinckrodt to carry out its legal responsibilities in connection with these education and support programs. I agree to let Mallinckrodt or its agents contact me in the future about these offerings. Once my health information has been disclosed to the education, informational and/or support program I choose to participate in, I understand that it may be redisclosed by Mallinckrodt or its agents, and they are authorized to use or disclose this information in the manner described here and as permitted by this authorization or as otherwise permitted or required by law, and that federal and state privacy laws may no longer protect the information. However, Mallinckrodt and its agents agree to protect my health information by using and disclosing it only for the purposes described in this authorization or as permitted or required by law. This authorization will remain in effect until I cancel it which I may do so at any time by contacting Mallinckrodt via fax at 877-937-2284. Cancelling this authorization will end further use or disclosure of my health information by Mallinckrodt or its agents (except to the extent that such parties took actions based on this authorization prior to my revocation). If I withdraw my permission, I know that this means I may no longer receive information on supplemental education or support programs. Once I withdraw my permission, no new information will be disclosed to Mallinckrodt or its agents, but Mallinckrodt and its agents may continue to use the information that was collected before I withdrew my permission as permitted by this authorization or as otherwise permitted or required by law. I may request a copy of this signed authorization.

PATIENT NAME OR LEGAL REPRESENTATIVE	PATIENT SIGNATURE	IF LEGAL REPRESENTATIVE, RELATIONSHIP TO PATIENT	DATE
--------------------------------------	-------------------	--------------------------------------------------	------

**INDICATIONS AND USAGE**

- **Infantile spasms:** H.P. Acthar Gel (repository corticotropin injection) is indicated as monotherapy for the treatment of infantile spasms in infants and children under 2 years of age
- **Multiple Sclerosis:** H.P. Acthar Gel (repository corticotropin injection) is indicated for the treatment of acute exacerbations of multiple sclerosis in adults. Controlled clinical trials have shown H.P. Acthar Gel to be effective in speeding the resolution of acute exacerbations of multiple sclerosis. However, there is no evidence that it affects the ultimate outcome or natural history of the disease
- **Rheumatic Disorders:** As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: psoriatic arthritis, rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy), ankylosing spondylitis
- **Collagen Diseases:** During an exacerbation or as maintenance therapy in selected cases of: systemic lupus erythematosus, systemic dermatomyositis (polymyositis)
- **Dermatologic Diseases:** Severe erythema multiforme, Stevens-Johnson syndrome
- **Allergic States:** Serum sickness
- **Ophthalmic Diseases:** Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: keratitis, iritis, iridocyclitis, diffuse posterior uveitis and choroiditis, optic neuritis, chorioretinitis, anterior segment inflammation
- **Respiratory Diseases:** Symptomatic sarcoidosis
- **Edematous State:** To induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus

**IMPORTANT SAFETY INFORMATION****CONTRAINDICATIONS**

- Acthar should never be administered intravenously
- Administration of live or live attenuated vaccines is contraindicated in patients receiving immunosuppressive doses of Acthar
- Acthar is contraindicated where congenital infections are suspected in infants
- Acthar is contraindicated in patients with scleroderma, osteoporosis, systemic fungal infections, ocular herpes simplex, recent surgery, history of or the presence of a peptic ulcer, congestive heart failure, uncontrolled hypertension, primary adrenocortical insufficiency, adrenocortical hyperfunction or sensitivity to proteins of porcine origins

**WARNINGS AND PRECAUTIONS**

- The adverse effects of Acthar are related primarily to its steroidogenic effects
- Acthar may increase susceptibility to new infection or reactivation of latent infections
- Suppression of the hypothalamic-pituitary-axis (HPA) may occur following prolonged therapy with the potential for adrenal insufficiency after withdrawal of the medication. Adrenal insufficiency may be minimized by tapering of the dose when discontinuing treatment. During recovery of the adrenal gland patients should be protected from the stress (e.g. trauma or surgery) by the use of corticosteroids. Monitor patients for effects of HPA suppression after stopping treatment
- Cushing's Syndrome may occur during therapy but generally resolves after therapy is stopped. Monitor patients for signs and symptoms
- Acthar can cause elevation of blood pressure, salt and water retention, and hypokalemia. Blood pressure, sodium and potassium levels may need to be monitored
- Acthar often acts by masking symptoms of other diseases/disorders. Monitor patients carefully during and for a period following discontinuation of therapy
- Acthar can cause GI bleeding and gastric ulcer. There is also an increased risk for perforation in patients with certain gastrointestinal disorders. Monitor for signs of bleeding
- Acthar may be associated with central nervous system effects ranging from euphoria, insomnia, irritability, mood swings, personality changes, and severe depression, and psychosis. Existing conditions may be aggravated
- Patients with comorbid disease may have that disease worsened. Caution should be used when prescribing Acthar in patients with diabetes and myasthenia gravis
- Prolonged use of Acthar may produce cataracts, glaucoma and secondary ocular infections. Monitor for signs and symptoms
- Acthar is immunogenic and prolonged administration of Acthar may increase the risk of hypersensitivity reactions. Neutralizing antibodies with chronic administration may lead to loss of endogenous ACTH activity
- There is an enhanced effect in patients with hypothyroidism and in those with cirrhosis of the liver
- Long-term use may have negative effects on growth and physical development in children. Monitor pediatric patients
- Decrease in bone density may occur. Bone density should be monitored for patients on long-term therapy
- Pregnancy Class C: Acthar has been shown to have an embryocidal effect and should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus

**ADVERSE REACTIONS**

- Common adverse reactions for Acthar are similar to those of corticosteroids and include fluid retention, alteration in glucose tolerance, elevation in blood pressure, behavioral and mood changes, increased appetite and weight gain
- Specific adverse reactions reported in IS clinical trials in infants and children under 2 years of age included: infection, hypertension, irritability, Cushingoid symptoms, constipation, diarrhea, vomiting, pyrexia, weight gain, increased appetite, decreased appetite, nasal congestion, acne, rash, and cardiac hypertrophy. Convulsions were also reported, but these may actually be occurring because some IS patients progress to other forms of seizures and IS sometimes mask other seizures, which become visible once the clinical spasms from IS resolve

**Other adverse events reported are included in the full Prescribing Information.**

**Please see accompanying full Prescribing Information.**

# EXHIBIT B





Q U E S T C O R

## URGENT PRODUCT ALERT H.P. Acthar<sup>®</sup> Gel

July 2, 2007

Dear Healthcare Professional,

As you know, H.P. Acthar<sup>®</sup> Gel (repository corticotropin injection) plays a critical role in many inpatient and outpatient treatment regimens. **Effective August 1, 2007, Acthar Gel (NDC # 63004-7731-1) will be available exclusively through Specialty Pharmacy Distribution.** Acthar Gel will no longer be available from traditional pharmaceutical wholesalers or retail pharmacies. Please be sure to share this information appropriately with your staff and patients.

### **For Hospital Stock Orders**

Beginning July 16, 2007, hospitals should place all stock orders with CuraScript Specialty Distribution (**877-599-7748**). We suggest that appropriate personnel at your facility contact CuraScript Specialty Distribution (**877-599-7748**) as soon as possible to establish an account.

### **Planning for Patient Discharge – Outpatient Prescriptions**

Beginning July 16, 2007, when treatment with Acthar Gel is initiated in a hospital setting with the intent to continue after discharge, it is imperative that the outpatient prescription order be placed immediately after treatment initiation to ensure an uninterrupted supply of Acthar Gel at discharge. Beginning July 16, 2007, please contact the following support and access program to get prescriptions filled and for assistance with reimbursement:

#### ***Acthar Support & Access Program (ASAP)***

- **PHONE: 888-435-2284**
- **FAX: 877-937-2284**

More information and referral forms can be obtained at **[www.acthar.com](http://www.acthar.com)**.

### **Filling Prescriptions**

Please tell your patients currently having Acthar Gel prescriptions filled at retail pharmacies to immediately confirm the pharmacy has stock on hand for their remaining refills. Beginning July 16, 2007, all new Acthar Gel prescriptions should be submitted to the Acthar Support & Access Program (**PHONE: 888-435-2284; FAX: 877-937-2284**).

Questcor is committed to providing uninterrupted availability of Acthar Gel for patients who critically need it. This change in Acthar Gel distribution and the creation of the Acthar Support & Access Program is an important part of this mission.

Sincerely,

Steve Cartt, Executive Vice President, Corporate Development  
Questcor Pharmaceuticals

# EXHIBIT C

**KATTEN MUCHIN ROSENMAN LLP**

Kristin L. Holland (SBN 187314)  
kristin.holland@kattenlaw.com  
Tami Kameda Sims (SBN 245628)  
tami.sims@kattenlaw.com  
2029 Century Park East, Suite 2600  
Los Angeles, CA 90067-3012  
Telephone: 310.788.4400  
Facsimile: 310.788.4471

**KATTEN MUCHIN ROSENMAN LLP**

James J. Calder (*applying for pro hac vice*)  
james.calder@kattenlaw.com  
Mark T. Ciani (*applying for pro hac vice*)  
mark.ciani@kattenlaw.com  
575 Madison Avenue  
New York, NY 10022-2585  
Telephone: 212.940.8800  
Facsimile: 212.940.8776

Attorneys for Plaintiff Retrophin, Inc.

**UNITED STATES DISTRICT COURT  
CENTRAL DISTRICT OF CALIFORNIA  
SOUTHERN DIVISION**

RETROPHIN, INC., a Delaware  
Corporation,

Plaintiff,

vs.


QUESTCOR PHARMACEUTICALS,  
INC., a California Corporation,

Defendant.

**COMPLAINT FOR:**

1. RESTRAINT OF TRADE IN VIOLATION OF SECTION 1 OF THE SHERMAN ACT (15 U.S.C. § 1 ET SEQ.)
2. MONOPOLIZATION IN VIOLATION OF SECTION 2 OF THE SHERMAN ACT (15 U.S.C. § 2 ET SEQ.)
3. ATTEMPTED MONOPOLIZATION IN VIOLATION OF SECTION 2 OF THE SHERMAN ACT (15 U.S.C. § 2 ET SEQ.)
4. UNLAWFUL MERGER IN VIOLATION OF SECTION 7 OF THE CLAYTON ACT (15 U.S.C. § 18 ET SEQ.)
5. VIOLATION OF CALIFORNIA ANTITRUST LAWS
6. VIOLATION OF CALIFORNIA UNFAIR COMPETITION LAWS

**DEMAND FOR JURY TRIAL**



FILED  
2014 JAN - 7 PM 3:54  
Clerk of Court

1 Plaintiff Retrophin, Inc. ("Retrophin"), as and for its complaint against  
2 Defendant Questcor Pharmaceuticals, Inc. ("Questcor"), alleges as follows:

3 **Nature of the Action**

4 1. Questcor is a monopolist. It is the sole provider in the US of approved  
5 therapeutic preparations of adrenocorticotrophic hormone ("ACTH"), a drug used to  
6 treat certain life threatening and often fatal diseases. Questcor's ACTH drug is sold  
7 under the brand name H.P. Acthar Gel ("Acthar"). The drug is not patented.

8 2. Questcor acquired the rights to Acthar in 2001. At the time, Acthar sold  
9 for \$50 a vial or less. Since then, Questcor has raised the price to \$28,000 – a  
10 56,000% price increase.

11 3. Questcor is able to charge such an extortionate price for Acthar because it  
12 holds a monopoly in the US. Its monopoly exists for several reasons. First, Acthar is  
13 the only long acting ACTH therapeutic drug approved by the Food and Drug  
14 Administration ("FDA") for use in the US. Second, Acthar is the most effective and  
15 dominant first line treatment for Infantile Spasms, an often fatal disorder that causes  
16 epileptic type seizures in babies, toddlers and children under the age of 5. In addition,  
17 Questcor has obtained "Orphan Drug Designation" for Acthar from the FDA under the  
18 Orphan Drug Act, 21 USC §§301 *et seq.*, giving it the exclusive right to market  
19 Acthar – and its chemical equivalent – for use in treating Infantile Spasms. Third,  
20 Acthar is also the most commonly used treatment of last resort for patients suffering  
21 from Nephrotic Syndrome, a condition that results in excessive protein being secreted  
22 through the urine that destroys the kidneys and can lead to kidney failure. Treatments  
23 of last resort, as the term implies, are used for patients who do not respond to or  
24 cannot tolerate other therapies used to treat their illness.

25 4. In June of 2013, plaintiff Retrophin was poised to challenge Questcor's  
26 monopoly. It had negotiated an agreement to purchase from Novartis AG  
27 ("Novartis"), the rights to sell in the US a product called Synacthen, an ACTH drug  
28 that contains the same sequence of the first 24 amino acids that is found in Acthar.

1 While there are differences between Acthar and Synacthen – the two are not  
2 chemically identical beyond the first 24 amino acids and they are produced differently  
3 – Synacthen has been sold for years outside of the US for the treatment of Infantile  
4 Spasms, Nephrotic Syndrome, Multiple Sclerosis and other diseases. On information  
5 and belief, it is not currently sold in the US because it has never been submitted to the  
6 FDA for approval.

7 5. Retrophin planned to obtain FDA approval to sell Synacthen in the US  
8 and compete head to head against Questor by dramatically undercutting Questcor's  
9 price for Acthar. It had negotiated and was ready to sign an agreement to purchase the  
10 US rights to Synacthen from Novartis. The signing was scheduled for June 11, 2013.  
11 The signing of the agreement was so imminent that a press release had been prepared  
12 to announce the deal.

13 6. On June 11, 2013, the day Retrophin was to sign its agreement with  
14 Novartis, Questcor swept in and acquired the rights to Synacthen. In so doing, it  
15 preserved and entrenched its ACTH monopoly in the US and eliminated the  
16 competitive threat posed by Retrophin's acquisition of Synacthen. There was no  
17 procompetitive aspect of Questcor's acquisition of Synacthen.

18 7. When it acquired the rights to Acthar, Questcor did not make a  
19 Premerger Notification Filing with the Department of Justice and the Federal Trade  
20 Commission under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, 15  
21 USC, §18a *et seq.*

22 8. Questcor was quite aware, however, that its agreement with Novartis  
23 raised serious antitrust questions. The agreement provides that, if Questcor is forced  
24 to divest its rights to Synacthen on antitrust grounds, Novartis will keep the entire \$60  
25 million that Questcor had paid it. In addition, Questcor remains obligated to make all  
26 future milestone payments owed to Novartis under that agreement – an amount in  
27 excess of \$75 million. Questcor has accepted the entire economic risk – an amount in  
28

1 excess of \$135 million – that the agreement with Novartis would be deemed illegal  
2 under the antitrust laws.

3 9. Questcor’s acquisition of Synacthen has delayed, and may completely  
4 foreclose, Retrophin’s entry into the markets defined below. It will delay, and may  
5 completely prevent, Retrophin from competing against Questcor. Retrophin brings  
6 this lawsuit to recover the damages it has incurred as a result of Questcor’s  
7 anticompetitive and monopolistic conduct. It also seeks injunctive relief against  
8 Questcor’s continuation of such conduct.

### 9 The Parties

10 10. Plaintiff Retrophin is organized and exists under the laws of Delaware.  
11 Its principal place of business is located at 777 Third Avenue, 22nd Floor, New York,  
12 New York 10017. It also does business in California and Massachusetts.

13 11. Retrophin is a biopharmaceutical company focused on the development,  
14 acquisition and commercialization of drugs for the treatment of serious, catastrophic  
15 or rare diseases for which there are currently no viable options for patients. The  
16 diseases on which Retrophin focuses are often considered “orphan” diseases because  
17 they affect fewer than 200,000 patients in the United States. Retrophin has acquired  
18 and is building a pipeline of innovative product candidates for several catastrophic  
19 diseases, including: Focal Segmental Glomerulosclerosis, a kidney disease;  
20 Pantothenate Kinase-Associated Neurodegeneration; and Duchenne Muscular  
21 Dystrophy.

22 12. Defendant Questcor is a corporation organized and existing under the  
23 laws of the State of California. It maintains its principal place of business in  
24 Anaheim, California.

### 25 Jurisdiction and Venue

26 13. Retrophin brings this action under Sections 4 and 16 of the Clayton Act,  
27 15 U.S.C. §§15 and 26, to recover treble damages and costs of suit, including  
28 reasonable attorneys’ fees, and for injunctive relief, for injuries suffered by Retrophin



Katzen Muehlen Rosenman LLP  
2029 Century Park East, Suite 2600  
Los Angeles, CA 90067-3012  
310.788.4400 tel 310.788.4471 fax

14. Additionally, this Court has diversity jurisdiction over this action pursuant to 28 U.S.C. § 1332(a) because the controversy exceeds the sum or value of \$75,000 and Retrophin and Questcor are citizens of different states. This Court has supplemental jurisdiction over Retrophin's state law claims pursuant to 28 U.S.C. § 1367(a).

15. Venue in this Court exists by virtue of Sections 4 and 12 of the Clayton Act, as amended, 15 U.S.C. §§ 15 and 22, and 28 U.S.C. § 1391(c). Defendant Questcor is found, has agents, transacts and is doing business in this District, and the unlawful activities complained of herein were carried on, in substantial part, within this District.

16. Defendant is subject to personal jurisdiction in this Court because it resides in this District and transacts business in this District.

17. The pharmaceutical products at issue in this case are sold in Interstate Commerce, and the unlawful activities alleged in this Complaint have occurred in, and have had and will have, a substantial effect upon, Interstate Commerce.

18. There are a number of separate relevant product markets at issue in this case. They include: (a) the market for ACTH therapeutic drugs (the “ACTH Therapeutic Drug Market”); (b) the market for first-line drug treatments for Infantile Spasms (the “Infantile Spasms Market”); and (c) the market for treatments of last resort for Nephrotic Syndrome for those patients who do not respond to or cannot tolerate primary and secondary treatments for that disease (the “Nephrotic Syndrome

1 Market”). The relevant geographic markets for each of these three relevant product  
2 markets is the United States, since drugs available in any of these markets are subject  
3 to FDA regulation. The ACTH Therapeutic Drug, Infantile Spasms, and Nephrotic  
4 Syndrome Markets are collectively referred to as the “Relevant Markets.”

### 5 **The ACTH Therapeutic Drug Market**

6 19. ACTH is a drug used to treat certain life threatening and often fatal  
7 diseases, including Infantile Spasms and Nephrotic Syndrome. It is a polypeptide  
8 tropic hormone produced and secreted by the anterior pituitary gland. In the human  
9 body, ACTH activates the Melanocortin System and is referred to as a “Melanocortin  
10 agonist.” The Melanocortin System affects a wide array of bodily functions ranging  
11 from skin pigmentation, inflammation, energy homeostasis and sexual function. As a  
12 consequence, ACTH can be used as a therapy for a variety of illnesses resulting from  
13 improper functioning of the Melanocortin System, including Infantile Spasms and  
14 Nephrotic Syndrome. There is no reasonable interchangeability between drug  
15 therapies used to treat other diseases and ACTH drug therapies used to stimulate the  
16 Melanocortin System.

17 20. Acthar is an ACTH. It is the only FDA approved long-acting ACTH  
18 available in the US. It is also the only FDA approved long-acting melanocortin  
19 agonist available in the US.

20 21. ACTH products have been approved for use as diagnostic agents which  
21 are used to test for the presence of certain conditions or diseases. However, those  
22 products are short acting and are not used as therapies in treating illnesses.

23 22. Consumers faced with a small but significant non-transitory increase in  
24 the price of ACTH therapeutic drugs, cannot and will not shift to other classes of  
25 drugs such that the increase in price will be rendered unprofitable. This is evidenced  
26 by the fact that Questcor, the only supplier of ACTH for therapeutic purposes in the  
27 US, has raised the price of a vial of Acthar to \$28,000 and is able to maintain that  
28 price.



23. FDA regulation and the difficulty of developing and manufacturing ACTH based therapeutic drugs reduce or eliminate any “supply elasticity” whereby manufacturers of other drug therapies convert their existing manufacturing facilities to the manufacture of ACTH therapeutic drugs.

24. The relevant geographic market for ACTH therapeutic drugs is national because therapeutic ACTH drugs cannot be sold in the US without FDA approval.

### **The Infantile Spasms Market**

25. Babies and little children suffering from Infantile Spasms must have treatments that cure that affliction. Without it they suffer from epileptic type seizures and other symptoms of the disease. If untreated, they may suffer permanent brain or neurological damage and may develop other seizure disorders. The disease can be fatal. Only therapies that treat Infantile Spasm Syndrome can meet the medical needs of these patients. Therapies for other diseases do not cure or control Infantile Spasms and are not substitutes for Infantile Spasm therapeutics. There is no reasonable interchangeability between drug therapies used to treat other diseases and drug therapies used to treat children with Infantile Spasms.

26. Consumers faced with a small but significant non-transitory increase in the price of therapeutic drugs to treat Infantile Spasms, cannot and will not shift to other drug treatments for Infantile Spasms such that the increase in price will be rendered unprofitable. This is evidenced by the fact that Questcor has raised the price of a vial of Acthar to \$28,000 and is able to maintain that price.

27. There are also regulatory entry barriers that limit the Relevant Market to first line therapies for Infantile Spasms. In 2010, Questcor obtained from the FDA, “Orphan Drug designation” for Acthar for Infantile Spasms under the Orphan Drug Act. Despite the fact that Acthar is not patented, the Orphan Drug designation gives Questcor a seven year exclusive right to sell Acthar, and its chemical equivalent, for Infantile Spasms with immunity from generic competition. Questcor’s exclusive marketing right extends to 2017. Therapies that are excluded by Acthar’s Orphans

1 Drug Designation (generic versions of Acthar) cannot be labeled or marketed for the  
2 treatment of Infantile Spasms.

3 28. FDA regulation and the difficulty of developing and manufacturing  
4 treatments for Infantile Spasms preclude any “supply elasticity” whereby  
5 manufacturers of other drug therapies convert their manufacturing facilities to the  
6 manufacture of Infantile Spasm therapies.

7 29. The relevant geographic market for first line Infantile Spasm drug  
8 therapies is national because therapeutic drugs cannot be marketed in the US for  
9 Infantile Spasms without FDA approval.

### 10 **The Nephrotic Syndrome Market**

11 30. Nephrotic Syndrome is a condition in which excessive amounts of  
12 protein pass through the kidneys and are secreted through the urine. This results in  
13 kidney damage and can lead to kidney failure. Nephrotic Syndrome is treated on a  
14 first and second line basis with corticosteroids, such as Prednisone, or  
15 immunosuppressant drugs. In some patients the disease does not respond to these  
16 treatments and in others the patient cannot tolerate the drugs’ side effects. In such  
17 cases, ACTH (Acthar) is the primary and dominant treatment of last resort. Only  
18 therapies that treat Nephrotic Syndrome effectively can meet the medical needs of  
19 Nephrotic Syndrome patients who do not respond to or cannot tolerate traditional first  
20 and second line therapies for that illness. Therapies for other diseases do not cure or  
21 control Nephrotic Syndrome and are not substitutes for last resort treatments for  
22 Nephrotic Syndrome. There is no reasonable interchangeability between drug  
23 therapies used to treat other diseases and drug therapies used to treat victims of  
24 Nephrotic Syndrome.

25 31. Consumers faced with a small but significant non-transitory increase in  
26 the price of last resort therapeutic drugs to treat Nephrotic Syndrome cannot and will  
27 not shift to other drug treatments such that the increase in price will be rendered  
28

1 unprofitable. This is evidenced by the fact that Questcor has raised the price of a vial  
2 of Acthar to \$28,000 and is able to maintain that price.

3 32. There are also regulatory entry barriers that limit the Relevant Market to  
4 therapies of last resort for Nephrotic Syndrome. Therapies for other conditions cannot  
5 be marketed for the treatment of Nephrotic Syndrome without FDA approval. In  
6 addition, it is particularly difficult for the maker of a generic drug to obtain FDA  
7 approval when it is trying to prove that its synthetically manufactured product, which  
8 is manufactured in a laboratory setting, is the biopharmaceutical equivalent of a drug  
9 such as Acthar which is produced from animals.

10 33. FDA regulation and the difficulty of developing and manufacturing  
11 treatments for Nephrotic Syndrome preclude any "supply elasticity" whereby  
12 manufacturers of other drug therapies convert their manufacturing facilities to the  
13 manufacture of Nephrotic Syndrome therapies.

14 34. The relevant geographic market for therapies of last resort for Nephrotic  
15 Syndrome is national because such therapies cannot be marketed in the US for  
16 Nephrotic Syndrome without FDA approval.

17 **Questcor Has Market and Monopoly Power in the Relevant Markets**

18 35. There are no meaningful substitutes for Acthar or ACTH in the Relevant  
19 Markets. Nor are manufacturers of other pharmaceutical products able to shift their  
20 production to the manufacture of Acthar or other ACTH products. Even if they were  
21 able to do so, they could not sell those products without first obtaining FDA approval.  
22 Questcor has market and monopoly power in all of the Relevant Markets.

23 36. Questcor's monopoly power in all three of the Relevant Markets is  
24 further evidenced by a single price increase that it imposed in 2007. In that year,  
25 Questcor raised the price of Acthar from \$1,650 per vial to \$23,000 per vial, an  
26 overnight increase of over 1,300%. Questcor's ability to make that price increase  
27 "stick" is conclusive evidence of its market and monopoly power.  
28

### **The ACTH Therapeutic Drug Market**

37. In the ACTH Therapeutic Drug Market, Acthar is the only FDA approved long acting ACTH therapeutic drug available to consumers in the United States.

38. Questcor's market and monopoly power in the ACTH Therapeutic Drug Market is further protected by the fact that other chemical variations of ACTH for use as therapeutic drugs require FDA approval for sale in the United States.

39. Questcor effectively has 100% of the market for ACTH Therapeutic Drugs. It has market and monopoly power in that market which is dramatically demonstrated by its continued ability to charge \$28,000 for a vial of Acthar.

### **The Infantile Spasms Market**

40. In the Infantile Spasms Market, Acthar is considered the "gold standard" of treatment.

41. Questcor's market and monopoly power in the Infantile Spasms Market is protected by the Orphan Drug Designation that protects Questcor from generic competition to Acthar. Its monopoly position is further protected by the fact that alternative therapies, that would not be precluded by the Orphan Designation, require FDA approval if they are to be marketed as therapies for Infantile Spasms.

42. Questcor admits that it has more than 50% share of the Infantile Spasms Market and its actual market share may be far greater. Questcor's market and monopoly power in the Infantile Spasms Market is demonstrated dramatically by its continued ability to charge \$28,000 for a vial of Acthar.

### **The Nephrotic Syndrome Market**

43. In the Nephrotic Syndrome Market, Acthar is the primary and dominant treatment of last resort for Nephrotic Syndrome patients who do not respond to or cannot tolerate first or second line treatments for that disease.

1 44. Questcor's market and monopoly power in the Nephrotic Syndrome  
2 Market is further protected by the fact that alternative drug therapies require FDA  
3 approval if they are to be marketed as therapies for Nephrotic Syndrome.

4 45. Questcor's market and monopoly power in the Nephrotic Syndrome  
5 Market is demonstrated dramatically by its continued ability to charge \$28,000 for a  
6 vial of Acthar.

7 **Retrophin's Acquisition of Synacthen Threatened Questcor's Monopoly**

8 46. Synacthen is an ACTH derivative that has been sold for years outside of  
9 the US and has been used successfully to treat patients with Infantile Spasms and  
10 Nephrotic Syndrome in other countries. It has not been commercially developed in  
11 the US and it has not been submitted to the FDA for approval for therapeutic use.

12 47. Synacthen is similar, but not chemically identical, to Acthar. Both drugs  
13 share the identical sequence of the first 24 amino acids in their respective molecules.  
14 This sequence of amino acids gives both drugs their therapeutic properties. Acthar,  
15 however, has a longer amino acid chain. The two drugs are also produced in very  
16 different ways. Acthar is "porcine derived." It is extracted from the pituitary gland  
17 found in the brains of slaughtered pigs. Synacthen, by contrast, is synthetically  
18 manufactured in a laboratory setting. These differences give Synacthen three  
19 competitive advantages over Acthar. First, Synacthen is less expensive to  
20 manufacture. Second, because it is manufactured in a controlled setting, the product is  
21 less susceptible to variation. Third, consumers are more comfortable knowing that the  
22 drugs they are taking – or giving to their infants – are produced in a sterile  
23 environment rather than being derived from slaughtered animals.

24 48. Retrophin planned to purchase the rights to Synacthen, obtain FDA  
25 approval for its use as a therapeutic, and enter the Relevant Markets in competition  
26 with Questcor. Retrophin planned to price Synacthen at a fraction of the price  
27 charged by Questcor and use its competitive pricing and Synacthen's other  
28 competitive advantages to take substantial market share from Acthar.



49. In the late summer of 2012, Retrophin entered negotiations with Novartis to purchase the rights to manufacture and sell Synacthen in the US. After approximately nine months of due diligence and negotiations, Retrophin and Novartis agreed to terms on which Retrophin would acquire the rights to Synacthen. Final documents had been prepared and were merely awaiting the parties' signatures. The signing was set for June 11, 2013. Retrophin had prepared a press release announcing the deal.

50. In anticipation of the transaction, Retrophin had prepared a plan to obtain regulatory approvals for, and sell Synacthen. It devised a strategy for going directly to Phase III clinical drug trials in order to obtain FDA approval for the use of Synacthen to treat Infantile Spasms and Nephrotic Syndrome. It also planned to file a Treatment Investigational New Drug Application which, if approved by the FDA, would have allowed Retrophin to offer Synacthen to patients for free while it was awaiting FDA approval to market Synacthen for Infantile Spasms and Nephrotic Syndrome. This would have given patients immediate relief from Questcor's pricing and would have developed substantial goodwill for Retrophin and Synacthen in both the patient and medical communities. Retrophin believed that the history of Synacthen's use in other countries would aid it in obtaining FDA approval.

51. In anticipation of the product launch, Retrophin had put in place a clinical apparatus to conduct clinical trials necessary to obtain FDA approval. It planned to begin to market Synacthen upon FDA approval.

52. Given its expertise as a biopharmaceutical company focusing on rare diseases, Retrophin was ready, willing and able to enter the Relevant Markets with Synacthen subject to FDA approval. Retrophin's entry into the Relevant Markets would have broken Questcor's monopoly. The result would have been unambiguously procompetitive. Retrophin's entry into the market and its introduction of Synacthen as an alternative to Acthar would have benefitted all participants in the markets – other than Questcor. Prices to patients and payors would have dropped;

1 patients who were unable to pay for the drug would have been able to get it; other  
2 patients who were forced by Questcor's pricing to limit their dosages of the drug  
3 would have been able to take the medically prescribed amounts; and Retrophin would  
4 have earned substantial profits from sales of its product.

### 5 **Questcor Illegally Acquires Synacthen to Preserve its Monopoly**

6 53. Faced with a direct threat to its monopoly, Questcor acted to preserve its  
7 market dominance and its ability to charge extraordinary prices for Acthar. It swept in  
8 and secretly negotiated a deal to buy the rights to Synacthen from Novartis.

9 54. On June 11, 2013, the very day that Retrophin and Novartis were to sign  
10 their agreement, Questcor acquired the rights to Synacthen. The acquisition was  
11 closed on the day of the announcement. Questcor made no Premerger Notification  
12 filing with the Department of Justice and the Federal Trade Commission under the  
13 Hart Scott Rodino Act Antitrust Improvements Act of 1976. Nor did it observe the  
14 waiting period provided by the Hart Scott Act before closing the acquisition.

15 55. As part of the Agreement, the entire risk of an antitrust challenge to the  
16 transaction is borne by Questcor. The Agreement between Novartis and Questcor  
17 provides that Novartis receives the full consideration it is entitled to from Questcor  
18 even if the US antitrust enforcement agencies (The Federal Trade Commission or the  
19 Department of Justice) force Questcor to divest its rights in Synacthen. If such a  
20 divestiture occurs, the Agreement provides that Novartis keeps the entire \$60 million  
21 that Questcor has paid it and Questcor will make all future milestone payments  
22 required by the Agreement – an amount in excess of \$75 million. In short, the  
23 acquisition of the rights to Synacthen was so important to Questcor that it put at least  
24 \$135 million at risk to keep Synacthen out of Retrophin's hands. There was no  
25 procompetitive aspect of Questcor's acquisition of Synacthen.

26 56. Questcor's acquisition of the rights to Synacthen unreasonably restrained  
27 trade, maintained Questcor's monopolies and may result in a substantial lessening of  
28 competition in the Relevant Markets. As a result of Questcor's acquisition of the

rights to Synacthen, prices to patients and payors for Acthar will remain at monopoly levels; patients who are unable to pay for the drug will not be able to get it; other patients who are forced by Questcor's pricing to limit their dosages of the drug will not be able to take the medically prescribed amounts; and Retrophin will not earn the substantial profits it expected to earn from selling Synacthen at a fraction of the price Questcor charges for Acthar.

### **Retrophin Is Continuing to Try to Enter the Relevant Markets**

57. Despite Questcor's anticompetitive and monopolistic conduct, Retrophin is continuing to try to enter the Relevant Product Markets. To that end, it has taken the highly unusual step of trying to create from scratch a drug – that it has designated as RE-034 – that will match Synacthen. Retrophin is endeavoring to create a new formulation of the drug that will incorporate the same active pharmaceutical ingredient used in Synacthen and match Synacthen's therapeutic effects for patients suffering from Infantile Spasms and Nephrotic Syndrome.

58. Retrophin's efforts to develop RE-034 will take substantial time and money and will require FDA approval. It will also require that the drug successfully complete both Phase I and Phase III clinical trials for both Infantile Spasms and Nephrotic Syndrome. There is no guarantee that RE-034 will succeed in the clinical trials or that Retrophin will succeed in obtaining FDA approval or entering the Relevant Markets.

59. Entering the Relevant Markets through RE-034 is more difficult, risky and time consuming than entering those markets through Synacthen. Synacthen is an existing product that has been manufactured and used outside of the US for decades in the treatment of a variety of illnesses, including Infantile Spasms and Nephrotic Syndrome. The owner of the rights to Synacthen has the information, know-how and ability to manufacture the drug and has decades of clinical data from outside the United States that can be used to facilitate and speed the regulatory approval process



1 in the US. Retrophin will need to develop all of that knowledge from scratch in  
2 seeking to enter the Relevant Markets with RE-034.

3 60. Entering the Relevant Markets through RE-034 will be more difficult,  
4 less likely to succeed and take longer than entry into those markets through the  
5 acquisition of Synacthen. Questcor's conduct has delayed, and may entirely foreclose,  
6 Retrophin from entering the Relevant Markets.

7 **Questcor Has Damaged Competition in the Relevant Markets and Has Caused**  
8 **Retrophin to Suffer Both Injury in Fact and Antitrust Injury**

9 61. Questcor's unlawful acquisition of the rights to Synacthen has foreclosed  
10 or delayed Retrophin from entering the Relevant Markets, has restrained trade, and  
11 has preserved and entrenched Questcor's monopoly and may substantially lessen  
12 competition. As a result, competition in the Relevant Markets has been damaged and  
13 Retrophin has been injured. Those injuries are intertwined and inseparable.  
14 Excluding or delaying Retrophin from entering the Relevant Markets with Synacthen  
15 was and is an integral aspect of Questcor's anticompetitive conduct.

16 62. Retrophin has suffered and continues to suffer injury in fact from  
17 Questcor's acquisition of the rights to Synacthen and the preservation of its monopoly.

18 63. Retrophin has suffered and continues to suffer antitrust injury from  
19 Questcor's acquisition of the rights to Synacthen and the preservation of its monopoly.  
20 Retrophin has been injured directly as a result of Questcor's unlawful conduct.  
21 Retrophin is a potential entrant into the Relevant Markets and, but for Questcor's  
22 unlawful conduct, would be entering those markets with Synacthen. There are no  
23 aspects of Questcor's conduct that are beneficial to competition. Retrophin's injury is  
24 an integral aspect of Questcor's unlawful conduct; flows from that which renders  
25 Questcor's conduct unlawful; and its injury is of the type the antitrust laws were  
26 intended to prevent.

Kurtzlin Muchlin Rosenman LLP  
2029 Century Park East, Suite 2600  
Los Angeles, CA 90067-3012  
310.788.4400 tel 310.788.4471 fax

1 71. Questcor's violation of Section 2 of the Sherman Act has caused, and  
2 will cause, damages to Retrophin in an amount to be determined at trial, such damages  
3 to be trebled in accordance with Section 4 of the Clayton Act, 15 U.S.C. § 15.

4 72. Questcor's unlawful conduct is ongoing, irreparably injures Retrophin,  
5 harms the public interest, and unless restrained will continue. Retrophin has no  
6 adequate remedy at law.

7 **THIRD CAUSE OF ACTION**

8 **(ATTEMPTED MONOPOLIZATION IN VIOLATION OF SECTION 2 OF**  
9 **THE SHERMAN ACT)**

10 73. Retrophin repeats and realleges the allegations set forth in paragraphs 1  
11 through 72 as if fully set forth herein.

12 74. In acquiring the rights to Synacthen, Questcor has engaged in  
13 monopolistic and anticompetitive conduct with the specific purpose and intent of  
14 monopolizing the Relevant Markets in violation of Section 2 of the Sherman Act, 15  
15 U.S.C. § 2.

16 75. The sole purpose of Questcor's acquisition of the rights to Synacthen is  
17 to enable Questcor to gain or maintain a monopoly position in the Relevant Markets.

18 76. A dangerous probability exists that Questcor has succeeded, and if not  
19 restrained, will continue to succeed in monopolizing the Relevant Markets.

20 77. Questcor's acts of attempted monopolization has unlawfully prevented  
21 and delayed Retrophin from entering the Relevant Markets and otherwise injure  
22 competition in those markets by reducing choice, inflating prices, and lessening  
23 innovation.

24 78. Questcor's violation of Section 2 of the Sherman Act has caused, and  
25 will cause, damages to Retrophin in an amount to be determined at trial, such damages  
26 to be trebled in accordance with Section 4 of the Clayton Act, 15 U.S.C. § 15.

1 79. Questcor's unlawful conduct is ongoing, irreparably injures Retrophin,  
2 harms the public interest, and unless restrained will continue. Retrophin has no  
3 adequate remedy at law.

4 **FOURTH CAUSE OF ACTION**

5 **(UNLAWFUL MERGER IN VIOLATION OF SECTION 7 OF THE**  
6 **CLAYTON ACT)**

7 80. Retrophin repeats and realleges the allegations set forth in paragraphs 1  
8 through 79 as if fully set forth herein.

9 81. Questcor's acquisition of the rights to Synacthen is likely to substantially  
10 lessen competition in interstate trade and commerce in violation of Section 7 of the  
11 Clayton Act, 15 U.S.C. § 18.

12 82. Questcor's acquisition of the rights to Synacthen is likely to result in a  
13 substantial lessening of competition in the Relevant Markets.

14 83. Questcor's violation of Section 7 of the Clayton Act has caused, and will  
15 cause, damages to Retrophin in an amount to be determined at trial, such damages to  
16 be trebled in accordance with Section 4 of the Clayton Act, 15 U.S.C. § 15.

17 84. Questcor's unlawful conduct is ongoing, irreparably injures Retrophin,  
18 harms the public interest, and unless restrained will continue. Retrophin has no  
19 adequate remedy at law.

20 **FIFTH CAUSE OF ACTION**

21 **(VIOLATION OF CALIFORNIA ANTITRUST LAWS)**

22 85. Retrophin repeats and realleges the allegations set forth in paragraphs 1  
23 through 84 as if fully set forth herein.

24 86. In acquiring the rights to Synacthen, Questcor entered into and engaged  
25 in a continuing unlawful trust in restraint of the trade and commerce described above  
26 in violation of the California antitrust laws referenced below. Questcor has acted in  
27 violation of these laws in an effort to maintain, entrench, and/or create a monopoly,  
28

1 and otherwise injure competition in the Relevant Markets. Questcor's conduct  
2 substantially affected commerce in California.

3 87. In acquiring the rights to Synacthen in the US, Questcor has maintained  
4 and entrenched its monopoly position in the Relevant Markets.

5 88. Questcor's acquisition of the rights to Synacthen is likely to result in a  
6 substantial lessening of competition in the Relevant Markets.

7 89. By reason of the foregoing, Questcor violated California's Cartwright  
8 Act, California Business and Professions Code §§ 16720 *et seq.*

9 90. Questcor's violation of California's Cartwright Act, California Business  
10 and Professions Code §§ 16720 *et seq.* has caused, and will cause, damages to  
11 Retrophin in an amount to be determined at trial, with such damages to be trebled.

12 91. Questcor's unlawful conduct is ongoing, irreparably injures Retrophin,  
13 harms the public interest, and unless restrained will continue. Retrophin has no  
14 adequate remedy at law.

### 15 **SIXTH CAUSE OF ACTION**

#### 16 **(UNFAIR COMPETITION UNDER CAL. BUS. & PROF. CODE**

#### 17 **§ 17200 *ET SEQ.*)**

18 92. Retrophin repeats and realleges the allegations set forth in paragraphs 1  
19 through 91 as if fully set forth herein.

20 93. California Unfair Competition Law, Business and Professions Code  
21 Section 17200 *et seq.*, provides that "unfair competition shall mean and include any  
22 unlawful, unfair or fraudulent business act."

23 94. Questcor's conduct as alleged herein meets the "unlawfulness" prong of  
24 California Business and Professions Code §§ 17200 *et seq.* Questcor has committed  
25 and continues to commit unlawful business practices by illegally acquiring the rights  
26 to Synacthen and engaging in anticompetitive and monopolistic conduct in violation  
27 of antitrust laws.  
28

**Kathleen Muchlin Rosenman LLP**  
2029 Century Park East, Suite 2600  
Los Angeles, CA 90067-3012  
310.788.4400 tel 310.788.4471 fax

---

19



1 D. DECLARING that Questcor's acquisition of the rights to Synacthen  
2 constitutes an acquisition that may result in a substantial lessening of competition in  
3 the Relevant Markets in violation of Section 7 of the Clayton Act;

4 E. DECLARING that Questcor's acquisition of the rights to Synacthen  
5 constitutes an unlawful trust in restraint of trade and commerce in violation of  
6 California Business and Professions Code §§ 16720 *et seq.*;

7 F. DECLARING that Questcor's acquisition of the rights to Synacthen  
8 constitutes unfair competition in violation of California Business and Professions  
9 Code § 17200 *et seq.*;

10 G. PERMANENTLY ENJOINING Questcor from enforcing or maintaining  
11 its Rights to Synacthen under its agreement with Novartis or any similar formal or  
12 informal agreement;

13 H. PERMANENTLY ENJOINING Questcor from engaging in further  
14 anticompetitive conduct in violation of Section 1 of the Sherman Act;

15 I. PERMANENTLY ENJOINING Questcor from engaging in further  
16 anticompetitive conduct in violation of Section 2 of the Sherman Act;

17 J. PERMANENTLY ENJOINING Questcor from engaging in further  
18 anticompetitive conduct in violation of Section 7 of the Clayton Act;

19 K. PERMANENTLY ENJOINING Questcor from engaging in further  
20 anticompetitive conduct in violation of California Business and Professions Code §§  
21 16720, *et seq.*;

22 L. PERMANENTLY ENJOINING Questcor from engaging in further  
23 unlawful and/or unfair business practices in violation of California Business and  
24 Professions Code § 17200 *et seq.*;

25 M. DISGORGING any profits generated by Questcor as a result of its  
26 unlawful and/or unfair business practices to the extent it constitutes restitution to  
27 Retrophin;  
28

1 N. AWARDING Retrophin damages in an amount to be proved at trial, such  
2 damages to be trebled, including its costs and attorneys' fees, pursuant to Section 4 of  
3 the Clayton Act, 15 U.S.C. § 15 and/or California's Cartwright Act, California  
4 Business and Professions Code §§ 16720, *et seq.*;

5 O. AWARDING Retrophin its costs, expenses and attorneys' fees incurred  
6 in connection with the action;

7 P. AWARDING Retrophin interest to the maximum extent permitted by  
8 law; and

9 Q. GRANTING Retrophin such other and further relief as this Court deems  
10 just and proper.

11 Dated: January 7, 2014

KATTEN MUCHIN ROSENMAN LLP

12  
13 By: 

14 Kristin L. Holland  
15 Attorneys for Plaintiff Retrophin, Inc.

**Katten**  
Katten Muchin Rosenman LLP

2019 Century Park East, Suite 2600  
Los Angeles, CA 90067-9023  
310.788.4400 tel. 310.788.4471 fax




**DEMAND FOR JURY TRIAL**

Retrophin hereby demands a trial by jury on all of its claims and causes of action.

Dated: January 7, 2014

KATTEN MUCHIN ROSENMAN LLP

By: 

Kristin L. Holland  
Attorneys for Plaintiff Retrophin, Inc.

**Katten**  
Katten Muchin Rosenman LLP

2059 Century Park East, Suite 2600  
Los Angeles, CA 90067-9012  
310.788.4400 tel 310.788.4471 fax

UNITED STATES DISTRICT COURT, CENTRAL DISTRICT OF CALIFORNIA  
CIVIL COVER SHEET

<b>I. (a) PLAINTIFFS</b> ( Check box if you are representing yourself <input type="checkbox"/> )  Retrophin, Inc.  (b) County of Residence of First Listed Plaintiff <u>New York, NY</u> <i>(EXCEPT IN U.S. PLAINTIFF CASES)</i>  (c) Attorneys (Firm Name, Address and Telephone Number) If you are representing yourself, provide the same information. Katten Muchin Rosenman LLP 2029 Century Park East, Suite 2600 Los Angeles, CA 90067-3012 310-788-4400	<b>DEFENDANTS</b> ( Check box if you are representing yourself <input type="checkbox"/> )  Questcor Pharmaceuticals, Inc.  County of Residence of First Listed Defendant <u>Orange, CA</u> <i>(IN U.S. PLAINTIFF CASES ONLY)</i>  Attorneys (Firm Name, Address and Telephone Number) If you are representing yourself, provide the same information.  N/A
--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

<b>II. BASIS OF JURISDICTION</b> (Place an X in one box only.)  <input type="checkbox"/> 1. U.S. Government Plaintiff <input type="checkbox"/> 2. U.S. Government Defendant <input checked="" type="checkbox"/> 3. Federal Question (U.S. Government Not a Party) <input type="checkbox"/> 4. Diversity (Indicate Citizenship of Parties in Item III)	<b>III. CITIZENSHIP OF PRINCIPAL PARTIES</b> -For Diversity Cases Only (Place an X in one box for plaintiff and one for defendant) <table border="1" style="width:100%"><tr><td>Citizen of This State</td><td>PTF <input type="checkbox"/> 1</td><td>DEF <input type="checkbox"/> 1</td><td>Incorporated or Principal Place of Business in this State</td><td>PTF <input type="checkbox"/> 4</td><td>DEF <input checked="" type="checkbox"/> 4</td></tr><tr><td>Citizen of Another State</td><td><input type="checkbox"/> 2</td><td><input type="checkbox"/> 2</td><td>Incorporated and Principal Place of Business in Another State</td><td><input checked="" type="checkbox"/> 5</td><td><input type="checkbox"/> 5</td></tr><tr><td>Citizen or Subject of a Foreign Country</td><td><input type="checkbox"/> 3</td><td><input type="checkbox"/> 3</td><td>Foreign Nation</td><td><input type="checkbox"/> 6</td><td><input type="checkbox"/> 6</td></tr></table>	Citizen of This State	PTF <input type="checkbox"/> 1	DEF <input type="checkbox"/> 1	Incorporated or Principal Place of Business in this State	PTF <input type="checkbox"/> 4	DEF <input checked="" type="checkbox"/> 4	Citizen of Another State	<input type="checkbox"/> 2	<input type="checkbox"/> 2	Incorporated and Principal Place of Business in Another State	<input checked="" type="checkbox"/> 5	<input type="checkbox"/> 5	Citizen or Subject of a Foreign Country	<input type="checkbox"/> 3	<input type="checkbox"/> 3	Foreign Nation	<input type="checkbox"/> 6	<input type="checkbox"/> 6
Citizen of This State	PTF <input type="checkbox"/> 1	DEF <input type="checkbox"/> 1	Incorporated or Principal Place of Business in this State	PTF <input type="checkbox"/> 4	DEF <input checked="" type="checkbox"/> 4														
Citizen of Another State	<input type="checkbox"/> 2	<input type="checkbox"/> 2	Incorporated and Principal Place of Business in Another State	<input checked="" type="checkbox"/> 5	<input type="checkbox"/> 5														
Citizen or Subject of a Foreign Country	<input type="checkbox"/> 3	<input type="checkbox"/> 3	Foreign Nation	<input type="checkbox"/> 6	<input type="checkbox"/> 6														

**IV. ORIGIN** (Place an X in one box only.)  
☒ 1. Original Proceeding    ☐ 2. Removed from State Court    ☐ 3. Remanded from Appellate Court    ☐ 4. Reinstated or Reopened    ☐ 5. Transferred from Another District (Specify)    ☐ 6. Multi-District Litigation**V. REQUESTED IN COMPLAINT: JURY DEMAND:** ☒ Yes ☐ No (Check "Yes" only if demanded in complaint.)**CLASS ACTION under F.R.Cv.P. 23:** ☐ Yes ☒ No    **MONEY DEMANDED IN COMPLAINT:** \$ Over \$75k, TBD**VI. CAUSE OF ACTION** (Cite the U.S. Civil Statute under which you are filing and write a brief statement of cause. Do not cite jurisdictional statutes unless diversity.)  
Plaintiff is suing defendant for entering an illegal agreement and engaging in conduct that violates federal and state antitrust and competition laws, 15 U.S.C. §§ 1, 2, 18, and California Business and Professions Code §§ 16720, et seq, California Business and Professions Code §§ 17200, et seq**VII. NATURE OF SUIT** (Place an X in one box only.)

OTHER STATUTES	CONTRACT	REAL PROPERTY CONT.	IMMIGRATION	PRISONER PETITIONS	PROPERTY RIGHTS
<input type="checkbox"/> 375 False Claims Act <input type="checkbox"/> 400 State Reapportionment <input checked="" type="checkbox"/> 410 Antitrust <input type="checkbox"/> 430 Banks and Banking <input type="checkbox"/> 450 Commerce/ICC Rates/Etc. <input type="checkbox"/> 460 Deportation <input type="checkbox"/> 470 Racketeer Influenced & Corrupt Org. <input type="checkbox"/> 480 Consumer Credit <input type="checkbox"/> 490 Cable/Sat TV <input type="checkbox"/> 850 Securities/Commodities/Exchange <input type="checkbox"/> 890 Other Statutory Actions <input type="checkbox"/> 891 Agricultural Acts <input type="checkbox"/> 893 Environmental Matters <input type="checkbox"/> 895 Freedom of Info. Act <input type="checkbox"/> 896 Arbitration <input type="checkbox"/> 899 Admin. Procedures Act/Review of Appeal of Agency Decision <input type="checkbox"/> 950 Constitutionality of State Statutes	<input type="checkbox"/> 110 Insurance <input type="checkbox"/> 120 Marine <input type="checkbox"/> 130 Miller Act <input type="checkbox"/> 140 Negotiable Instrument <input type="checkbox"/> 150 Recovery of Overpayment & Enforcement of Judgment <input type="checkbox"/> 151 Medicare Act <input type="checkbox"/> 152 Recovery of Defaulted Student Loan (Excl. Vet.) <input type="checkbox"/> 153 Recovery of Overpayment of Vet. Benefits <input type="checkbox"/> 160 Stockholders' Suits <input type="checkbox"/> 190 Other Contract <input type="checkbox"/> 195 Contract Product Liability <input type="checkbox"/> 196 Franchise <b>REAL PROPERTY</b> <input type="checkbox"/> 210 Land Condemnation <input type="checkbox"/> 220 Foreclosure <input type="checkbox"/> 230 Rent Lease & Ejectment	<input type="checkbox"/> 240 Torts to Land <input type="checkbox"/> 245 Tort Product Liability <input type="checkbox"/> 290 All Other Real Property <b>TORTS</b> <b>PERSONAL INJURY</b> <input type="checkbox"/> 310 Airplane <input type="checkbox"/> 315 Airplane Product Liability <input type="checkbox"/> 320 Assault, Libel & Slander <input type="checkbox"/> 330 Fed. Employers' Liability <input type="checkbox"/> 340 Marine <input type="checkbox"/> 345 Marine Product Liability <input type="checkbox"/> 350 Motor Vehicle <input type="checkbox"/> 355 Motor Vehicle Product Liability <input type="checkbox"/> 360 Other Personal Injury <input type="checkbox"/> 362 Personal Injury-Med Malpractice <input type="checkbox"/> 365 Personal Injury-Product Liability <input type="checkbox"/> 367 Health Care/Pharmaceutical Personal Injury Product Liability <input type="checkbox"/> 368 Asbestos Personal Injury Product Liability	<input type="checkbox"/> 462 Naturalization Application <input type="checkbox"/> 465 Other Immigration Actions <b>TORTS</b> <b>PERSONAL PROPERTY</b> <input type="checkbox"/> 370 Other Fraud <input type="checkbox"/> 371 Truth in Lending <input type="checkbox"/> 380 Other Personal Property Damage <input type="checkbox"/> 385 Property Damage Product Liability <b>BANKRUPTCY</b> <input type="checkbox"/> 422 Appeal 28 USC 158 <input type="checkbox"/> 423 Withdrawal 28 USC 157 <b>CIVIL RIGHTS</b> <input type="checkbox"/> 440 Other Civil Rights <input type="checkbox"/> 441 Voting <input type="checkbox"/> 442 Employment <input type="checkbox"/> 443 Housing/Accommodations <input type="checkbox"/> 445 American with Disabilities-Employment <input type="checkbox"/> 446 American with Disabilities-Other <input type="checkbox"/> 448 Education	<b>Habeas Corpus:</b> <input type="checkbox"/> 463 Alien Detainee <input type="checkbox"/> 510 Motions to Vacate Sentence <input type="checkbox"/> 530 General <input type="checkbox"/> 535 Death Penalty <b>Other:</b> <input type="checkbox"/> 540 Mandamus/Other <input type="checkbox"/> 550 Civil Rights <input type="checkbox"/> 555 Prison Condition <input type="checkbox"/> 560 Civil Detainee Conditions of Confinement <b>FORFEITURE/PENALTY</b> <input type="checkbox"/> 625 Drug Related Seizure of Property 21 USC 881 <input type="checkbox"/> 690 Other <b>LABOR</b> <input type="checkbox"/> 710 Fair Labor Standards Act <input type="checkbox"/> 720 Labor/Mgmt. Relations <input type="checkbox"/> 740 Railway Labor Act <input type="checkbox"/> 751 Family and Medical Leave Act <input type="checkbox"/> 790 Other Labor Litigation <input type="checkbox"/> 791 Employee Ret. Inc. Security Act	<input type="checkbox"/> 820 Copyrights <input type="checkbox"/> 830 Patent <input type="checkbox"/> 840 Trademark <b>SOCIAL SECURITY</b> <input type="checkbox"/> 861 HIA (1395ff) <input type="checkbox"/> 862 Black Lung (923) <input type="checkbox"/> 863 DIWC/DIWW (405 (g)) <input type="checkbox"/> 864 SSID Title XVI <input type="checkbox"/> 865 RSI (405 (g)) <b>FEDERAL TAX SUITS</b> <input type="checkbox"/> 870 Taxes (U.S. Plaintiff or Defendant) <input type="checkbox"/> 871 IRS-Third Party 26 USC 7609

FOR OFFICE USE ONLY:

Case Number:

CV14-00026

CV-71 (11/13)

CIVIL COVER SHEET

Page 1 of 3

**UNITED STATES DISTRICT COURT, CENTRAL DISTRICT OF CALIFORNIA  
CIVIL COVER SHEET**

**VIII. VENUE:** Your answers to the questions below will determine the division of the Court to which this case will most likely be initially assigned. This initial assignment is subject to change, in accordance with the Court's General Orders, upon review by the Court of your Complaint or Notice of Removal.

<b>Question A: Was this case removed from state court?</b> <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No If "no," go to Question B. If "yes," check the box to the right that applies, enter the corresponding division in response to Question D, below, and skip to Section IX.	<b>STATE CASE WAS PENDING IN THE COUNTY OF:</b>		<b>INITIAL DIVISION IN CACD IS:</b>
	<input type="checkbox"/> Los Angeles		Western
	<input type="checkbox"/> Ventura, Santa Barbara, or San Luis Obispo		Western
	<input type="checkbox"/> Orange		Southern
	<input type="checkbox"/> Riverside or San Bernardino		Eastern

<b>Question B: Is the United States, or one of its agencies or employees, a party to this action?</b> <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No If "no," go to Question C. If "yes," check the box to the right that applies, enter the corresponding division in response to Question D, below, and skip to Section IX.	<b>If the United States, or one of its agencies or employees, is a party, is it:</b>		<b>INITIAL DIVISION IN CACD IS:</b>
	<b>A PLAINTIFF?</b>	<b>A DEFENDANT?</b>	
	Then check the box below for the county in which the majority of DEFENDANTS reside.	Then check the box below for the county in which the majority of PLAINTIFFS reside.	
	<input type="checkbox"/> Los Angeles	<input type="checkbox"/> Los Angeles	Western
	<input type="checkbox"/> Ventura, Santa Barbara, or San Luis Obispo	<input type="checkbox"/> Ventura, Santa Barbara, or San Luis Obispo	Western
	<input type="checkbox"/> Orange	<input type="checkbox"/> Orange	Southern
	<input type="checkbox"/> Riverside or San Bernardino	<input type="checkbox"/> Riverside or San Bernardino	Eastern
	<input type="checkbox"/> Other	<input type="checkbox"/> Other	Western

<b>Question C: Location of plaintiffs, defendants, and claims? (Make only one selection per row)</b>	<b>A. Los Angeles County</b>	<b>B. Ventura, Santa Barbara, or San Luis Obispo Counties</b>	<b>C. Orange County</b>	<b>D. Riverside or San Bernardino Counties</b>	<b>E. Outside the Central District of California</b>	<b>F. Other</b>
Indicate the location in which a majority of plaintiffs reside:	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>
Indicate the location in which a majority of defendants reside:	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Indicate the location in which a majority of claims arose:	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

**C.1. Is either of the following true? If so, check the one that applies:**

- ☒ 2 or more answers in Column C  
☐ only 1 answer in Column C and no answers in Column D

Your case will initially be assigned to the  
SOUTHERN DIVISION.  
Enter "Southern" in response to Question D, below.

If none applies, answer question C2 to the right. →

**C.2. Is either of the following true? If so, check the one that applies:**

- ☐ 2 or more answers in Column D  
☐ only 1 answer in Column D and no answers in Column C

Your case will initially be assigned to the  
EASTERN DIVISION.  
Enter "Eastern" in response to Question D, below.

If none applies, go to the box below. ↓

Your case will initially be assigned to the  
WESTERN DIVISION.  
Enter "Western" in response to Question D below.

<b>Question D: Initial Division?</b>	<b>INITIAL DIVISION IN CACD</b>
Enter the initial division determined by Question A, B, or C above: →	Southern Division

**UNITED STATES DISTRICT COURT, CENTRAL DISTRICT OF CALIFORNIA  
CIVIL COVER SHEET**

**IX(a). IDENTICAL CASES:** Has this action been previously filed in **this court** and dismissed, remanded or closed? ☒ NO ☐ YES

If yes, list case number(s): \_\_\_\_\_

**IX(b). RELATED CASES:** Have any cases been previously filed in **this court** that are related to the present case? ☒ NO ☐ YES

If yes, list case number(s): \_\_\_\_\_

**Civil cases are deemed related if a previously filed case and the present case:**

(Check all boxes that apply)

- ☐ A. Arise from the same or closely related transactions, happenings, or events; or
- ☐ B. Call for determination of the same or substantially related or similar questions of law and fact; or
- ☐ C. For other reasons would entail substantial duplication of labor if heard by different judges; or
- ☐ D. Involve the same patent, trademark or copyright, and one of the factors identified above in a, b or c also is present.

**X. SIGNATURE OF ATTORNEY**

**(OR SELF-REPRESENTED LITIGANT):** \_\_\_\_\_

DATE: 1/7/2014

**Notice to Counsel/Parties:** The CV-71 (JS-44) Civil Cover Sheet and the information contained herein neither replace nor supplement the filing and service of pleadings or other papers as required by law. This form, approved by the Judicial Conference of the United States in September 1974, is required pursuant to Local Rule 3-1 is not filed but is used by the Clerk of the Court for the purpose of statistics, venue and initiating the civil docket sheet. (For more detailed instructions, see separate instructions sheet).

Key to Statistical codes relating to Social Security Cases:

Nature of Suit Code	Abbreviation	Substantive Statement of Cause of Action
861	HIA	All claims for health insurance benefits (Medicare) under Title 18, Part A, of the Social Security Act, as amended. Also, include claims by hospitals, skilled nursing facilities, etc., for certification as providers of services under the program. (42 U.S.C. 1935FF(b))
862	BL	All claims for "Black Lung" benefits under Title 4, Part B, of the Federal Coal Mine Health and Safety Act of 1969. (30 U.S.C. 923)
863	DIWC	All claims filed by insured workers for disability insurance benefits under Title 2 of the Social Security Act, as amended; plus all claims filed for child's insurance benefits based on disability. (42 U.S.C. 405 (g))
863	DIWW	All claims filed for widows or widowers insurance benefits based on disability under Title 2 of the Social Security Act, as amended. (42 U.S.C. 405 (g))
864	SSID	All claims for supplemental security income payments based upon disability filed under Title 16 of the Social Security Act, as amended.
865	RSI	All claims for retirement (old age) and survivors benefits under Title 2 of the Social Security Act, as amended. (42 U.S.C. 405 (g))